

Table S1. article excluded with reason and round.

| key              | Title  | reason for exclusion | round of exclusion |
|------------------|--|----------------------|--------------------|
| rayyan-661154035 | Chapter 1 - Special Diagnostic Techniques in Surgical Pathology  | wrong population     | round I            |
| rayyan-661154036 | The natural history of adenomas  | wrong population     | round I            |
| rayyan-661154037 | 20 - Molecular pathology   | wrong population     | round I            |
| rayyan-661154038 | Chapter 6 - Gastrointestinal System  | wrong population     | round I            |
| rayyan-661154039 | Chapter 164 - Adenocarcinoma of the Colon and Rectum   | wrong population     | round I            |
| rayyan-661154040 | Chapter Four - Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual       | wrong population     | round I            |
| rayyan-661154041 | 13 - Tumours and Tumour-like Lesions of the Liver  | wrong population     | round I            |
| rayyan-661154042 | The therapeutic landscape of hepatocellular carcinoma  | wrong population     | round I            |
| rayyan-661154043 | Chapter 12 - Genetics of Adrenal Tumors  | wrong population     | round I            |
| rayyan-661154044 | 86 - Carcinoma of the Ovaries and Fallopian Tubes  | wrong population     | round I            |
| rayyan-661154046 | 13 - Neoplasms of the Testis   | wrong population     | round I            |
| rayyan-661154047 | Chapter 4 - Tumor Heterogeneity  | wrong population     | round I            |
| rayyan-661154048 | Glossary   | wrong population     | round I            |
| rayyan-661154049 | 5 - Neoplasia  | wrong population     | round I            |
| rayyan-661154050 | The role of cell cycle regulatory proteins in the pathogenesis of melanoma                               | wrong population     | round I            |
| rayyan-661154051 | Chapter 3 - Pharmacogenetics of therapeutics   | wrong population     | round I            |
| rayyan-661154052 | "Chapter 6 - Pharmacoepigenetic Processors: Epigenetic Drugs   | wrong population     | round I            |
| rayyan-661154053 | Intraductal Papillary Mucinous Neoplasm: A Clinicopathologic Review                                      | wrong population     | round I            |
| rayyan-661154054 | Chapter Seven - Synergistic combination of oncolytic virotherapy with CAR T-cell therapy                 | wrong population     | round I            |
| rayyan-661154055 | Chapter 57 - Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies | wrong population     | round I            |
| rayyan-661154056 | Gastroenteropancreatic endocrine tumors  | wrong population     | round I            |
| rayyan-661154057 | Chapter 9 - Hereditary predisposition to uveal melanoma  | wrong population     | round I            |
| rayyan-661154058 | Chapter 4 - Precision Surgery and Surgical Spectroscopy  | wrong population     | round I            |
| rayyan-661154059 | Architects meets Repairers: The interplay between homeobox genes and DNA repair                          | wrong population     | round I            |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661154060 | 1 - Ovarian Carcinoma: An Introduction  | wrong population | round I |
| rayyan-661154061 | 7 - Special Studies   | wrong population | round I |
| rayyan-661154062 | CHAPTER 7 - Molecular Biology   | wrong population | round I |
| rayyan-661154063 | 47 - Cholangiocarcinoma   | wrong population | round I |
| rayyan-661154064 | Kapitel 5 - Viszeralchirurgie   | wrong population | round I |
| rayyan-661154065 | Index   | wrong population | round I |
| rayyan-661154066 | Chapter 12 - Therapies II: Specific Non-surgical Treatments   | wrong population | round I |
| rayyan-661154067 | Chapter 11 - Clinical Trial Design in Immuno-Oncology   | wrong population | round I |
| rayyan-661154068 | Subject Index   | wrong population | round I |
| rayyan-661154069 | Chapter 11 - Surface Epithelial Stromal Tumors of the Ovary   | wrong population | round I |
| rayyan-661154070 | Molecular techniques in anatomic pathology: An overview   | wrong population | round I |
| rayyan-661154071 | Molecular biology of testicular germ cell tumors: Unique features awaiting clinical application     | wrong population | round I |
| rayyan-661154072 | Cholangiocarcinoma: New Insights into Disease Pathogenesis and Biology                              | wrong population | round I |
| rayyan-661154073 | 6 - Salivary Glands   | wrong population | round I |
| rayyan-661154074 | Some thoughts on what's ahead for GI in 2006 and beyond   | wrong population | round I |
| rayyan-661154075 | Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies | wrong population | round I |
| rayyan-661154076 | CHAPTER 42 - Tumour markers   | wrong population | round I |
| rayyan-661154077 | 1 - Pancreatic Carcinoma: An Introduction   | wrong population | round I |
| rayyan-661154078 | Chapter Three - Advances in Circulating Tumor DNA Analysis  | wrong population | round I |
| rayyan-661154079 | The Gastrointestinal Tumor Microenvironment   | wrong population | round I |
| rayyan-661154080 | "Chapter 14 - Biomarkers: Discovery   | wrong population | round I |
| rayyan-661154081 | Index   | wrong population | round I |
| rayyan-661154082 | CHAPTER 23 - Large Intestine (Colon)  | wrong population | round I |
| rayyan-661154083 | Mechanisms regulating T-cell infiltration and activity in solid tumors                              | wrong population | round I |
| rayyan-661154084 | Chapter 99 - Vitamin D and Colon Cancer   | wrong population | round I |
| rayyan-661154086 | Index   | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661154087 | "Chapter 10 - Typing  | wrong population | round I |
| rayyan-661154088 | Chapter 13 - Tumours and Tumour-Like Lesions  | wrong population | round I |
| rayyan-661154091 | Chapter 7 - Hepatobiliary System  | wrong population | round I |
| rayyan-661154095 | Molecular diagnostics in melanoma   | wrong population | round I |
| rayyan-661154098 | Subject Index   | wrong population | round I |
| rayyan-661154108 | 13 - Genetic Factors: Hereditary Cancer Predisposition Syndromes  | wrong population | round I |
| rayyan-661154109 | Immune cellular components and signaling pathways in the tumor microenvironment   | wrong population | round I |
| rayyan-661154111 | Genetic Changes in Ovarian Cancer   | wrong population | round I |
| rayyan-661154114 | Targeting the tumour microenvironment in platinum-resistant ovarian cancer  | wrong population | round I |
| rayyan-661154115 | Ovarian cancer: Novel molecular aspects for clinical assessment   | wrong population | round I |
| rayyan-661154116 | 25 - Nanoparticle and Targeted Systems for Colon Cancer Therapy   | wrong population | round I |
| rayyan-661154117 | Predictive markers in early research and companion diagnostic developments in oncology  | wrong population | round I |
| rayyan-661154118 | Molecular Biology of Head and Neck Cancer: Risks and Pathways   | wrong population | round I |
| rayyan-661154121 | Chapter 5 - Mucinous ovarian carcinomas   | wrong population | round I |
| rayyan-661154122 | Chapter 8A - Pancreatic cancer and premalignant tumors: Molecular aspects   | wrong population | round I |
| rayyan-661154123 | Turning tumors from cold to inflamed to improve immunotherapy response  | wrong population | round I |
| rayyan-661154125 | Genetic profiling of hepatocellular carcinoma using next-generation sequencing  | wrong population | round I |
| rayyan-661154126 | "The Dualistic Model of Ovarian Carcinogenesis: Revisited   | wrong population | round I |
| rayyan-661154129 | Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts                                   | wrong population | round I |
| rayyan-661154131 | Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach | wrong population | round I |
| rayyan-661154132 | Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary   | wrong population | round I |
| rayyan-661154133 | Combination of Novel Agents with Radiotherapy to Treat Rectal Cancer  | wrong population | round I |
| rayyan-661154134 | Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment   | wrong population | round I |
| rayyan-661154137 | Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma   | wrong population | round I |
| rayyan-661154138 | Sirtuins' control of autophagy and mitophagy in cancer  | wrong population | round I |
| rayyan-661154140 | HOX cluster-embedded micro-RNAs and cancer  | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661154141 | "Chapter 8 - Microbiota   | wrong population | round I |
| rayyan-661154142 | Pancreatic cancer   | wrong population | round I |
| rayyan-661154143 | Targeted therapies in germ cell tumors  | wrong population | round I |
| rayyan-661154144 | Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis                                  | wrong population | round I |
| rayyan-661154145 | Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance   | wrong population | round I |
| rayyan-661154146 | Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk  | wrong population | round I |
| rayyan-661154148 | The War on Cancer Rages On  | wrong population | round I |
| rayyan-661154149 | 89 - Cancers Arising in the Ovary   | wrong population | round I |
| rayyan-661154150 | 13 - Genetic and Epigenetic Alterations in Cancer   | wrong population | round I |
| rayyan-661154151 | Chapter 5 - Intracranial metastases   | wrong population | round I |
| rayyan-661154152 | Prognostic Factors and Differences in Survival of Right and Left Colon Carcinoma: A STROBE Compliant Retrospective Cohort Study           | wrong population | round I |
| rayyan-661154153 | Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications   | wrong population | round I |
| rayyan-661154156 | Pancreatic Carcinogenesis   | wrong population | round I |
| rayyan-661154157 | Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications                               | wrong population | round I |
| rayyan-661154161 | Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence                                    | wrong population | round I |
| rayyan-661154173 | Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine | wrong population | round I |
| rayyan-661154180 | Cancer-associated genodermatoses: Skin neoplasms as clues to hereditary tumor syndromes   | wrong population | round I |
| rayyan-661154183 | Ovarian cancer  | wrong population | round I |
| rayyan-661154184 | Genetics and epigenetics of adrenocortical tumors   | wrong population | round I |
| rayyan-661154189 | Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma                           | wrong population | round I |
| rayyan-661154191 | "Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past   | wrong population | round I |
| rayyan-661154203 | "Biologics  | wrong population | round I |
| rayyan-661154204 | Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma   | wrong population | round I |
| rayyan-661154209 | DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies  | wrong population | round I |
| rayyan-661154210 | Targeting TRK: A fast-tracked application of precision oncology and future directions   | wrong population | round I |
| rayyan-661154211 | Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment                                | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661154212 | Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials  | wrong population | round I |
| rayyan-661154214 | The Changing Face of Percutaneous Image-guided Biopsy: Molecular Profiling and Genomic Analysis in Current Practice   | wrong population | round I |
| rayyan-661154215 | Pathology of borderline and invasive cancers  | wrong population | round I |
| rayyan-661154216 | Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)  | wrong population | round I |
| rayyan-661154217 | Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients   | wrong population | round I |
| rayyan-661154218 | Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology   | wrong population | round I |
| rayyan-661154221 | "The biological complexity of urothelial carcinoma: Insights into carcinogenesis  | wrong population | round I |
| rayyan-661154222 | Chapter Two - The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer   | wrong population | round I |
| rayyan-661154225 | Dysregulation of ubiquitin ligases in cancer  | wrong population | round I |
| rayyan-661154226 | Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?  | wrong population | round I |
| rayyan-661154232 | Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients   | wrong population | round I |
| rayyan-661154233 | Targeted and immunotherapy in the era of personalised gastric cancer treatment  | wrong population | round I |
| rayyan-661154235 | Hereditary Ovarian Cancer and Risk Reduction  | wrong population | round I |
| rayyan-661154237 | Clinicopathological and prognostic significance of PD-L1 expression in colon adenocarcinoma tumor budding   | wrong population | round I |
| rayyan-661154238 | Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment  | wrong population | round I |
| rayyan-661154241 | Therapy of Primary Liver Cancer   | wrong population | round I |
| rayyan-661154242 | Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study | wrong population | round I |
| rayyan-661154248 | Endometriosis-associated ovarian cancer: What have we learned so far?   | wrong population | round I |
| rayyan-661154249 | microRNAs as pharmacological targets in cancer  | wrong population | round I |
| rayyan-661154251 | Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?  | wrong population | round I |
| rayyan-661154255 | Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?  | wrong population | round I |
| rayyan-661154257 | Spatiotemporal heterogeneity and clinical challenge of pancreatic neuroendocrine tumors   | wrong population | round I |
| rayyan-661154261 | Biomarkers for predicting the outcome of various cancer immunotherapies   | wrong population | round I |
| rayyan-661154262 | Current Controversies in the Management of Colon Cancer   | wrong population | round I |
| rayyan-661154263 | "Pathogenesis   | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154266 | "27 - Molecular oncology in gynecologic cancer: Immunologic Response   | wrong population | round I |
| rayyan-661154268 | 6.05 - Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids                               | wrong population | round I |
| rayyan-661154271 | Circulating Methylated Septin 9 Nucleic Acid in the Plasma of Patients with Gastrointestinal Cancer in the Stomach and Colon         | wrong population | round I |
| rayyan-661154273 | Retinal toxicities of systemic anticancer drugs  | wrong population | round I |
| rayyan-661154274 | Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases  | wrong population | round I |
| rayyan-661154278 | Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021                                     | wrong population | round I |
| rayyan-661154280 | Molecular diagnostics and biomarkers in cholangiocarcinoma   | wrong population | round I |
| rayyan-661154284 | Updates and emerging therapies for rare epithelial ovarian cancers: One size no longer fits all                                      | wrong population | round I |
| rayyan-661154289 | Chapter 35 - Molecular Assessment of Ovarian Cancer and Translation to Clinical Management   | wrong population | round I |
| rayyan-661154292 | Ovarian Cancer: Pathology and Genetics   | wrong population | round I |
| rayyan-661154296 | Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade   | wrong population | round I |
| rayyan-661154300 | Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy  | wrong population | round I |
| rayyan-661154302 | Clinical treatment of cholangiocarcinoma: an updated comprehensive review  | wrong population | round I |
| rayyan-661154304 | Mucinous Colloid Carcinoma of the Colon Metastatic to the Breast   | wrong population | round I |
| rayyan-661154307 | Chapter 14 - Cancer Vaccines   | wrong population | round I |
| rayyan-661154310 | Endometrial cancer: Molecular markers and management of advanced stage disease   | wrong population | round I |
| rayyan-661154313 | Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC   | wrong population | round I |
| rayyan-661154315 | Update on current problems in colorectal liver metastasis  | wrong population | round I |
| rayyan-661154317 | Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications                                  | wrong population | round I |
| rayyan-661154319 | Progress and challenges in gastroesophageal cancer   | wrong population | round I |
| rayyan-661154321 | Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer                                    | wrong population | round I |
| rayyan-661154323 | Genomic insights in gynecologic cancer   | wrong population | round I |
| rayyan-661154324 | Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology                     | wrong population | round I |
| rayyan-661154325 | Translational genomics of sinonasal cancers  | wrong population | round I |
| rayyan-661154326 | TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions  | wrong population | round I |
| rayyan-661154327 | TGF- $\beta$ 2 Receptor Inactivation and Mutant Kras Induce Intestinal Neoplasms in Mice via a $\beta$ 2-Catenin-Independent Pathway | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154328 | Looking beyond drivers and passengers in cancer genome sequencing data   | wrong population | round I |
| rayyan-661154331 | Emerging avenues linking inflammation and cancer   | wrong population | round I |
| rayyan-661154334 | Biomarker discovery and application“An opportunity to resolve the challenge of liver cancer diagnosis and treatment  | wrong population | round I |
| rayyan-661154335 | Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors  | wrong population | round I |
| rayyan-661154340 | Identifying patients with NTRK fusion cancer   | wrong population | round I |
| rayyan-661154346 | Emerging biomarkers for cancer immunotherapy in melanoma   | wrong population | round I |
| rayyan-661154348 | Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer  | wrong population | round I |
| rayyan-661154350 | Endoscopic polypectomy for malignant polyps: Should tumor location (right versus left side) guide clinical decisions?  | wrong population | round I |
| rayyan-661154352 | Brain malignancies: Glioblastoma and brain metastases  | wrong population | round I |
| rayyan-661154356 | Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial                                     | wrong population | round I |
| rayyan-661154357 | Genetic mutations in gynaecological cancers  | wrong population | round I |
| rayyan-661154358 | Oncogenic Signaling Pathways in The Cancer Genome Atlas  | wrong population | round I |
| rayyan-661154359 | Modeling Human Digestive Diseases With CRISPR-Cas9“Modified Organoids  | wrong population | round I |
| rayyan-661154362 | Epigenetics and therapeutic targets in gastrointestinal malignancies   | wrong population | round I |
| rayyan-661154366 | Chapter 10 - Overcoming chemotherapy resistance in endometrial cancer  | wrong population | round I |
| rayyan-661154367 | Quantitative proteomic analysis of paired colorectal cancer and non-tumorigenic tissues reveals signature proteins and perturbed pathways involved in CRC progression and metastasis | wrong population | round I |
| rayyan-661154368 | A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy   | wrong population | round I |
| rayyan-661154371 | Genetics of Pancreatic Cancer and Its Implications on Therapy  | wrong population | round I |
| rayyan-661154372 | Novel biomarkers in bladder cancer   | wrong population | round I |
| rayyan-661154373 | Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma   | wrong population | round I |
| rayyan-661154374 | Chapter 8 - Linking oxidative stress and ovarian cancers   | wrong population | round I |
| rayyan-661154381 | Insight updating of the molecular hallmarks in ovarian carcinoma   | wrong population | round I |
| rayyan-661154382 | "Identification of CRKL as an oncogenic biomarker for prognosis and immunotherapy in melanoma  | wrong population | round I |
| rayyan-661154383 | "Management of Stage IV rectal disease “ How to incorporate radiation therapy  | wrong population | round I |
| rayyan-661154385 | Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154390 | Dysregulated FOXM1 signaling in the regulation of cancer stem cells  | wrong population | round I |
| rayyan-661154391 | Evolving role of regorafenib for the treatment of advanced cancers   | wrong population | round I |
| rayyan-661154392 | Integrative Clinical Genomics of Advanced Prostate Cancer  | wrong population | round I |
| rayyan-661154393 | Cell-free DNA in the blood as a solid tumor biomarker”A critical appraisal of the literature   | wrong population | round I |
| rayyan-661154395 | Chapter 22 - Neurological complications of GI cancers  | wrong population | round I |
| rayyan-661154397 | "Obesity   | wrong population | round I |
| rayyan-661154401 | Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists   | wrong population | round I |
| rayyan-661154402 | When should we order a next generation sequencing test in a patient with cancer?   | wrong population | round I |
| rayyan-661154404 | Cancer of Unknown Primary in the Molecular Era   | wrong population | round I |
| rayyan-661154405 | High expression of meningioma 1 is correlated with reduced survival rates in colorectal cancer patients  | wrong population | round I |
| rayyan-661154409 | Advances in the systemic treatment of therapeutic approaches in biliary tract cancer   | wrong population | round I |
| rayyan-661154410 | A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology                          | wrong population | round I |
| rayyan-661154416 | Proteome biology of primary colorectal carcinoma and corresponding liver metastases  | wrong population | round I |
| rayyan-661154418 | Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement   | wrong population | round I |
| rayyan-661154419 | ETS transcription factors: Multifaceted players from cancer progression to tumor immunity  | wrong population | round I |
| rayyan-661154420 | "Molecular pathogenesis  | wrong population | round I |
| rayyan-661154422 | Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications  | wrong population | round I |
| rayyan-661154425 | Capturing cancer evolution using genetically engineered mouse models (GEMMs)   | wrong population | round I |
| rayyan-661154430 | Low frequency of somatic mutations in uterine sarcomas: A molecular analysis and review of the literature  | wrong population | round I |
| rayyan-661154432 | Health-Promoting Lifestyle in Colorectal Cancer Survivors: A Qualitative Study on the Experiences and Perspectives of Colorectal Cancer Survivors and Healthcare Providers | wrong population | round I |
| rayyan-661154438 | Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer  | wrong population | round I |
| rayyan-661154448 | Molecular mechanistic pathway of colorectal carcinogenesis associated with intestinal microbiota   | wrong population | round I |
| rayyan-661154451 | Molecular pathogenesis of gallbladder cancer: An update  | wrong population | round I |
| rayyan-661154452 | Intrathyroid thymic carcinoma: A clinicopathological analysis of 22 cases  | wrong population | round I |
| rayyan-661154453 | Not all cancers are created equal: Tissue specificity in cancer genes and pathways   | wrong population | round I |



|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154454 | Use of molecular markers for predicting therapy response in cancer patients  | wrong population | round I |
| rayyan-661154455 | Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review  | wrong population | round I |
| rayyan-661154456 | A genome-wide assessment of variations of primary colorectal cancer maintained in metastases   | wrong population | round I |
| rayyan-661154457 | A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract   | wrong population | round I |
| rayyan-661154459 | Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges   | wrong population | round I |
| rayyan-661154460 | "Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX)   | wrong population | round I |
| rayyan-661154463 | Predicting liver metastases growth patterns: Current status and future possibilities   | wrong population | round I |
| rayyan-661154465 | Molecular targets and biological modifiers in gastric cancer   | wrong population | round I |
| rayyan-661154466 | Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance   | wrong population | round I |
| rayyan-661154467 | "Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer | wrong population | round I |
| rayyan-661154471 | Altered RECQ Helicase Expression in Sporadic Primary Colorectal Cancers  | wrong population | round I |
| rayyan-661154475 | "Primary tumor type prediction based on US nationwide genomic profiling data in 13   | wrong population | round I |
| rayyan-661154477 | The impact of recent next generation sequencing and the need for a new classification in gastric cancer  | wrong population | round I |
| rayyan-661154478 | Ibuprofen Inhibits Colitis-Induced Overexpression of TumorRelated Rac1b  | wrong population | round I |
| rayyan-661154480 | DNA methylation in breast and colorectal cancers   | wrong population | round I |
| rayyan-661154481 | Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma   | wrong population | round I |
| rayyan-661154482 | The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer  | wrong population | round I |
| rayyan-661154483 | Survival outcomes for right-versus left-sided colon cancer and rectal cancer in England: A propensity-score matched population-based cohort study  | wrong population | round I |
| rayyan-661154484 | Chapter Two - Wnt/ $\beta$ 2 Catenin-Mediated Signaling Commonly Altered in Colorectal Cancer  | wrong population | round I |
| rayyan-661154486 | "Development of Rationally Designed  | wrong population | round I |
| rayyan-661154487 | Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer   | wrong population | round I |
| rayyan-661154488 | "Methylation analysis of APC   | wrong population | round I |
| rayyan-661154491 | Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features  | wrong population | round I |
| rayyan-661154495 | Molecular Diagnostics in the Neoplasms of Small Intestine and Appendix: 2018 Update  | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661154497 | Influence of the primary tumour location in patients undergoing surgery for colorectal liver metastases   | wrong population | round I |
| rayyan-661154499 | Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis                                | wrong population | round I |
| rayyan-661154506 | RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells  | wrong population | round I |
| rayyan-661154509 | Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine  | wrong population | round I |
| rayyan-661154510 | Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer   | wrong population | round I |
| rayyan-661154514 | The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma  | wrong population | round I |
| rayyan-661154518 | Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins  | wrong population | round I |
| rayyan-661154520 | Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors  | wrong population | round I |
| rayyan-661154521 | Endometrial carcinoma: pathology and genetics   | wrong population | round I |
| rayyan-661154522 | Pervasive conditional selection of driver mutations and modular epistasis networks in cancer  | wrong population | round I |
| rayyan-661154527 | Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation  | wrong population | round I |
| rayyan-661154528 | Does the site of primary colorectal cancer influence the outcome after resection of isolated liver metastases?  | wrong population | round I |
| rayyan-661154531 | The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management  | wrong population | round I |
| rayyan-661154532 | Decoding colorectal cancer epigenomics  | wrong population | round I |
| rayyan-661154535 | Discovery of Aberrant Alteration of Genome in Colorectal Cancer by Exome Sequencing   | wrong population | round I |
| rayyan-661154536 | Is More Not Better?: Combination Therapies in Colorectal Cancer Treatment   | wrong population | round I |
| rayyan-661154544 | Impact of molecular markers on treatment selection in advanced colorectal cancer  | wrong population | round I |
| rayyan-661154545 | ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group                              | wrong population | round I |
| rayyan-661154547 | Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix            | wrong population | round I |
| rayyan-661154551 | "Mouse models in colon cancer   | wrong population | round I |
| rayyan-661154555 | Molecular profiling of longitudinally observed small colorectal polyps: A cohort study  | wrong population | round I |
| rayyan-661154557 | Clinicopathologic and genetic characteristics of interval colorectal carcinomas favor origin from missed or incompletely excised precursors                                     | wrong population | round I |
| rayyan-661154558 | Hypoxia induced deregulation of sphingolipids in colon cancer is a prognostic marker for patient outcome  | wrong population | round I |
| rayyan-661154559 | MicroRNA-nanoparticles against cancer: Opportunities and challenges for personalized medicine   | wrong population | round I |
| rayyan-661154562 | Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154567 | NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis   | wrong population | round I |
| rayyan-661154568 | "KRAS and aneusomy of chromosomes 4  | wrong population | round I |
| rayyan-661154574 | Identification of recurrent mutational events in anorectal melanoma  | wrong population | round I |
| rayyan-661154577 | Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer   | wrong population | round I |
| rayyan-661154584 | Molecular Carcinogenesis of Endometrial Cancer   | wrong population | round I |
| rayyan-661154586 | First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: the Phase II CheckMate 142 Study  | wrong population | round I |
| rayyan-661154587 | "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label   | wrong population | round I |
| rayyan-661154589 | Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer   | wrong population | round I |
| rayyan-661154590 | The role of genetic instability in stimulation of angiogenesis in liver metastases of sporadic colorectal cancer   | wrong population | round I |
| rayyan-661154594 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer  | wrong population | round I |
| rayyan-661154597 | Meat consumption and BRAF mutation status in colorectal cancer   | wrong population | round I |
| rayyan-661154598 | Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008) | wrong population | round I |
| rayyan-661154599 | Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer   | wrong population | round I |
| rayyan-661154602 | Pembrolizumab vs Chemotherapy in Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer   | wrong population | round I |
| rayyan-661154603 | Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation  | wrong population | round I |
| rayyan-661154604 | Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer  | wrong population | round I |
| rayyan-661154605 | Development and Interpretation of a Clinicopathological-Based Model for the Identification of Microsatellite Instability in Colorectal Cancer  | wrong population | round I |
| rayyan-661154606 | Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients  | wrong population | round I |
| rayyan-661154607 | Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer  | wrong population | round I |
| rayyan-661154608 | Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: a Randomized Clinical Trial  | wrong population | round I |
| rayyan-661154610 | Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy   | wrong population | round I |
| rayyan-661154612 | "Tumor mutational load   | wrong population | round I |
| rayyan-661154613 | Genotype-environment interactions in microsatellite stable/microsatellite instability-low colorectal cancer: results from a genome-wide association study  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154614 | Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer   | wrong population | round I |
| rayyan-661154615 | Oncologists' selection of genetic and molecular testing in the evolving landscape of stage II colorectal cancer  | wrong population | round I |
| rayyan-661154616 | The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer   | wrong population | round I |
| rayyan-661154617 | "Pathological Features   | wrong population | round I |
| rayyan-661154618 | Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF   | wrong population | round I |
| rayyan-661154619 | Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colon Cancer   | wrong population | round I |
| rayyan-661154620 | Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women  | wrong population | round I |
| rayyan-661154621 | Deficient mismatch repair system in patients with sporadic advanced colorectal cancer  | wrong population | round I |
| rayyan-661154622 | P-35 Zanzalintinib (XL092) in combination with atezolizumab for previously treated metastatic colorectal cancer  | wrong population | round I |
| rayyan-661154623 | Pilot study: high dose fish oil in colorectal cancer (CRC) prevention in patients with lynch syndrome  | wrong population | round I |
| rayyan-661154624 | "A Study of Nivolumab  | wrong population | round I |
| rayyan-661154625 | O-8 Final overall survival for the phase 3 KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer                                    | wrong population | round I |
| rayyan-661154627 | P-27 Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer   | wrong population | round I |
| rayyan-661154628 | "Single-nucleotide variants  | wrong population | round I |
| rayyan-661154629 | Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: asia subgroup results of the phase III KEYNOTE-177 study                        | wrong population | round I |
| rayyan-661154630 | The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer                       | wrong population | round I |
| rayyan-661154631 | Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomised phase II trial                                   | wrong population | round I |
| rayyan-661154632 | "Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability   | wrong population | round I |
| rayyan-661154634 | EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French Perspective | wrong population | round I |
| rayyan-661154635 | Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases  | wrong population | round I |
| rayyan-661154637 | ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective  | wrong population | round I |
| rayyan-661154639 | A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility   | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661154640 | Urachal carcinoma: The journey so far and the road ahead  | wrong population | round I |
| rayyan-661154644 | Precision Oncology in Pediatric Cancer Surgery  | wrong population | round I |
| rayyan-661154646 | Meeting report from the joint IARC–NCI international cancer seminar series: a focus on colorectal cancer  | wrong population | round I |
| rayyan-661154649 | Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation   | wrong population | round I |
| rayyan-661154650 | Chapter 24 - Molecular testing in lung cancer   | wrong population | round I |
| rayyan-661154651 | Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis  | wrong population | round I |
| rayyan-661154653 | c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival  | wrong population | round I |
| rayyan-661154654 | The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome  | wrong population | round I |
| rayyan-661154655 | Unveiling the role of KRAS in tumor immune microenvironment   | wrong population | round I |
| rayyan-661154657 | Comprehensive genomic profiling of small bowel adenocarcinoma by tissue and plasma biopsy   | wrong population | round I |
| rayyan-661154658 | Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials | wrong population | round I |
| rayyan-661154659 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group                       | wrong population | round I |
| rayyan-661154666 | Combination therapies with HSP90 inhibitors against colorectal cancer   | wrong population | round I |
| rayyan-661154668 | Chemotherapy of metastatic colon cancer in France: A population-based study   | wrong population | round I |
| rayyan-661154669 | Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?  | wrong population | round I |
| rayyan-661154670 | Curcuma as an adjuvant in colorectal cancer treatment   | wrong population | round I |
| rayyan-661154672 | "Relation between expression of hMLH1 and p53 mRNA genes  | wrong population | round I |
| rayyan-661154675 | Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases  | wrong population | round I |
| rayyan-661154676 | Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study                               | wrong population | round I |
| rayyan-661154677 | Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?   | wrong population | round I |
| rayyan-661154678 | Rational development of combination therapies for biliary tract cancers   | wrong population | round I |
| rayyan-661154679 | Correlation of polypoid colorectal adenocarcinoma with pre-existing adenomatous polyps and KRAS mutation  | wrong population | round I |
| rayyan-661154680 | Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation                              | wrong population | round I |
| rayyan-661154683 | The pattern of peritoneal colorectal metastasis predicts survival after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154684 | Chapter 9 - Targeted therapy and drug resistance in gastric and pancreatic cancer  | wrong population | round I |
| rayyan-661154685 | LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO-PRODIGE 54 randomised phase II trial  | wrong population | round I |
| rayyan-661154686 | "Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised   | wrong population | round I |
| rayyan-661154687 | Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial   | wrong population | round I |
| rayyan-661154689 | Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)  | wrong population | round I |
| rayyan-661154690 | A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States  | wrong population | round I |
| rayyan-661154691 | CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer   | wrong population | round I |
| rayyan-661154692 | In-depth clinical and biological exploration of DNA damage immune response as a biomarker for oxaliplatin use in colorectal cancer   | wrong population | round I |
| rayyan-661154693 | PS1-2 Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: asia subgroup of phase 3 KEYNOTE-177   | wrong population | round I |
| rayyan-661154694 | Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy  | wrong population | round I |
| rayyan-661154695 | O7-3 Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup  | wrong population | round I |
| rayyan-661154696 | KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer  | wrong population | round I |
| rayyan-661154697 | A phase Ib biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer   | wrong population | round I |
| rayyan-661154698 | Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer   | wrong population | round I |
| rayyan-661154700 | Pharmacogenomic Study for Individual Response to CPT-11 in Colorectal Cancer Patients (Step 2)   | wrong population | round I |
| rayyan-661154701 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer   | wrong population | round I |
| rayyan-661154702 | Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system | wrong population | round I |
| rayyan-661154703 | Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer   | wrong population | round I |
| rayyan-661154704 | AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer   | wrong population | round I |
| rayyan-661154705 | Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: biomarker Analyses From LUME-Colon 1   | wrong population | round I |
| rayyan-661154706 | Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: results from two prospective cohorts and CALGB 89803 (Alliance) trial  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154707 | Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: the Canadian Cancer Trials Group CO.26 Study  | wrong population | round I |
| rayyan-661154708 | Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)  | wrong population | round I |
| rayyan-661154709 | HCRN GI16-288: a phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer   | wrong population | round I |
| rayyan-661154710 | "Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1   | wrong population | round I |
| rayyan-661154712 | A study on microsatellite instability status for colorectal serrated lesions   | wrong population | round I |
| rayyan-661154713 | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Metastatic Cancer  | wrong population | round I |
| rayyan-661154714 | Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation   | wrong population | round I |
| rayyan-661154715 | Association of high microsatellite instability (MSI-H) with a high immunoscore (IS) compared to PD-L1 expression and increased survival in patients (pts) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (Ox) and fluoropyrimidine (FP): a pooled analysis of the AIO KRK 0207 and RO91 trials  | wrong population | round I |
| rayyan-661154717 | Circulating tumor DNA analysis for predictive and prognostic factors in patients with metastatic colorectal cancer: an exploratory analysis from the phase III PARADIGM study  | wrong population | round I |
| rayyan-661154718 | STELLAR-303: a phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)  | wrong population | round I |
| rayyan-661154719 | "Efficacy and safety results from IMblaze370   | wrong population | round I |
| rayyan-661154720 | "A global  | wrong population | round I |
| rayyan-661154722 | NRG-GI004/SWOG-S1610: colorectal cancer metastatic dMMR immunotherapy (COMMIT) study-A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC) | wrong population | round I |
| rayyan-661154725 | Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503   | wrong population | round I |
| rayyan-661154728 | SEAMARK: randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC)  | wrong population | round I |
| rayyan-661154729 | "A phase III study of nivolumab (NIVO)   | wrong population | round I |
| rayyan-661154730 | "Nivolumab ± ipilimumab treatment (Tx) efficacy  | wrong population | round I |
| rayyan-661154731 | Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group   | wrong population | round I |
| rayyan-661154732 | "Microsatellite instability (MSI)  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154733 | "Neoadjuvant PD-1 blockade with toripalimab  | wrong population | round I |
| rayyan-661154734 | "Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label  | wrong population | round I |
| rayyan-661154735 | LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study  | wrong population | round I |
| rayyan-661154737 | Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): phase III KEYNOTE-177 study | wrong population | round I |
| rayyan-661154738 | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer   | wrong population | round I |
| rayyan-661154739 | BRAF V600E-mutant and MSI-H Metastatic Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus Pembrolizumab Compared to Pembrolizumab Alone  | wrong population | round I |
| rayyan-661154740 | KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial  | wrong population | round I |
| rayyan-661154741 | "Association Between Baseline Circulating Tumor Cells  | wrong population | round I |
| rayyan-661154742 | AVEVAC: a phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)  | wrong population | round I |
| rayyan-661154743 | A Study of Novel Oncology Therapies in Combination with FOLFOX and Bevacizumab in Metastatic Microsatellite-Stable Colorectal Cancer   | wrong population | round I |
| rayyan-661154744 | Hide and Seek with Hereditary Cancer: improving detection of colorectal cancer patients with a high risk of Lynch syndrome   | wrong population | round I |
| rayyan-661154745 | 506TiP Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): phase III LEAP-017 study  | wrong population | round I |
| rayyan-661154747 | Microsatellite instability and cytogenetic survey in myeloid leukemias   | wrong population | round I |
| rayyan-661154749 | "Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre  | wrong population | round I |
| rayyan-661154751 | Local ablation of liver and lung metastases in patients with colorectal cancer after failure of first- or later-line systemic chemotherapy – a prospective trial   | wrong population | round I |
| rayyan-661154752 | A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: a Clinical Trial Protocol   | wrong population | round I |
| rayyan-661154753 | Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting  | wrong population | round I |
| rayyan-661154755 | Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): final results of the phase II AVETUX trial (AIO-KRK-0216)   | wrong population | round I |
| rayyan-661154756 | BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): results from phase III TRIBE and FIRE-3 trials   | wrong population | round I |
| rayyan-661154757 | "P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated   | wrong population | round I |
| rayyan-661154758 | P-23 Phase II study (daNIS-3) of the anti- $\text{TGF-}\beta^2$ monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy   | wrong population | round I |



|                  |  |                  |         |
|------------------|--|------------------|---------|
|                  | vs standard-of-care alone in patients with second-line metastatic colorectal cancer  |                  |         |
| rayyan-661154759 | P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1“positive metastatic colorectal cancer (mCRC)  | wrong population | round I |
| rayyan-661154760 | Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials | wrong population | round I |
| rayyan-661154762 | "Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes   | wrong population | round I |
| rayyan-661154764 | 2020 ASCO Annual Meeting II  | wrong population | round I |
| rayyan-661154765 | Abstract Book of the 19th National Congress of Medical Oncology  | wrong population | round I |
| rayyan-661154766 | Linked color imaging improves detection rate of sessile serrated adenoma/polyp in the colon: a prospective randomized controlled trial   | wrong population | round I |
| rayyan-661154767 | "ENVASARC: a pivotal trial of envafolimab  | wrong population | round I |
| rayyan-661154768 | "Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre  | wrong population | round I |
| rayyan-661154769 | Effectiveness of each Bethesda marker in defining microsatellite instability when screening for Lynch syndrome   | wrong population | round I |
| rayyan-661154771 | Effects of a decision support intervention on decisional conflict associated with microsatellite instability testing   | wrong population | round I |
| rayyan-661154772 | CAVE-2 (Cetuximab-AVElumab) mCRC: a Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients   | wrong population | round I |
| rayyan-661154773 | Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial  | wrong population | round I |
| rayyan-661154774 | "RELATIVITY-123: a phase 3   | wrong population | round I |
| rayyan-661154775 | "Phase 2   | wrong population | round I |
| rayyan-661154776 | FDA Approval Summary: pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma  | wrong population | round I |
| rayyan-661154777 | "A multicenter randomized phase 2 study to compare the efficacy and safety of avelumab versus standard second line treatment   | wrong population | round I |
| rayyan-661154782 | Distinct clinical and genetic mutation characteristics in sporadic and Lynch syndrome-associated endometrial cancer in a Chinese population  | wrong population | round I |
| rayyan-661154785 | Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019)  | wrong population | round I |
| rayyan-661154786 | Total neoadjuvant therapy in rectal cancer: the evidence and expectations  | wrong population | round I |
| rayyan-661154790 | Coiled-coil domain-containing 154 promotes colorectal cancer proliferation and metastasis via interacting with minichromosome maintenance complex component 2  | wrong population | round I |
| rayyan-661154793 | Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras)   | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661154794 | Racial differences in colorectal cancer survival at a safety net hospital   | wrong population | round I |
| rayyan-661154795 | Chapter 9 - Rac1b: An emerging therapeutic target for chemoresistance in colorectal cancer  | wrong population | round I |
| rayyan-661154798 | The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis                             | wrong population | round I |
| rayyan-661154805 | Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma                     | wrong population | round I |
| rayyan-661154806 | Chapter 46 - Signaling pathways in CRC  | wrong population | round I |
| rayyan-661154807 | The genetic factors associated with Wnt signaling pathway in colorectal cancer  | wrong population | round I |
| rayyan-661154808 | Chapter 2 - Translational epigenetics in precision medicine of colorectal cancer  | wrong population | round I |
| rayyan-661154809 | Chapter 89 - Vitamin D and colorectal cancer  | wrong population | round I |
| rayyan-661154811 | Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study | wrong population | round I |
| rayyan-661154815 | Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma  | wrong population | round I |
| rayyan-661154821 | An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer   | wrong population | round I |
| rayyan-661154825 | Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas     | wrong population | round I |
| rayyan-661154826 | Wnt/ $\beta$ -catenin signaling in colorectal cancer: Is therapeutic targeting even possible?   | wrong population | round I |
| rayyan-661154829 | "Outcomes of Patients With Colorectal Liver Metastasis in the Developing World: Is Liver Transplantation for Unresectable Liver Metastasis                            | wrong population | round I |
| rayyan-661154831 | "Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100  | wrong population | round I |
| rayyan-661154832 | A perspective on medicinal chemistry approaches towards adenomatous polyposis coli and Wnt signal based colorectal cancer inhibitors                                  | wrong population | round I |
| rayyan-661154834 | Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets  | wrong population | round I |
| rayyan-661154839 | Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF-mutated serrated lesions   | wrong population | round I |
| rayyan-661154840 | Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)                         | wrong population | round I |
| rayyan-661154841 | Clinical and Molecular Biologic Characteristics of Early-onset Versus Late-onset Colorectal Carcinoma in Filipinos  | wrong population | round I |
| rayyan-661154842 | Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer  | wrong population | round I |
| rayyan-661154843 | Impact of high-risk features for stage II adenocarcinoma of the appendix  | wrong population | round I |
| rayyan-661154844 | Camrelizumab and apatinib combined with chemotherapy (mFOLFOX6) as neoadjuvant therapy for locally advanced right-sided colon cancer (ambition)                       | wrong population | round I |
| rayyan-661154848 | The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs   | wrong population | round I |
| rayyan-661154850 | Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: a Nonrandomized Controlled Trial                    | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661154851 | Phase 2 Basket study of Pembrolizumab or MK1308A in mCRC   | wrong population | round I |
| rayyan-661154852 | A clinical trial to evaluate the mechanism of action and the safety of the cancer vaccine L-BLP25 in rectal cancer subjects undergoing treatment with chemotherapy and radiotherapy              | wrong population | round I |
| rayyan-661154853 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy  | wrong population | round I |
| rayyan-661154854 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | wrong population | round I |
| rayyan-661154855 | Endoscopic Surveillance in Serrated Polyposis Syndrome and Low-risk of Advanced Neoplasia  | wrong population | round I |
| rayyan-661154981 | Early screening for colorectal cancer via a simple blood sample  | wrong population | round I |
| rayyan-661154982 | Comparative analysis of the protective effect of different screening strategies for colorectal cancer  | wrong population | round I |
| rayyan-661154983 | Intestinal cancer and the risk for other cancer in the same person   | wrong population | round I |
| rayyan-661154984 | Could supported weight loss reduce bowel cancer surgery complications?   | wrong population | round I |
| rayyan-661154985 | Exercise prehabilitation in colorectal cancer  | wrong population | round I |
| rayyan-661154988 | Quality of life after surgery and other options to prevent cancer of the lining of the womb (endometrial cancer)   | wrong population | round I |
| rayyan-661155008 | COLO-DETECT: Can an artificial intelligence device increase detection of polyps during colonoscopy?  | wrong population | round I |
| rayyan-661155009 | The effect of a dietary intervention with rice bran on intestinal health among adults at high risk of colorectal cancer  | wrong population | round I |
| rayyan-661155010 | "Scaling Colorectal cancer screening through Outreach  | wrong population | round I |
| rayyan-661155011 | Planning using MRI for anal and rectal cancer radiotherapy treatment   | wrong population | round I |
| rayyan-661155012 | "A randomised multicenter clinical trial for patients with multi-organ   | wrong population | round I |
| rayyan-661155014 | APHRODITE - A phase II trial of higher radiotherapy dose in the eradication of early rectal cancer   | wrong population | round I |
| rayyan-661155015 | Participation in colorectal cancer screening among asymptomatic average-risk Chinese aged 50 to 75: A population-based survey  | wrong population | round I |
| rayyan-661155016 | Testing the effectiveness of a new screening system for colorectal cancer screening: a community trial   | wrong population | round I |
| rayyan-661155018 | Can neurotensin and IL-8 levels in blood be used to identify colorectal (large bowel) cancer and adenomas (polyps)?  | wrong population | round I |
| rayyan-661155019 | Detection of bowel cancer using urinary biomarkers   | wrong population | round I |
| rayyan-661155020 | Evaluation of colon cancer screening on colon cancer mortality   | wrong population | round I |
| rayyan-661155021 | Yorkshire Cancer Research Bowel Cancer Improvement Program   | wrong population | round I |
| rayyan-661155022 | Psychological determiners of distincts fatigue trajectories in colorectal patients undergoing chemotherapy   | wrong population | round I |
| rayyan-661155023 | A decision aid for helping people to decide about colorectal cancer screening  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155024 | Short term Water-only Fasting prior to chemotherapy Trial (SWiFT)  | wrong population | round I |
| rayyan-661155025 | Comparing two optical technologies when screening for bowel cancer: a trial from several UK hospitals  | wrong population | round I |
| rayyan-661155026 | Handicraft classes for colorectal cancer patients with chemotherapy-induced neuropathy: improving neuropathic symptoms in hands through exercising the hand muscles  | wrong population | round I |
| rayyan-661155027 | Effect of a family-based multimedia program on the utilisation rate of colorectal cancer screening among South Asian older adults in Hong Kong   | wrong population | round I |
| rayyan-661155028 | Does intravenous lidocaine speed up gut recovery after large bowel surgery?  | wrong population | round I |
| rayyan-661155029 | Factors impacting on prognosis and treatment in patients with liver and lung metastases from colorectal cancer   | wrong population | round I |
| rayyan-661155030 | Raman spectroscopy and colorectal cancer   | wrong population | round I |
| rayyan-661155031 | FITâ€” Can a Dipstick Test Rule Out Bowel Cancer?  | wrong population | round I |
| rayyan-661155032 | Trifluridine/tipiracil (FTD/TPI) quality of life study in mCRC patients  | wrong population | round I |
| rayyan-661155033 | Personalised risk information and its impact on informed choice and intention to undergo colonoscopy in the Scottish Bowel Screening Programme   | wrong population | round I |
| rayyan-661155034 | Saliva to predict risk of disease using transcriptomics and epigenetics  | wrong population | round I |
| rayyan-661155036 | Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer   | wrong population | round I |
| rayyan-661155038 | Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set | wrong population | round I |
| rayyan-661155041 | Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases  | wrong population | round I |
| rayyan-661155046 | External validation of COMPASS and BIOSCOPE prognostic scores in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)   | wrong population | round I |
| rayyan-661155052 | Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer  | wrong population | round I |
| rayyan-661155054 | "Genomic characterization of metastatic patterns from prospective clinical sequencing of 25  | wrong population | round I |
| rayyan-661155055 | Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer  | wrong population | round I |
| rayyan-661155057 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155059 | Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use   | wrong population | round I |
| rayyan-661155060 | Gene heterogeneity in metastasis of colorectal cancer to the lung  | wrong population | round I |
| rayyan-661155062 | "Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer  | wrong population | round I |
| rayyan-661155064 | Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines  | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661155065 | Acquired resistance to EGFR-targeted therapies in colorectal cancer   | wrong population | round I |
| rayyan-661155066 | "TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated             | wrong population | round I |
| rayyan-661155072 | Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis  | wrong population | round I |
| rayyan-661155076 | Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS   | wrong population | round I |
| rayyan-661155078 | Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting   | wrong population | round I |
| rayyan-661155080 | "Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO"ESMO initiative endorsed by CSCO          | wrong population | round I |
| rayyan-661155082 | Emerging paradigms in the treatment of liver metastases in colorectal cancer  | wrong population | round I |
| rayyan-661155083 | NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas   | wrong population | round I |
| rayyan-661155084 | Treatment of Liver Metastases With Focused Ultrasound and Microbubbles in Patients With Colorectal Cancer Receiving Chemotherapy                                | wrong population | round I |
| rayyan-661155085 | A Study on the accuracy and development of best practices using fluorescence for precision surgery in colorectal cancer   | wrong population | round I |
| rayyan-661155086 | IntAct- IFA to prevent anastomotic leak in rectal cancer surgery  | wrong population | round I |
| rayyan-661155087 | Investigating the use of a new fluorescent compound to identify pre cancerous and cancerous lesions in the bowel  | wrong population | round I |
| rayyan-661155088 | The CReST2 Trial: Are uncovered or covered stents more effective in relieving bowel obstruction in people with colorectal cancer                                | wrong population | round I |
| rayyan-661155089 | Cancer detection by analysing non-invasively collected colorectal mucus   | wrong population | round I |
| rayyan-661155090 | Study of efficacy and safety of S 95005 (TAS-102) in patients with metastatic colorectal cancer who failed standard chemotherapies                              | wrong population | round I |
| rayyan-661155091 | Supportive exercise programmes for accelerating recovery after major abdominal cancer surgery   | wrong population | round I |
| rayyan-661155092 | Assessing the impact of a new fit test in the context of a population based organized screening programme for colorectal cancer                                 | wrong population | round I |
| rayyan-661155093 | Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancer  | wrong population | round I |
| rayyan-661155094 | Phase I study of S 95005 in combination with oxaliplatin in metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155095 | Measuring omega-3 fatty acid levels in terminal ileal content following four weeks of omega-3 fatty acid supplementation in patients with a temporary ileostomy | wrong population | round I |
| rayyan-661155096 | A personal electronic health record (PEPA)  | wrong population | round I |
| rayyan-661155097 | The MAGENTA trial: The molecular biology of metastatic cancer   | wrong population | round I |
| rayyan-661155100 | Assessing the additional benefit of an innovative imaging system for colonoscopy  | wrong population | round I |
| rayyan-661155101 | General practice endorsement in the Bowel Cancer Screening Programme  | wrong population | round I |
| rayyan-661155102 | A trial to establish whether laser treatment of anal precancer prevents development of anal cancer in HIV-positive men who have sex with men                    | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661155103 | MEK and MET Inhibition in Colorectal Cancer   | wrong population | round I |
| rayyan-661155104 | Comparison of precancerous lesions detection between standard colonoscopy and novel balloon colonoscopy   | wrong population | round I |
| rayyan-661155105 | PPALM - Palm oil and Pentoxifylline Against Late Morbidity  | wrong population | round I |
| rayyan-661155106 | Comparison of intervals between colonoscopic examinations in Familial Colorectal Cancer: The Dutch FAMilial ColorecTAl cancer Surveillance study (the FACTS study) Group  | wrong population | round I |
| rayyan-661155107 | ACTION: cancer patient involvement in medical decision making   | wrong population | round I |
| rayyan-661155108 | eRAPID Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: randomised controlled trial in systemic cancer treatment  | wrong population | round I |
| rayyan-661155109 | A randomised controlled trial examining the effectiveness of a STOMA psychosocial intervention programme on the outcomes of colorectal patients with a stoma  | wrong population | round I |
| rayyan-661155110 | Assessing accuracy of PillCam Colon 2 in a screening setting: a prospective study in Italy  | wrong population | round I |
| rayyan-661155111 | Effect of exercise on insulin resistance and adiponectin in colorectal cancer survivors   | wrong population | round I |
| rayyan-661155112 | Safety and tolerability of Capecitabine and Aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet/triplet chemotherapy   | wrong population | round I |
| rayyan-661155113 | Effect of exercise on fitness in colorectal cancer survivors  | wrong population | round I |
| rayyan-661155114 | Clinical trial comparing epidurals to rectus sheath catheters for pain relief following major abdominal surgery   | wrong population | round I |
| rayyan-661155115 | Biomarkers Of Colorectal cancer After Bariatric Surgery   | wrong population | round I |
| rayyan-661155116 | "A phase II double-blind  | wrong population | round I |
| rayyan-661155118 | PARC (Promoting Adhesion to Referral for Colonoscopy) study: to compare different ways to invite subjects with a positive fecal occult blood test to colonoscopy  | wrong population | round I |
| rayyan-661155119 | What carcinoembryonic antigen (CEA) level should trigger further investigation during colorectal cancer follow-up?  | wrong population | round I |
| rayyan-661155120 | Estimating uptake of colorectal cancer screening tests  | wrong population | round I |
| rayyan-661155122 | CRIB (Cancer Rehabilitation In Bowel cancer): the use of cardiac rehabilitation services to aid the recovery of colorectal cancer patients: a pilot randomised controlled trial (RCT) with embedded feasibility study | wrong population | round I |
| rayyan-661155123 | Study on narrow band imaging versus conventional colonoscopy for polyps detection in patients with positive fecal occult blood test undergoing colonoscopy screening  | wrong population | round I |
| rayyan-661155124 | Invitation strategies for colorectal (CRC) screening programmes - The impact of an advance notification letter  | wrong population | round I |
| rayyan-661155125 | Strategies to reduce the social gradient in bowel cancer screening: the ASCEND project  | wrong population | round I |
| rayyan-661155126 | Systemic chemotheRapy and the liVEr-fiRSt approach compared to index colorectal resection for colorectal cancer presenting with synchronous liver metastases (the RVERS trial)  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155127 | Hughes Abdominal Repair Trial - abdominal wall closure techniques to reduce incidence of incisional hernias  | wrong population | round I |
| rayyan-661155128 | Streamlining Staging of Colorectal cancer with Whole Body MRI  | wrong population | round I |
| rayyan-661155129 | "Adjuvant therapy: colorectal cancer chemotherapy study (LitÄänÄshoito: Paksu- ja PerÄsuoliSYÄÄn SYtostaattiTerapiaTutkimus): comparison of 5-fluorouracil (5-FU) and leucovorin as bolus injection or continuous infusion with special emphasis on toxicity                                     | wrong population | round I |
| rayyan-661155130 | Dexamethasone Reduces Emesis After Major gastrointestinal Surgery (DREAMS trial)   | wrong population | round I |
| rayyan-661155131 | Surgical timing after radiotherapy for rectal cancer   | wrong population | round I |
| rayyan-661155132 | A Phase II study of chemotherapy given before radiotherapy as treatment for patients with rectal cancer  | wrong population | round I |
| rayyan-661155133 | Traditional lateral ileostomy vs percutaneous ileostomy by exclusion probe for the protection of the extraperitoneal colo-rectal anastomosis (Ileostomia laterale tradizionale vs ileostomia percutanea escludente su sonda dedicata a protezione della anastomosi colorettali extraperitoneali) | wrong population | round I |
| rayyan-661155134 | Pre-operative oral supplementation in colorectal cancer patients   | wrong population | round I |
| rayyan-661155137 | "A phase I/IIa study combining curcumin (Curcumin C3 Complex   | wrong population | round I |
| rayyan-661155138 | Investigating the optimal scheduling of chemotherapy in patients with colorectal and liver cancer  | wrong population | round I |
| rayyan-661155139 | Improving the prediction of metastatic disease in primary colorectal cancer  | wrong population | round I |
| rayyan-661155140 | Capsule colonoscopy option increases uptake of colorectal cancer screening   | wrong population | round I |
| rayyan-661155141 | Study of colonoscopic surveillance intervals after removal of colorectal adenomas  | wrong population | round I |
| rayyan-661155142 | "A bowel management intervention for individuals following rectal cancer treatment: assessing feasibility  | wrong population | round I |
| rayyan-661155143 | The seAFOod (Systematic Evaluation of Aspirin and Fish Oil) polyp prevention trial and STOP-ADENOMA (STudy Of Prevention by Aspirin and EPA  | wrong population | round I |
| rayyan-661155144 | TroVax® and cyclophosphamide treatment in colorectal cancer  | wrong population | round I |
| rayyan-661155145 | The SYMPTOM Study: factors influencing patient appraisal of symptoms   | wrong population | round I |
| rayyan-661155147 | Wnt signalling in colon cancer   | wrong population | round I |
| rayyan-661155148 | A pilot study to test the effects of physical activity consultations on the physical activity levels and other health outcomes of people living with colorectal cancer and their partners  | wrong population | round I |
| rayyan-661155149 | BeWEL: the impact of a bodyweight and physical activity intervention on adults at risk of developing colorectal adenomas   | wrong population | round I |
| rayyan-661155150 | Effects of mutations in KRAS and BRAF gene and histological parameters on the clinical course of disease in patients with metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155151 | "The effect of red meat consumption on the formation of N-nitroso compounds  | wrong population | round I |
| rayyan-661155152 | Italian multicentre randomised controlled trial of 'once-only sigmoidoscopy'   | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155153 | Safety assessment of treatment with bevacizumab in metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155154 | "Feasibility of a personalised   | wrong population | round I |
| rayyan-661155155 | Monitoring of treatment with bevacizumab in patients with metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155156 | Identifying biomarkers to predict clinical benefit in patients with colorectal cancer treated with bevacizumab   | wrong population | round I |
| rayyan-661155157 | Diet and exercise and high risk adenomas   | wrong population | round I |
| rayyan-661155158 | Public perceptions of bowel cancer screening   | wrong population | round I |
| rayyan-661155159 | Detection of bowel disease using cells from the colon  | wrong population | round I |
| rayyan-661155160 | Mailing of the Faecal Occult Blood Test (FOBT) to increase compliance to colorectal cancer screening and to reduce costs   | wrong population | round I |
| rayyan-661155161 | Erbix in preoperative chemo-radiotherapy followed by excisional surgery  | wrong population | round I |
| rayyan-661155162 | "Radiotherapy  | wrong population | round I |
| rayyan-661155163 | "EXCITE: Erbitux   | wrong population | round I |
| rayyan-661155164 | Safety assessment of treatment with cetuximab in metastatic colorectal cancer patients   | wrong population | round I |
| rayyan-661155165 | In vivo response monitoring of treatment with the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155166 | Colonic curcumin tissue levels in patients awaiting colorectal endoscopy or patients with colorectal cancer awaiting resection   | wrong population | round I |
| rayyan-661155167 | Epidural Analgesic Therapy (EAT) versus IntraVenous patient-controlled Analgesia (IVA)   | wrong population | round I |
| rayyan-661155168 | Protein acetylation as a diet-modifiable biomarker of colorectal cancer risk   | wrong population | round I |
| rayyan-661155169 | "FOCUS 3 - the feasibility of molecular selection of therapy using KRAS  | wrong population | round I |
| rayyan-661155170 | Fluorouracil and folinic acid (FOLFIRI) plus an endothelin receptor antagonist (ERAT) in advanced colorectal cancer patients who have failed on oxaliplatin-containing chemotherapy                                      | wrong population | round I |
| rayyan-661155171 | The influence of two policies of closure of the laparotomy wound in the rate of surgical site infection in colorectal cancer surgery: the New Operation trial  | wrong population | round I |
| rayyan-661155172 | ISAAC: a randomised trial for patients with asymptomatic advanced colorectal cancer to look at the benefits of undergoing surgical removal of their primary tumour before receiving chemotherapy for metastatic disease  | wrong population | round I |
| rayyan-661155173 | Study on the benefits of fluid restriction on the recovery from surgery  | wrong population | round I |
| rayyan-661155174 | Prospective randomised clinical trial phase II: 5-fluorouracil/folinic acid (5-FU/FA) and irinotecan versus combination cepecitabin and irinotecan in patients with metastatic colorectal cancer as first line treatment | wrong population | round I |
| rayyan-661155175 | "FOXFIRE: an open-label randomised phase III trial of 5-Fluorouracil   | wrong population | round I |
| rayyan-661155176 | Colon cancer detection by measuring DNA of cells collected from rectum: A case-control study   | wrong population | round I |



|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155177 | The role of endoluminal stenting in the acute management of obstructing colorectal cancer  | wrong population | round I |
| rayyan-661155179 | Traditional Chinese medicine (TCM) for cancer  | wrong population | round I |
| rayyan-661155180 | CINATRA: Chromosomal Instability and Anti-Tubulin Response Assessment  | wrong population | round I |
| rayyan-661155181 | Early diagnosis of colorectal cancer by faecal occult blood detection - the Goteborg trial   | wrong population | round I |
| rayyan-661155182 | Conventional versus laparoscopic surgery for colorectal cancer within an Enhanced Recovery program   | wrong population | round I |
| rayyan-661155183 | Screening Or NO Screening: differences in survival during follow-up after random colorectal cancer screening with faecal occult blood test or no screening   | wrong population | round I |
| rayyan-661155184 | Implementation of colorectal cancer screening with Faecal Occult Blood Test (FOBT) in the Netherlands  | wrong population | round I |
| rayyan-661155186 | "Pre-operative short-course radiotherapy versus neoadjuvant radiochemotherapy in locally advanced rectal cancer (uT2N+   | wrong population | round I |
| rayyan-661155187 | Evaluation of the diagnostic quality of manganese chloride tetrahydrate (CMC-001®) in liver magnetic resonance imaging in patients with liver metastases in comparison to gadolinium benzyloxypropionictetraacetate (BOPTA): a randomised cross-over phase III trial | wrong population | round I |
| rayyan-661155188 | "A phase II study of up-front red blood cell transfusion before chemotherapy followed by maintenance Erythropoietin-alpha subcutaneous support during chemotherapy of anaemic breast-  | wrong population | round I |
| rayyan-661155189 | Video autofluorescence imaging for detection of adenomatous POLyps of the colon in intermediate and high-risk PATieNts   | wrong population | round I |
| rayyan-661155190 | A two-arm phase II randomised trial of intermittent chemotherapy plus continuous cetuximab and of intermittent chemotherapy plus intermittent cetuximab in first line treatment of patients with K-ras-normal (wild-type) metastatic colorectal cancer               | wrong population | round I |
| rayyan-661155191 | p53 immunotherapy in patients treated for metastasised colorectal cancer   | wrong population | round I |
| rayyan-661155192 | The influence of methylenetetrahydrofolate reductase C677T genotype and folate status on deoxyribonucleic acid methylation and uracil misincorporation in the colon of healthy volunteers  | wrong population | round I |
| rayyan-661155193 | "Comparing colonoscopy   | wrong population | round I |
| rayyan-661155194 | A prospective randomised open label trial of oxaliplatin/fluoropyrimidine versus oxaliplatin/fluoropyrimidine plus cetuximab pre- and post-operatively in patients with resectable colorectal liver metastasis requiring chemotherapy                                | wrong population | round I |
| rayyan-661155195 | An evaluation of an Advanced Symptom Management System to monitor and manage chemotherapy-related toxicity   | wrong population | round I |
| rayyan-661155196 | "A multicentre study using the chemotherapy combination of bi-monthly Xeloda and Eloxatin  | wrong population | round I |
| rayyan-661155197 | Influence of laparoscopy and/or fast-track multimodal management on gastrointestinal motility in comparison to open surgery and/or standard care   | wrong population | round I |
| rayyan-661155198 | Relevance of circulating tumour cells in patients undergoing laparoscopic colon resection versus open resection: a randomised trial  | wrong population | round I |
| rayyan-661155199 | Influence of MLH1 gene on anti-neoplastic effects of Resistant Starch  | wrong population | round I |
| rayyan-661155200 | FOCUS 2: Drug treatment for bowel cancer - making the best choices when a milder treatment is needed   | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155201 | Is blinding the endoscopists to bowel preparations in randomised controlled trials a reality?  | wrong population | round I |
| rayyan-661155202 | A blended knowledge translation initiative to improve colorectal cancer staging  | wrong population | round I |
| rayyan-661155203 | A randomised controlled study into the effect of an audiovisual intervention on patient recruitment to cancer clinical trials  | wrong population | round I |
| rayyan-661155204 | Trying to improve the compliance to colorectal cancer screening: type of test provider (GP versus hospital) and type of faecal occult blood test (Guaiac versus immunochemical)  | wrong population | round I |
| rayyan-661155205 | "Influence of intraperitoneal application of taurolidine on the perioperative metastases   | wrong population | round I |
| rayyan-661155206 | PACT (Patient Preferences in Adjuvant Colorectal Cancer Therapy): a randomised crossover clinical trial comparing bolus fluorouracil/leucovorin to capecitabine as treatment for moderate to high risk resected colorectal cancer                                    | wrong population | round I |
| rayyan-661155207 | Influence of two different resection techniques of liver metastases from colorectal cancer on haematogenous tumour cell dissemination  | wrong population | round I |
| rayyan-661155208 | "PICCOLO Trial: Panitumumab  | wrong population | round I |
| rayyan-661155209 | A Phase III trial comparing either COntinuous chemotherapy plus cetuximab or IIntermittent chemotherapy with standard continuous palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment of metastatic colorectal cancer | wrong population | round I |
| rayyan-661155210 | Cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent - main trial   | wrong population | round I |
| rayyan-661155211 | "Inter-individual variation in susceptibility to colorectal neoplasia: the interaction between diet  | wrong population | round I |
| rayyan-661155212 | Evaluation of guidelines for open access flexible sigmoidoscopy  | wrong population | round I |
| rayyan-661155213 | Multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer   | wrong population | round I |
| rayyan-661155214 | Randomised phase III study of the local treatment of liver metastases by radiofrequency combined with chemotherapy versus chemotherapy alone in patients with unresectable colorectal liver metastases   | wrong population | round I |
| rayyan-661155215 | Cluster randomised controlled trial of computer decision support for management of familial cancer in primary care   | wrong population | round I |
| rayyan-661155216 | A Trial to Establish the Role of Leukocyte Concentration and Tissue Type of Transfused Blood in Immunomodulation of Patients Undergoing Elective Surgery for Colorectal Cancer   | wrong population | round I |
| rayyan-661155217 | A randomised trial comparing 8 cycles of CPT11 with CPT11 until disease progression in patients with colorectal cancer resistant to 5-fluorouracil   | wrong population | round I |
| rayyan-661155218 | Post-Operative Radiotherapy for Selected High Risk Rectal Adenocarcinoma   | wrong population | round I |
| rayyan-661155220 | The effect of rofecoxib on colorectal liver metastases   | wrong population | round I |
| rayyan-661155221 | A randomised controlled trial of colorectal polyp and cancer prevention using aspirin and resistant starch in carriers of hereditary nonpolyposis colorectal cancer  | wrong population | round I |
| rayyan-661155222 | Adjuvant X-ray & 5-Fluorouracil (5-FU) Infusion Study  | wrong population | round I |
| rayyan-661155223 | QUASAR (stands for QUick and Simple And Reliable). UKCCCR randomised study of adjuvant chemotherapy in colon and rectal cancer   | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155224 | A randomised controlled trial of faecal occult blood screening for colorectal cancer   | wrong population | round I |
| rayyan-661155225 | A randomised trial of intravenous versus intrahepatic arterial 5-Fluorouracil (5-FU) and leucovorin for colorectal liver metastases  | wrong population | round I |
| rayyan-661155226 | Multicentre randomised trial of 'once only' flexible sigmoidoscopy screening for prevention of bowel cancer morbidity and mortality  | wrong population | round I |
| rayyan-661155227 | A randomised controlled trial of laparoscopic surgery for colorectal cancer  | wrong population | round I |
| rayyan-661155228 | A randomised trial assessing the role of two new agents in the management of advanced colorectal cancer  | wrong population | round I |
| rayyan-661155229 | Chemotherapy choices in advanced colorectal cancer - a randomised trial comparing two durations and three chemotherapy regimens in the palliative treatment of advanced colorectal cancer          | wrong population | round I |
| rayyan-661155231 | Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?   | wrong population | round I |
| rayyan-661155232 | Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer  | wrong population | round I |
| rayyan-661155233 | The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial | wrong population | round I |
| rayyan-661155235 | Predictive Molecular Classifiers in Colorectal Cancer  | wrong population | round I |
| rayyan-661155239 | Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial  | wrong population | round I |
| rayyan-661155240 | Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity   | wrong population | round I |
| rayyan-661155241 | Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)   | wrong population | round I |
| rayyan-661155248 | The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients   | wrong population | round I |
| rayyan-661155250 | Colorectal cancer screening – Methodology  | wrong population | round I |
| rayyan-661155251 | Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (V. 2023)  | wrong population | round I |
| rayyan-661155256 | "Epidermal growth factor receptor  | wrong population | round I |
| rayyan-661155259 | "The Unmet Needs of the Diagnosis  | wrong population | round I |
| rayyan-661155264 | Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases   | wrong population | round I |
| rayyan-661155266 | Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation   | wrong population | round I |
| rayyan-661155267 | The role of molecular biomarkers in outcomes and patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin          | wrong population | round I |
| rayyan-661155268 | BRAF mutation detection in hairy cell leukaemia from archival haematolymphoid specimens  | wrong population | round I |
| rayyan-661155272 | Nonoperative management of the primary tumor in patients with unresectable stage IV colon cancer treated with systemic chemotherapy: Higher complication rates for left-sided colon tumors         | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661155277 | Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials               | wrong population | round I |
| rayyan-661155279 | Performance of prognostic models incorporating KRAS mutation status to predict survival after resection of colorectal liver metastases  | wrong population | round I |
| rayyan-661155281 | Rigosertib promotes anti-tumor immunity via autophagic degradation of PD-L1 in colorectal cancer cells  | wrong population | round I |
| rayyan-661155283 | Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study                | wrong population | round I |
| rayyan-661155284 | "Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern  | wrong population | round I |
| rayyan-661155286 | SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases  | wrong population | round I |
| rayyan-661155287 | Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies  | wrong population | round I |
| rayyan-661155288 | Adnexal masses in patients with colorectal cancer   | wrong population | round I |
| rayyan-661155293 | Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features   | wrong population | round I |
| rayyan-661155294 | Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)  | wrong population | round I |
| rayyan-661155295 | Prognostic score for synchronous metastatic rectal cancer: A real-world study   | wrong population | round I |
| rayyan-661155297 | Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial  | wrong population | round I |
| rayyan-661155302 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective –Real-World Study–                          | wrong population | round I |
| rayyan-661155303 | Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies                  | wrong population | round I |
| rayyan-661155304 | Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer  | wrong population | round I |
| rayyan-661155305 | Colorectal cancer immunotherapy-Recent progress and future directions   | wrong population | round I |
| rayyan-661155309 | Mutational analysis of $\beta^2$ -catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours  | wrong population | round I |
| rayyan-661155310 | "KRAS   | wrong population | round I |
| rayyan-661155314 | BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall   | wrong population | round I |
| rayyan-661155316 | "Chapter 10 - Colorectal cancer heterogeneity and targeted therapy: clinical implications   | wrong population | round I |
| rayyan-661155318 | Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? | wrong population | round I |
| rayyan-661155321 | FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival   | wrong population | round I |
| rayyan-661155324 | Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)   | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155326 | Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience  | wrong population | round I |
| rayyan-661155328 | Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer   | wrong population | round I |
| rayyan-661155332 | Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer   | wrong population | round I |
| rayyan-661155335 | Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers  | wrong population | round I |
| rayyan-661155340 | Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group                                    | wrong population | round I |
| rayyan-661155346 | "Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm  | wrong population | round I |
| rayyan-661155351 | Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis                                  | wrong population | round I |
| rayyan-661155353 | Clinical Trials and Progress in Metastatic Colon Cancer  | wrong population | round I |
| rayyan-661155354 | Integrated Omics of Metastatic Colorectal Cancer   | wrong population | round I |
| rayyan-661155356 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials | wrong population | round I |
| rayyan-661155359 | The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials  | wrong population | round I |
| rayyan-661155360 | Single-cell transcriptome analysis reveals T population heterogeneity and functions in tumor microenvironment of colorectal cancer metastases  | wrong population | round I |
| rayyan-661155363 | Genomic profiling of sporadic liver metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155368 | "Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre   | wrong population | round I |
| rayyan-661155373 | "Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF  | wrong population | round I |
| rayyan-661155374 | Chapter 19 - Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors  | wrong population | round I |
| rayyan-661155376 | Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155378 | Updated Management of Colorectal Cancer Liver Metastases: Scientific Advances Driving Modern Therapeutic Innovations   | wrong population | round I |
| rayyan-661155380 | KRAS and BRAF mutations in sinonasal cancer  | wrong population | round I |
| rayyan-661155381 | Dichotomous colorectal cancer behaviour  | wrong population | round I |
| rayyan-661155382 | Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable                  | wrong population | round I |
| rayyan-661155387 | Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer  | wrong population | round I |
| rayyan-661155388 | The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing  | wrong population | round I |
| rayyan-661155389 | Chapter 33 - Molecularly targeted therapy in metastatic CRC  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155390 | Chapter 34 - A roadmap for medical treatment of metastatic CRC   | wrong population | round I |
| rayyan-661155391 | Chapter 15 - Immunotherapy and targeted therapies for colorectal liver metastasis  | wrong population | round I |
| rayyan-661155397 | The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases   | wrong population | round I |
| rayyan-661155401 | Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer                                    | wrong population | round I |
| rayyan-661155403 | Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155404 | Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?   | wrong population | round I |
| rayyan-661155405 | Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155406 | Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival   | wrong population | round I |
| rayyan-661155407 | Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair  | wrong population | round I |
| rayyan-661155410 | Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study                                 | wrong population | round I |
| rayyan-661155411 | Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155414 | Treatment sequencing in metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155417 | "Trifluridine+tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised | wrong population | round I |
| rayyan-661155419 | Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials | wrong population | round I |
| rayyan-661155421 | Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study  | wrong population | round I |
| rayyan-661155422 | NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?"Case series and review of the literature  | wrong population | round I |
| rayyan-661155425 | Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer                | wrong population | round I |
| rayyan-661155427 | HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study   | wrong population | round I |
| rayyan-661155428 | Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer                                 | wrong population | round I |
| rayyan-661155429 | Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis   | wrong population | round I |
| rayyan-661155431 | RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer  | wrong population | round I |
| rayyan-661155432 | Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis   | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155433 | Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study | wrong population | round I |
| rayyan-661155434 | FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and â€³ circulating tumour cells: the randomised phase III VISNÅŠ-1 trial                             | wrong population | round I |
| rayyan-661155437 | Liver Transplantation for Colorectal Liver Metastases  | wrong population | round I |
| rayyan-661155439 | Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155440 | Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study                        | wrong population | round I |
| rayyan-661155441 | FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies   | wrong population | round I |
| rayyan-661155443 | "Unified framework for patient-derived   | wrong population | round I |
| rayyan-661155444 | Microsatellite instability status affects gene expression profiles in early onset colorectal cancer patients   | wrong population | round I |
| rayyan-661155445 | Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics  | wrong population | round I |
| rayyan-661155446 | Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer   | wrong population | round I |
| rayyan-661155447 | Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155448 | "Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine   | wrong population | round I |
| rayyan-661155449 | "FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox  | wrong population | round I |
| rayyan-661155451 | Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING caseâ€“control study   | wrong population | round I |
| rayyan-661155452 | Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions   | wrong population | round I |
| rayyan-661155453 | "Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study  | wrong population | round I |
| rayyan-661155454 | "Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre  | wrong population | round I |
| rayyan-661155455 | Chapter 4 - Use of molecular markers and other personalized factors in treatment decisions for metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155457 | Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)  | wrong population | round I |
| rayyan-661155460 | Long-Term Clinical Outcomes of Patients with Colorectal Cancer with Metastatic Epidural Spinal Cord Compression Treated with Hybrid Therapy (Surgery Followed by Stereotactic Body Radiation Therapy)          | wrong population | round I |
| rayyan-661155462 | Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer  | wrong population | round I |
| rayyan-661155467 | Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer  | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661155471 | Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer&#xA0;% 70 years  | wrong population | round I |
| rayyan-661155472 | Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion   | wrong population | round I |
| rayyan-661155473 | The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy  | wrong population | round I |
| rayyan-661155474 | Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC): Personalized Medicine at Work  | wrong population | round I |
| rayyan-661155475 | Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group  | wrong population | round I |
| rayyan-661155481 | How we treat metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155482 | "Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than   | wrong population | round I |
| rayyan-661155484 | Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?   | wrong population | round I |
| rayyan-661155485 | Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer  | wrong population | round I |
| rayyan-661155488 | Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? | wrong population | round I |
| rayyan-661155489 | Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155490 | Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study  | wrong population | round I |
| rayyan-661155491 | Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone   | wrong population | round I |
| rayyan-661155494 | Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study  | wrong population | round I |
| rayyan-661155495 | Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy  | wrong population | round I |
| rayyan-661155496 | Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155497 | Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISN&#xA0;-1 and Phase II VISN&#xA0;-2 Randomized Trials | wrong population | round I |
| rayyan-661155500 | Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155501 | BRAF V600E mutations in right-side colon cancer: Heterogeneity detected by liquid biopsy  | wrong population | round I |
| rayyan-661155504 | Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors   | wrong population | round I |
| rayyan-661155505 | Clinical-Molecular characteristics and Post-Translational modifications of colorectal cancer in north China: Implications for future targeted therapies   | wrong population | round I |



|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661155506 | KRAS inhibition in metastatic colorectal cancer: An update  | wrong population | round I |
| rayyan-661155507 | "Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13   | wrong population | round I |
| rayyan-661155508 | Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer                                  | wrong population | round I |
| rayyan-661155510 | Metastasectomy and BRAF mutation  | wrong population | round I |
| rayyan-661155511 | Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC studyâ†   | wrong population | round I |
| rayyan-661155513 | Immunotherapy in mismatch repair-deficient metastatic colorectal cancer â€œ Outcome and novel predictive markers  | wrong population | round I |
| rayyan-661155514 | Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer  | wrong population | round I |
| rayyan-661155517 | Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer                                  | wrong population | round I |
| rayyan-661155523 | Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer  | wrong population | round I |
| rayyan-661155526 | BRAF gene as a potential target to attenuate drug resistance and treat cancer   | wrong population | round I |
| rayyan-661155527 | Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic ColorectalÂ Cancer  | wrong population | round I |
| rayyan-661155529 | BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis   | wrong population | round I |
| rayyan-661155530 | Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas  | wrong population | round I |
| rayyan-661155531 | Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials                           | wrong population | round I |
| rayyan-661155532 | European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer   | wrong population | round I |
| rayyan-661155535 | "Sintilimab plus bevacizumab  | wrong population | round I |
| rayyan-661155536 | Application of histology-agnostic treatments in metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155538 | "Tucatinib plus trastuzumab for chemotherapy-refractory   | wrong population | round I |
| rayyan-661155539 | Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component   | wrong population | round I |
| rayyan-661155540 | "Cliniciansâ€™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter | wrong population | round I |
| rayyan-661155542 | Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7                     | wrong population | round I |
| rayyan-661155543 | "Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661155546 | Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan     | wrong population | round I |
| rayyan-661155549 | Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis                         | wrong population | round I |
| rayyan-661155551 | "CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre  | wrong population | round I |
| rayyan-661155552 | MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway  | wrong population | round I |
| rayyan-661155553 | Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA  | wrong population | round I |
| rayyan-661155555 | Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155556 | Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study  | wrong population | round I |
| rayyan-661155557 | "Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international   | wrong population | round I |
| rayyan-661155560 | "KRAS  | wrong population | round I |
| rayyan-661155562 | The mechanism investigation of mutation genes in liver and lung metastasis of colorectal cancer by using NGS technique   | wrong population | round I |
| rayyan-661155564 | Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer  | wrong population | round I |
| rayyan-661155567 | Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer  | wrong population | round I |
| rayyan-661155568 | "Tumor profiling of KRAS   | wrong population | round I |
| rayyan-661155570 | Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial | wrong population | round I |
| rayyan-661155571 | Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study  | wrong population | round I |
| rayyan-661155573 | The Pan-Immune-Inflammation Value in microsatellite instability“high metastatic colorectal cancer patients treated with immune checkpoint inhibitors                                 | wrong population | round I |
| rayyan-661155574 | High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases  | wrong population | round I |
| rayyan-661155577 | RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies                                   | wrong population | round I |
| rayyan-661155578 | "Metastatic colorectal carcinoma with signet-ring cells: Clinical  | wrong population | round I |
| rayyan-661155582 | Immunopeptidomic Analyses of Colorectal Cancers With and Without Microsatellite Instability  | wrong population | round I |
| rayyan-661155584 | "Tumour mutational burden  | wrong population | round I |
| rayyan-661155585 | Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency                | wrong population | round I |
| rayyan-661155586 | TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer   | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661155587 | Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability   | wrong population | round I |
| rayyan-661155588 | Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update  | wrong population | round I |
| rayyan-661155590 | Microsatellite instability is associated with worse overall survival in resectable colorectal liver metastases  | wrong population | round I |
| rayyan-661155591 | Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer  | wrong population | round I |
| rayyan-661155592 | Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV | wrong population | round I |
| rayyan-661155798 | "KRAS   | wrong population | round I |
| rayyan-661155800 | RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer.                                     | wrong population | round I |
| rayyan-661155802 | Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.   | wrong population | round I |
| rayyan-661155803 | BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.           | wrong population | round I |
| rayyan-661155806 | Mutation status and surgical selection.   | wrong population | round I |
| rayyan-661155817 | Recent advances in understanding colorectal cancer.   | wrong population | round I |
| rayyan-661155822 | Genomic and prognostic heterogeneity among RAS/BRAF(V600E) /TP53 co-mutated resectable colorectal liver metastases.                                       | wrong population | round I |
| rayyan-661155823 | Colorectal cancer: genetics of development and metastasis.  | wrong population | round I |
| rayyan-661155832 | Colorectal cancers with a residual adenoma component: Clinicopathologic features and KRAS mutation.   | wrong population | round I |
| rayyan-661155834 | "Chromosomal instability in BRAF mutant   | wrong population | round I |
| rayyan-661155835 | Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.   | wrong population | round I |
| rayyan-661155840 | Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.   | wrong population | round I |
| rayyan-661155843 | "Neuroendocrine Differentiation   | wrong population | round I |
| rayyan-661155845 | Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.                                  | wrong population | round I |
| rayyan-661155852 | Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.   | wrong population | round I |
| rayyan-661155857 | Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations.                                 | wrong population | round I |
| rayyan-661155858 | Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma.   | wrong population | round I |
| rayyan-661155865 | Molecular characteristics of colorectal hyperplastic polyp subgroups.   | wrong population | round I |
| rayyan-661155867 | KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.   | wrong population | round I |
| rayyan-661155872 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.  | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661155874 | "Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence   | wrong population | round I |
| rayyan-661155877 | Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.                  | wrong population | round I |
| rayyan-661155879 | Microsatellite instability and survival in rectal cancer.   | wrong population | round I |
| rayyan-661155881 | "p53 mutation is common in microsatellite stable  | wrong population | round I |
| rayyan-661155889 | Epithelial-mesenchymal transition and somatic alteration in colorectal cancer with and without peritoneal carcinomatosis.                                     | wrong population | round I |
| rayyan-661155890 | The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer.  | wrong population | round I |
| rayyan-661155891 | Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study.                                  | wrong population | round I |
| rayyan-661155906 | Clinical and Molecular Features of Post-Colonoscopy Colorectal Cancers.   | wrong population | round I |
| rayyan-661155909 | BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer.                  | wrong population | round I |
| rayyan-661155910 | Genetic Characteristics of Resectable Colorectal Cancer with Pulmonary Metastasis.  | wrong population | round I |
| rayyan-661155911 | Association of BMI and major molecular pathological markers of colorectal cancer in men and women.  | wrong population | round I |
| rayyan-661155917 | Marine 1%-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability.  | wrong population | round I |
| rayyan-661155918 | "[Landscape of KRAS   | wrong population | round I |
| rayyan-661155920 | Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.                         | wrong population | round I |
| rayyan-661155929 | Improved Detection of Microsatellite Instability in Early Colorectal Lesions.   | wrong population | round I |
| rayyan-661155937 | "BRAF   | wrong population | round I |
| rayyan-661155939 | "Microsatellite instability   | wrong population | round I |
| rayyan-661155940 | Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients.   | wrong population | round I |
| rayyan-661155948 | Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.                                | wrong population | round I |
| rayyan-661155949 | Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.                   | wrong population | round I |
| rayyan-661155950 | Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.                     | wrong population | round I |
| rayyan-661155951 | The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.                                      | wrong population | round I |
| rayyan-661155952 | Epigenetics could explain some Moroccan population colorectal cancers peculiarities: microsatellite instability pathway exploration.                          | wrong population | round I |
| rayyan-661155953 | Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening. | wrong population | round I |
| rayyan-661155955 | Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).                                  | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661155957 | KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.  | wrong population | round I |
| rayyan-661155967 | Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.   | wrong population | round I |
| rayyan-661155971 | Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.  | wrong population | round I |
| rayyan-661155973 | KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.                                | wrong population | round I |
| rayyan-661155975 | Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer.               | wrong population | round I |
| rayyan-661155984 | Expression Profile of LGR5 and Its Prognostic Significance in Colorectal Cancer Progression.  | wrong population | round I |
| rayyan-661155992 | KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability.           | wrong population | round I |
| rayyan-661155997 | Chr20q Amplification Defines a Distinct Molecular Subtype of Microsatellite Stable Colorectal Cancer.   | wrong population | round I |
| rayyan-661155998 | "Specific mutations in KRAS codons 12 and 13  | wrong population | round I |
| rayyan-661156005 | Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies.   | wrong population | round I |
| rayyan-661156007 | Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. | wrong population | round I |
| rayyan-661156011 | N_LyST: a simple and rapid screening test for Lynch syndrome.   | wrong population | round I |
| rayyan-661156013 | DNA content analysis of colorectal cancer defines a distinct 'microsatellite and chromosome stable' group but does not predict response to radiotherapy.              | wrong population | round I |
| rayyan-661156014 | "[Clinicopathological characteristics   | wrong population | round I |
| rayyan-661156015 | BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.                                     | wrong population | round I |
| rayyan-661156017 | Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.  | wrong population | round I |
| rayyan-661156018 | A Prospective Study of Smoking and Risk of Synchronous Colorectal Cancers.  | wrong population | round I |
| rayyan-661156020 | Traditional serrated adenoma has two distinct genetic pathways for molecular tumorigenesis with potential neoplastic progression.                                     | wrong population | round I |
| rayyan-661156022 | Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia.   | wrong population | round I |
| rayyan-661156023 | Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.  | wrong population | round I |
| rayyan-661156028 | Similarities of molecular genetic changes in synchronous and metachronous colorectal cancers are limited and related to the cancers' proximities to each other.       | wrong population | round I |
| rayyan-661156031 | Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.  | wrong population | round I |
| rayyan-661156032 | Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability.                                     | wrong population | round I |
| rayyan-661156033 | "Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations   | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661156034 | Serrated polyposis associated with a family history of colorectal cancer and/or polyps: The preferential location of polyps in the colon and rectum defines two molecular entities.                                      | wrong population | round I |
| rayyan-661156035 | Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis. | wrong population | round I |
| rayyan-661156036 | Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas.                              | wrong population | round I |
| rayyan-661156037 | "Comprehensive analysis of CpG island methylator phenotype (CIMP)-high   | wrong population | round I |
| rayyan-661156038 | "Dietary intake of fiber   | wrong population | round I |
| rayyan-661156039 | Molecular markers and pathway analysis of colorectal carcinoma in the Middle East.   | wrong population | round I |
| rayyan-661156041 | Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.  | wrong population | round I |
| rayyan-661156043 | "Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis  | wrong population | round I |
| rayyan-661156048 | A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal cancer.  | wrong population | round I |
| rayyan-661156049 | Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.   | wrong population | round I |
| rayyan-661156052 | "Comparison of microsatellite instability  | wrong population | round I |
| rayyan-661156054 | Population-based screening for Lynch syndrome in Western Australia.  | wrong population | round I |
| rayyan-661156056 | Age at onset should be a major criterion for subclassification of colorectal cancer.   | wrong population | round I |
| rayyan-661156057 | A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.   | wrong population | round I |
| rayyan-661156060 | A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status.   | wrong population | round I |
| rayyan-661156061 | Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.   | wrong population | round I |
| rayyan-661156063 | Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study.  | wrong population | round I |
| rayyan-661156064 | Conventional colon adenomas harbor various disturbances in microsatellite stability and contain micro-serrated foci with microsatellite instability.   | wrong population | round I |
| rayyan-661156065 | Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.                                    | wrong population | round I |
| rayyan-661156066 | "Microsatellite instability affecting the T17 repeats in intron 8 of HSP110  | wrong population | round I |
| rayyan-661156069 | Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.  | wrong population | round I |
| rayyan-661156073 | Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes.   | wrong population | round I |
| rayyan-661156076 | "Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation  | wrong population | round I |

|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661156077 | Retrospective Analysis of Treatment Pathways in Patients With BRAF(V600E)-mutant Metastatic Colorectal Carcinoma - MORSE(CRC).   | wrong population | round I |
| rayyan-661156083 | Methylation in p14(ARF) is frequently observed in colorectal cancer with low-level microsatellite instability.   | wrong population | round I |
| rayyan-661156084 | Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. | wrong population | round I |
| rayyan-661156094 | Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.   | wrong population | round I |
| rayyan-661156098 | Genetic characteristics of mitochondrial DNA was associated with colorectal carcinogenesis and its prognosis.  | wrong population | round I |
| rayyan-661156099 | Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.  | wrong population | round I |
| rayyan-661156100 | Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women.   | wrong population | round I |
| rayyan-661156105 | NDRG4 stratifies the prognostic value of body mass index in colorectal cancer.   | wrong population | round I |
| rayyan-661156107 | Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach.                             | wrong population | round I |
| rayyan-661156109 | Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317.  | wrong population | round I |
| rayyan-661156110 | Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma.  | wrong population | round I |
| rayyan-661156111 | Molecular profiling and genome-wide analysis based on somatic copy number alterations in advanced colorectal cancers.  | wrong population | round I |
| rayyan-661156116 | Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon.  | wrong population | round I |
| rayyan-661156118 | Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.   | wrong population | round I |
| rayyan-661156124 | KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis.  | wrong population | round I |
| rayyan-661156127 | Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer.   | wrong population | round I |
| rayyan-661156128 | Molecular Subtypes Are Frequently Discordant Between Lesions in Patients With Synchronous Colorectal Cancer: Molecular Analysis of 59 Patients.  | wrong population | round I |
| rayyan-661156129 | Molecular alterations in colitis-associated colorectal neoplasia: study from a low prevalence area using magnifying chromo colonoscopy.  | wrong population | round I |
| rayyan-661156130 | A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations.   | wrong population | round I |
| rayyan-661156131 | "Commentary: Lifestyle factors and colorectal cancer microsatellite instability--molecular pathological epidemiology science   | wrong population | round I |
| rayyan-661156137 | Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level.   | wrong population | round I |
| rayyan-661156141 | Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.   | wrong population | round I |
| rayyan-661156143 | The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel.  | wrong population | round I |
| rayyan-661156145 | Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway.  | wrong population | round I |
| rayyan-661156146 | Externalization of saw-tooth architecture in small serrated polyps implies the presence of methylation of IGFBP7.  | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661156147 | Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome.                         | wrong population | round I |
| rayyan-661156151 | "Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location   | wrong population | round I |
| rayyan-661156152 | Clinicopathological and molecular features of colorectal serrated neoplasias with different mucosal crypt patterns.   | wrong population | round I |
| rayyan-661156159 | Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.   | wrong population | round I |
| rayyan-661156165 | The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.   | wrong population | round I |
| rayyan-661156166 | A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma.  | wrong population | round I |
| rayyan-661156169 | Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. | wrong population | round I |
| rayyan-661156173 | A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome.  | wrong population | round I |
| rayyan-661156182 | HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.         | wrong population | round I |
| rayyan-661156183 | A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification.  | wrong population | round I |
| rayyan-661156188 | Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications.                                       | wrong population | round I |
| rayyan-661156189 | Evidence for possible non-canonical pathway(s) driven early-onset colorectal cancer in India.   | wrong population | round I |
| rayyan-661156190 | Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival.                | wrong population | round I |
| rayyan-661156193 | Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.                             | wrong population | round I |
| rayyan-661156195 | "Aberrant promoter methylation of beta-1  | wrong population | round I |
| rayyan-661156196 | "Small Bowel Carcinomas in Coeliac or Crohn's Disease: Clinico-pathological   | wrong population | round I |
| rayyan-661156197 | Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.  | wrong population | round I |
| rayyan-661156198 | Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.             | wrong population | round I |
| rayyan-661156199 | Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.                            | wrong population | round I |
| rayyan-661156203 | Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.   | wrong population | round I |
| rayyan-661156206 | Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype.   | wrong population | round I |
| rayyan-661156210 | Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.  | wrong population | round I |
| rayyan-661156211 | Right-sided rhabdoid colorectal tumors might be related to the serrated pathway.  | wrong population | round I |
| rayyan-661156212 | Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea.  | wrong population | round I |



|                  |  |                  |         |
|------------------|--|------------------|---------|
| rayyan-661156216 | Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer: What Happens at Relapse?                                 | wrong population | round I |
| rayyan-661156217 | A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.  | wrong population | round I |
| rayyan-661156219 | "Tumor TP53 expression status  | wrong population | round I |
| rayyan-661156221 | Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis.   | wrong population | round I |
| rayyan-661156222 | Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans.              | wrong population | round I |
| rayyan-661156228 | "Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic   | wrong population | round I |
| rayyan-661156229 | The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability.   | wrong population | round I |
| rayyan-661156232 | "CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size   | wrong population | round I |
| rayyan-661156233 | Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy.         | wrong population | round I |
| rayyan-661156235 | Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers.  | wrong population | round I |
| rayyan-661156236 | Down-regulation of epidermal growth factor receptor by selective expansion of a 5'-end regulatory dinucleotide repeat in colon cancer with microsatellite instability. | wrong population | round I |
| rayyan-661156238 | APC mutations and other genetic and epigenetic changes in colon cancer.  | wrong population | round I |
| rayyan-661156239 | BRAF: a driver of the serrated pathway in colon cancer.  | wrong population | round I |
| rayyan-661156240 | Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.                  | wrong population | round I |
| rayyan-661156242 | The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform.  | wrong population | round I |
| rayyan-661156243 | Decreased Tumoral Expression of Colon-Specific Water Channel Aquaporin 8 Is Associated With Reduced Overall Survival in Colon Adenocarcinoma.                          | wrong population | round I |
| rayyan-661156244 | A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer.  | wrong population | round I |
| rayyan-661156248 | BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome.  | wrong population | round I |
| rayyan-661156249 | Occurrence of Aurora A positive multipolar mitoses in distinct molecular classes of colorectal carcinomas and effect of Aurora A inhibition.                           | wrong population | round I |
| rayyan-661156251 | A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation.   | wrong population | round I |
| rayyan-661156252 | Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.   | wrong population | round I |
| rayyan-661156253 | Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.  | wrong population | round I |
| rayyan-661156255 | IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.  | wrong population | round I |
| rayyan-661156259 | "CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation  | wrong population | round I |
| rayyan-661156263 | The serrated polyp comes of age.   | wrong population | round I |

|                  |   |                  |         |
|------------------|---|------------------|---------|
| rayyan-661156264 | Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer.   | wrong population | round I |
| rayyan-661156266 | CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer.  | wrong population | round I |
| rayyan-661156267 | Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry.  | wrong population | round I |
| rayyan-661156272 | CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.  | wrong population | round I |
| rayyan-661156278 | A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial.  | wrong population | round I |
| rayyan-661156279 | Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.   | wrong population | round I |
| rayyan-661156282 | Genetic and molecular diversity of colon cancer hepatic metastases.   | wrong population | round I |
| rayyan-661156284 | SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.   | wrong population | round I |
| rayyan-661156286 | BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients.  | wrong population | round I |
| rayyan-661156287 | Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G > T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue.                                | wrong population | round I |
| rayyan-661156288 | Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers.            | wrong population | round I |
| rayyan-661156290 | Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study.                    | wrong population | round I |
| rayyan-661156291 | The non-crosslinking fixative RCL2 <sup>®</sup> -CS100 is compatible with both pathology diagnosis and molecular analyses.  | wrong population | round I |
| rayyan-661156298 | Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.   | wrong population | round I |
| rayyan-661156300 | Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.  | wrong population | round I |
| rayyan-661156301 | Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.   | wrong population | round I |
| rayyan-661156302 | Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation. | wrong population | round I |
| rayyan-661156303 | "The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles  | wrong population | round I |
| rayyan-661156305 | Sporadic microsatellite instability-high colon cancers rarely display immunohistochemical evidence of Wnt signaling activation.   | wrong population | round I |
| rayyan-661156312 | The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer.  | wrong population | round I |
| rayyan-661156314 | Colon Cancer Tumor Location Defined by Gene Expression May Disagree With Anatomic Tumor Location.   | wrong population | round I |
| rayyan-661156316 | [Prognostic biomarkers for metastatic colorectal cancer].   | wrong population | round I |
| rayyan-661156317 | Comprehensive mutation analysis in colorectal flat adenomas.  | wrong population | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661156324 | Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer â‰‰ 70 years.  | wrong population       | round I |
| rayyan-661156325 | The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection.  | wrong population       | round I |
| rayyan-661156326 | Targeted gene sequencing of Lynch syndrome-related and sporadic endometrial carcinomas.   | wrong population       | round I |
| rayyan-661156327 | "Simplified identification of Lynch syndrome: a prospective   | wrong population       | round I |
| rayyan-661156328 | MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.   | wrong population       | round I |
| rayyan-661156330 | [Hereditary polyposis: update on molecular genetics and clinicopathologic features].  | wrong population       | round I |
| rayyan-661156331 | Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.  | wrong population       | round I |
| rayyan-661156332 | "Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations   | wrong population       | round I |
| rayyan-661156333 | A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. | wrong population       | round I |
| rayyan-661154048 | Glossary  | wrong publication type | round I |
| rayyan-661154061 | 7 - Special Studies   | wrong publication type | round I |
| rayyan-661154063 | 47 - Cholangiocarcinoma   | wrong publication type | round I |
| rayyan-661154064 | Kapitel 5 - Viszeralchirurgie   | wrong publication type | round I |
| rayyan-661154065 | Index   | wrong publication type | round I |
| rayyan-661154066 | Chapter 12 - Therapies II: Specific Non-surgical Treatments   | wrong publication type | round I |
| rayyan-661154067 | Chapter 11 - Clinical Trial Design in Immuno-Oncology   | wrong publication type | round I |
| rayyan-661154068 | Subject Index   | wrong publication type | round I |
| rayyan-661154070 | Molecular techniques in anatomic pathology: An overview   | wrong publication type | round I |
| rayyan-661154074 | Some thoughts on what's ahead for GI in 2006 and beyond   | wrong publication type | round I |
| rayyan-661154076 | CHAPTER 42 - Tumour markers   | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661154079 | The Gastrointestinal Tumor Microenvironment   | wrong publication type | round I |
| rayyan-661154080 | "Chapter 14 - Biomarkers: Discovery   | wrong publication type | round I |
| rayyan-661154082 | CHAPTER 23 - Large Intestine (Colon)  | wrong publication type | round I |
| rayyan-661154085 | A - ERKRANKUNGEN DER VERDAUUNGSORGANE   | wrong publication type | round I |
| rayyan-661154087 | "Chapter 10 - Typing  | wrong publication type | round I |
| rayyan-661154088 | Chapter 13 - Tumours and Tumour-Like Lesions  | wrong publication type | round I |
| rayyan-661154090 | 2 - Intracellular Signaling   | wrong publication type | round I |
| rayyan-661154092 | Chapter 12 - Clinical pharmacogenetics  | wrong publication type | round I |
| rayyan-661154093 | "XIII National Congress of Digestive Diseases   | wrong publication type | round I |
| rayyan-661154094 | 17 - Tumors of the Brain and Spinal Cord  | wrong publication type | round I |
| rayyan-661154096 | Chapter Three - A Macro View of MicroRNAs: The Discovery of MicroRNAs and Their Role in Hematopoiesis and Hematologic Disease | wrong publication type | round I |
| rayyan-661154097 | Chapter 2 - Nasopharyngeal Carcinoma: Genetics and Genomics   | wrong publication type | round I |
| rayyan-661154099 | C   | wrong publication type | round I |
| rayyan-661154100 | Chapter 34 - Novel Therapeutic Approaches and Targets for Ovarian Cancer  | wrong publication type | round I |
| rayyan-661154101 | Minimizing the risk of small-for-size syndrome after liver surgery  | wrong publication type | round I |
| rayyan-661154102 | Analysis of Molecular Aberrations in Ovarian Cancer Allows Novel Target Identification  | wrong publication type | round I |
| rayyan-661154104 | The Future of Precision Medicine in Oncology  | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661154105 | "15 - Pathology  | wrong publication type | round I |
| rayyan-661154106 | Chapter 60 - Pathology of the Lower Gastrointestinal Tract   | wrong publication type | round I |
| rayyan-661154107 | Chapter 13 - Application of Molecular Diagnostics  | wrong publication type | round I |
| rayyan-661154110 | Chapter 2 - Immunotherapeutic Approaches in Cancer   | wrong publication type | round I |
| rayyan-661154112 | Chapter 3 - DNA Methylation Alterations in Human Cancers   | wrong publication type | round I |
| rayyan-661154113 | Cancer modelling in the NGS era – Part I: Emerging technology and initial modelling                                      | wrong publication type | round I |
| rayyan-661154120 | 25 - Cancer Pharmacology   | wrong publication type | round I |
| rayyan-661154127 | Immune checkpoint therapy – current perspectives and future directions   | wrong publication type | round I |
| rayyan-661154128 | "External Quality Assessment Schemes for Biomarker Testing in Oncology: Comparison of Performance between Formalin-Fixed | wrong publication type | round I |
| rayyan-661154130 | Chapter 11 - Prognostic Epigenetics  | wrong publication type | round I |
| rayyan-661154135 | "Chapter Two - From immune checkpoints to vaccines: The past   | wrong publication type | round I |
| rayyan-661154136 | Chapter 6 - Which technology performs better? From sample volume to extraction and molecular profiling                   | wrong publication type | round I |
| rayyan-661154139 | Chapter 4 - Tumor immunology   | wrong publication type | round I |
| rayyan-661154147 | Toward a More Precise Future for Oncology  | wrong publication type | round I |
| rayyan-661154154 | Chapter Eight - Patient-derived organoids as a model for tumor research  | wrong publication type | round I |
| rayyan-661154155 | Towards interpretable imaging genomics analysis: Methodological developments and applications                            | wrong publication type | round I |
| rayyan-661154158 | "Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment                 | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661154159 | CHAPTER 34 - New techniques   | wrong publication type | round I |
| rayyan-661154264 | Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review   | wrong publication type | round I |
| rayyan-661154265 | Early detection of lung cancer biomarkers through biosensor technology: A review  | wrong publication type | round I |
| rayyan-661154269 | Molecular Profiling of Cancerâ€™The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic | wrong publication type | round I |
| rayyan-661154384 | Adjuvant colon cancer chemotherapy: where we are and where we'll go   | wrong publication type | round I |
| rayyan-661154386 | Precision Oncology: Current Scenario and Future Promises and Challenges   | wrong publication type | round I |
| rayyan-661154388 | Longitudinal ctDNA profiling in precision oncology and immunî-oncology  | wrong publication type | round I |
| rayyan-661154399 | Nanotechnologies for the treatment of colon cancer: From old drugs to new hope  | wrong publication type | round I |
| rayyan-661154406 | Interplay between MAPK/ERK signaling pathway and MicroRNAs: A crucial mechanism regulating cancer cell metabolism and tumor progression                                 | wrong publication type | round I |
| rayyan-661154408 | KRAS mutations: Analytical considerations   | wrong publication type | round I |
| rayyan-661154413 | Complete pathological response in rectal cancer utilising novel treatment strategies for neo-adjuvant therapy: A systematic review                                      | wrong publication type | round I |
| rayyan-661154472 | "Adjuvant chemotherapy in resected colon cancer: When   | wrong publication type | round I |
| rayyan-661154479 | Performance of prediction models on survival outcomes of colorectal cancer with surgical resection: A systematic review and meta-analysis                               | wrong publication type | round I |
| rayyan-661154492 | Dietary phytochemicals in colorectal cancer prevention and treatment: A focus on the molecular mechanisms involved  | wrong publication type | round I |
| rayyan-661154503 | Integration of genetic variants and gene network for drug repurposing in colorectal cancer  | wrong publication type | round I |
| rayyan-661154504 | Development of circulating tumour DNA analysis for gastrointestinal cancers   | wrong publication type | round I |
| rayyan-661154507 | "Deciphering the role of KRAS gene in oncogenesis: Focus on signaling pathways  | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661154508 | Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers   | wrong publication type | round I |
| rayyan-661154523 | Omics technologies for improved diagnosis and treatment of colorectal cancer: Technical advancement and major perspectives | wrong publication type | round I |
| rayyan-661154524 | Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine                                    | wrong publication type | round I |
| rayyan-661154526 | Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions       | wrong publication type | round I |
| rayyan-661154529 | Advances on colorectal cancer 3D models: The needed translational technology for nanomedicine screening                    | wrong publication type | round I |
| rayyan-661154530 | Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer       | wrong publication type | round I |
| rayyan-661154533 | Natural language processing of German clinical colorectal cancer notes for guideline-based treatment evaluation            | wrong publication type | round I |
| rayyan-661154537 | Epigenetic modifications in colorectal cancer: Molecular insights and therapeutic challenges                               | wrong publication type | round I |
| rayyan-661154538 | The significance of gene mutations across eight major cancer types   | wrong publication type | round I |
| rayyan-661154540 | Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges           | wrong publication type | round I |
| rayyan-661154541 | Advances in adjuvant therapy of colon cancer   | wrong publication type | round I |
| rayyan-661154542 | "Refining adjuvant therapy for non-metastatic colon cancer   | wrong publication type | round I |
| rayyan-661154546 | Molecular approaches in cancer   | wrong publication type | round I |
| rayyan-661154548 | Epigenetics of Colorectal Cancer   | wrong publication type | round I |
| rayyan-661154549 | Molecular Prognostic Markers in Locally Advanced Colon Cancer  | wrong publication type | round I |
| rayyan-661154552 | "Colorectal cancer peritoneal metastases: Biology  | wrong publication type | round I |
| rayyan-661154553 | Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients  | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661154560 | The role of protein tyrosine phosphatases in colorectal cancer  | wrong publication type | round I |
| rayyan-661154563 | "Drug resistance  | wrong publication type | round I |
| rayyan-661154564 | Oncogenic miRNAs and target therapies in colorectal cancer  | wrong publication type | round I |
| rayyan-661154566 | The primary tumor location impacts survival outcome of colorectal liver metastases after hepatic resection: A systematic review and meta-analysis | wrong publication type | round I |
| rayyan-661154569 | "DNA damage response and repair in colorectal cancer: Defects   | wrong publication type | round I |
| rayyan-661154570 | "5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past  | wrong publication type | round I |
| rayyan-661154578 | The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers  | wrong publication type | round I |
| rayyan-661154580 | Primary tumor location and the prognosis of patients after local treatment of colorectal liver metastases: a systematic review and meta-analysis  | wrong publication type | round I |
| rayyan-661154581 | Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy   | wrong publication type | round I |
| rayyan-661154583 | Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review        | wrong publication type | round I |
| rayyan-661154601 | A meta-analysis of microsatellite instability and colorectal cancer prognosis abstract  | wrong publication type | round I |
| rayyan-661154638 | "Clinical   | wrong publication type | round I |
| rayyan-661154641 | Probing the colorectal cancer proteome for biomarkers: Current status and perspectives  | wrong publication type | round I |
| rayyan-661154642 | A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer  | wrong publication type | round I |
| rayyan-661154643 | Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs   | wrong publication type | round I |
| rayyan-661154645 | "Molecular subtyping of colorectal cancer: Recent progress  | wrong publication type | round I |
| rayyan-661154656 | Predictive Markers in Colorectal Cancer   | wrong publication type | round I |



|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661154663 | Predictive and prognostic biomarkers in gastrointestinal tract tumours  | wrong publication type | round I |
| rayyan-661154664 | The molecular biology of colorectal carcinoma and its implications: A review  | wrong publication type | round I |
| rayyan-661154665 | Microbe-based therapies for colorectal cancer: Advantages and limitations   | wrong publication type | round I |
| rayyan-661154667 | A comprehensive overview of promising biomarkers in stage II colorectal cancer  | wrong publication type | round I |
| rayyan-661154673 | Intestinal multicellular organoids to study colorectal cancer   | wrong publication type | round I |
| rayyan-661154681 | The clinical relevance of gene expression based prognostic signatures in colorectal cancer  | wrong publication type | round I |
| rayyan-661154682 | "Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology                                     | wrong publication type | round I |
| rayyan-661154784 | The most recent advances in immunotherapy with checkpoint inhibitors in gastrointestinal cancers  | wrong publication type | round I |
| rayyan-661154787 | Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine  | wrong publication type | round I |
| rayyan-661154788 | Portrait of the PI3K/AKT pathway in colorectal cancer   | wrong publication type | round I |
| rayyan-661154789 | Rectal and colon cancer: Not just a different anatomic site   | wrong publication type | round I |
| rayyan-661154790 | Coiled-coil domain-containing 154 promotes colorectal cancer proliferation and metastasis via interacting with minichromosome maintenance complex component 2 | wrong publication type | round I |
| rayyan-661154792 | Simple classifiers for molecular subtypes of colorectal cancer  | wrong publication type | round I |
| rayyan-661154796 | Mutation Hotspots in the $\beta^2$ -Catenin Gene: Lessons from the Human Cancer Genome Databases  | wrong publication type | round I |
| rayyan-661154797 | Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist                | wrong publication type | round I |
| rayyan-661154799 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer   | wrong publication type | round I |
| rayyan-661154801 | Metabolic pathways regulating colorectal cancer initiation and progression  | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661154802 | Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer                        | wrong publication type | round I |
| rayyan-661154803 | Integrating Biomarkers Into Clinical Decision Making for Colorectal Cancer   | wrong publication type | round I |
| rayyan-661154804 | "Blood-based biomarkers for diagnosis  | wrong publication type | round I |
| rayyan-661154808 | Chapter 2 - Translational epigenetics in precision medicine of colorectal cancer   | wrong publication type | round I |
| rayyan-661154810 | An Update on Colorectal Cancer   | wrong publication type | round I |
| rayyan-661154812 | Exosomal-long non-coding RNAs journey in colorectal cancer: Evil and goodness faces of key players                                   | wrong publication type | round I |
| rayyan-661154813 | Association of DNA repair gene polymorphisms with colorectal cancer risk and treatment outcomes                                      | wrong publication type | round I |
| rayyan-661154814 | Peritoneal carcinomatosis from colorectal cancer in the pediatric population: Cytoreductive surgery and HIPEC. A systematic review   | wrong publication type | round I |
| rayyan-661154817 | B-Raf mutation: A key player in molecular biology of cancer  | wrong publication type | round I |
| rayyan-661154818 | Therapeutic Targeting of the Colorectal Tumor Stroma   | wrong publication type | round I |
| rayyan-661154819 | Dendritic cell vaccine therapy for colorectal cancer   | wrong publication type | round I |
| rayyan-661154822 | Precision Treatment and Prevention of Colorectal Cancer”Hope or Hype?  | wrong publication type | round I |
| rayyan-661154823 | Advances of immune checkpoints in colorectal cancer treatment  | wrong publication type | round I |
| rayyan-661154827 | Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes                                    | wrong publication type | round I |
| rayyan-661154830 | K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives                          | wrong publication type | round I |
| rayyan-661154832 | A perspective on medicinal chemistry approaches towards adenomatous polyposis coli and Wnt signal based colorectal cancer inhibitors | wrong publication type | round I |
| rayyan-661154833 | Cancers du cÃ´lon : prise en charge molÃ©culaire   | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661154836 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors  | wrong publication type | round I |
| rayyan-661154856 |  | wrong publication type | round I |
| rayyan-661154979 | Comparing international data between keyhole and robotic rectal cancer surgery                                       | wrong publication type | round I |
| rayyan-661154980 | Short treatment with the drug cyclophosphamide in bowel cancer   | wrong publication type | round I |
| rayyan-661154981 | Early screening for colorectal cancer via a simple blood sample  | wrong publication type | round I |
| rayyan-661154982 | Comparative analysis of the protective effect of different screening strategies for colorectal cancer                | wrong publication type | round I |
| rayyan-661154983 | Intestinal cancer and the risk for other cancer in the same person   | wrong publication type | round I |
| rayyan-661154984 | Could supported weight loss reduce bowel cancer surgery complications?   | wrong publication type | round I |
| rayyan-661154985 | Exercise prehabilitation in colorectal cancer  | wrong publication type | round I |
| rayyan-661154986 | Understanding Raman signatures in colorectal cancer  | wrong publication type | round I |
| rayyan-661154987 | Patient acceptability of FIT stool test and analysing a colorectal cancer risk tool                                  | wrong publication type | round I |
| rayyan-661154988 | Quality of life after surgery and other options to prevent cancer of the lining of the womb (endometrial cancer)     | wrong publication type | round I |
| rayyan-661154989 | Injection of IP-001 into thermally ablated solid tumors  | wrong publication type | round I |
| rayyan-661154990 | Evaluation of an intervention co-designed with key stakeholders to improve colorectal cancer screening participation | wrong publication type | round I |
| rayyan-661154991 | Can we analyse stool content to improve the prediction of the risk of developing bowel cancer?                       | wrong publication type | round I |
| rayyan-661154992 | The effects of a colorectal cancer screening programme for average-risk older Chinese adults                         | wrong publication type | round I |
| rayyan-661154993 | A study of functional and immunological outcomes in people undergoing robotic and non-robotic rectal cancer surgery  | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661154994 | A feasibility study of electron radiotherapy delivered during a surgical operation for rectal cancer   | wrong publication type | round I |
| rayyan-661154995 | Feasibility study of lidocaine infusion during bowel cancer surgery for cancer outcome   | wrong publication type | round I |
| rayyan-661154996 | Development of a chart that can be used to aid prediction of hidden cancerous growths in colorectal cancer patients before surgery   | wrong publication type | round I |
| rayyan-661154997 | A trial to assess the efficacy of a new drug versus standard care for anaemia following colorectal cancer surgery  | wrong publication type | round I |
| rayyan-661154998 | A study to determine the feasibility and impact of using a remote (app-based) lifestyle change program to reduce the length of stay and complications after colorectal resection surgery | wrong publication type | round I |
| rayyan-661154999 | Determining colorectal cancer features using a Rwandan population to lay a foundation and inform precise colorectal cancer clinical management   | wrong publication type | round I |
| rayyan-661155000 | Can extra tests on cancer samples identify more patients with bowel/colon cancer who should be treated with drugs called anti-EGFR agents?   | wrong publication type | round I |
| rayyan-661155001 | Is it possible to use home-based prehabilitation with added E-health in patients with colorectal cancer undergoing surgery?  | wrong publication type | round I |
| rayyan-661155002 | Testing if the SonoTran Platform can enhance drug delivery in metastatic colorectal cancer   | wrong publication type | round I |
| rayyan-661155003 | Examining the efficacy of faecal immunochemical testing (FIT) in patients with Lynch Syndrome  | wrong publication type | round I |
| rayyan-661155004 | Can messages based on behavioral economics increase participation in colorectal cancer screening programmes?   | wrong publication type | round I |
| rayyan-661155005 | The effect of supplementation with an amino acid that helps the body build protein (L-arginine) on change in the immune system of colorectal cancer patients                             | wrong publication type | round I |
| rayyan-661155006 | A pilot randomised controlled trial of an app with brief behavioural support to promote physical activity after a cancer diagnosis   | wrong publication type | round I |
| rayyan-661155007 | Clinical study to assess the outcomes of a patient-centred survivorship care plan enhanced with big data and artificial intelligence technologies  | wrong publication type | round I |
| rayyan-661155013 | Colorectal cancer cohort study (COLO-COHORT)   | wrong publication type | round I |
| rayyan-661155035 | Colorectal cancer subtypes: Translation to routine clinical pathology  | wrong publication type | round I |
| rayyan-661155037 | Colorectal cancer: epigenetic alterations and their clinical implications  | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661155039 | Opportunities on the horizon for the management of early colon cancer   | wrong publication type | round I |
| rayyan-661155042 | Chasing the personalized medicine dream through biomarker validation in colorectal cancer   | wrong publication type | round I |
| rayyan-661155044 | "An update on colorectal cancer microenvironment  | wrong publication type | round I |
| rayyan-661155047 | Could immunoscore improve the prognostic and therapeutic management in patients with solid tumors?  | wrong publication type | round I |
| rayyan-661155049 | Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens   | wrong publication type | round I |
| rayyan-661155051 | Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations  | wrong publication type | round I |
| rayyan-661155053 | Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis   | wrong publication type | round I |
| rayyan-661155058 | The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review   | wrong publication type | round I |
| rayyan-661155061 | HER2: An emerging target in colorectal cancer   | wrong publication type | round I |
| rayyan-661155063 | Current advances in detecting genetic and epigenetic biomarkers of colorectal cancer  | wrong publication type | round I |
| rayyan-661155068 | BRAF gene: From human cancers to developmental syndromes  | wrong publication type | round I |
| rayyan-661155071 | Molecular Testing of Colorectal Cancer in the Modern Era: What Are We Doing and Why?  | wrong publication type | round I |
| rayyan-661155079 | Drivers of cancer metastasis “ Arise early and remain present   | wrong publication type | round I |
| rayyan-661155135 | eRAPID cognitive interview study  | wrong publication type | round I |
| rayyan-661155136 | Evaluation of an e-health intervention for cancer patients support  | wrong publication type | round I |
| rayyan-661155230 | Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials | wrong publication type | round I |
| rayyan-661155234 | A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer  | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661155235 | Predictive Molecular Classifiers in Colorectal Cancer   | wrong publication type | round I |
| rayyan-661155242 | "Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent                                  | wrong publication type | round I |
| rayyan-661155243 | Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome  | wrong publication type | round I |
| rayyan-661155244 | Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies   | wrong publication type | round I |
| rayyan-661155253 | Clinical update on K-Ras targeted therapy in gastrointestinal cancers   | wrong publication type | round I |
| rayyan-661155254 | Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine   | wrong publication type | round I |
| rayyan-661155258 | Chapter 16 - Systemic treatment of localized colorectal cancer  | wrong publication type | round I |
| rayyan-661155262 | Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases  | wrong publication type | round I |
| rayyan-661155263 | A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology  | wrong publication type | round I |
| rayyan-661155264 | Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases  | wrong publication type | round I |
| rayyan-661155267 | The role of molecular biomarkers in outcomes and patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin | wrong publication type | round I |
| rayyan-661155269 | Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer   | wrong publication type | round I |
| rayyan-661155270 | Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer  | wrong publication type | round I |
| rayyan-661155273 | Personalizing Therapy for Colorectal Cancer   | wrong publication type | round I |
| rayyan-661155274 | KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice  | wrong publication type | round I |
| rayyan-661155275 | Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications   | wrong publication type | round I |
| rayyan-661155280 | "Colorectal cancer heterogeneity and targeted therapy: Clinical implications  | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661155282 | "Recent progress of targeted nanocarriers in diagnostic   | wrong publication type | round I |
| rayyan-661155284 | "Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern                    | wrong publication type | round I |
| rayyan-661155285 | A comprehensive framework for early-onset colorectal cancer research  | wrong publication type | round I |
| rayyan-661155289 | Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies  | wrong publication type | round I |
| rayyan-661155290 | Clinical relevance of colorectal cancer molecular subtypes  | wrong publication type | round I |
| rayyan-661155291 | Advances in radiological staging of colorectal cancer   | wrong publication type | round I |
| rayyan-661155292 | The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer                  | wrong publication type | round I |
| rayyan-661155298 | Biomarkers and Targeted Therapeutics in Colorectal Cancer   | wrong publication type | round I |
| rayyan-661155299 | Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery | wrong publication type | round I |
| rayyan-661155300 | Molecular Insights Into Colorectal Carcinoma  | wrong publication type | round I |
| rayyan-661155301 | Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer                        | wrong publication type | round I |
| rayyan-661155305 | Colorectal cancer immunotherapy-Recent progress and future directions   | wrong publication type | round I |
| rayyan-661155307 | "Methods and biomarkers for early detection   | wrong publication type | round I |
| rayyan-661155308 | Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside                  | wrong publication type | round I |
| rayyan-661155311 | "Integrated approaches for precision oncology in colorectal cancer: The more you know                         | wrong publication type | round I |
| rayyan-661155312 | Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer                     | wrong publication type | round I |
| rayyan-661155313 | The Changing Demographics of Colorectal Cancer: Rising Incidence in Younger Individuals                       | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661155315 | Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer  | wrong publication type | round I |
| rayyan-661155316 | "Chapter 10 - Colorectal cancer heterogeneity and targeted therapy: clinical implications   | wrong publication type | round I |
| rayyan-661155317 | Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance                              | wrong publication type | round I |
| rayyan-661155319 | Prognosis in colorectal cancer beyond TNM   | wrong publication type | round I |
| rayyan-661155322 | HER2 in Colorectal Carcinoma: Are We There yet?   | wrong publication type | round I |
| rayyan-661155323 | Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers  | wrong publication type | round I |
| rayyan-661155327 | Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm  | wrong publication type | round I |
| rayyan-661155331 | Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis   | wrong publication type | round I |
| rayyan-661155333 | Colorectal cancer cell exosome and cytoplasmic membrane for homotypic delivery of therapeutic molecules   | wrong publication type | round I |
| rayyan-661155335 | Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers   | wrong publication type | round I |
| rayyan-661155336 | Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy   | wrong publication type | round I |
| rayyan-661155338 | A practical guide to biomarkers for the evaluation of colorectal cancer   | wrong publication type | round I |
| rayyan-661155339 | "A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies | wrong publication type | round I |
| rayyan-661155340 | Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group | wrong publication type | round I |
| rayyan-661155342 | Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency                           | wrong publication type | round I |
| rayyan-661155343 | A synopsis of modern - day colorectal cancer: Where we stand  | wrong publication type | round I |
| rayyan-661155344 | The diverse molecular profiles of lynch syndrome-associated colorectal cancers are (highly) dependent on underlying germline mismatch repair mutations          | wrong publication type | round I |



|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661155345 | HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer   | wrong publication type | round I |
| rayyan-661155347 | Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR | wrong publication type | round I |
| rayyan-661155352 | Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer   | wrong publication type | round I |
| rayyan-661155355 | Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities   | wrong publication type | round I |
| rayyan-661155359 | The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials                          | wrong publication type | round I |
| rayyan-661155362 | Nano-enabled colorectal cancer therapy   | wrong publication type | round I |
| rayyan-661155364 | MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing   | wrong publication type | round I |
| rayyan-661155365 | HER2 targeted therapy in colorectal cancer: New horizons   | wrong publication type | round I |
| rayyan-661155366 | Evaluation of immune infiltrate according to the HER2 status in colorectal cancer  | wrong publication type | round I |
| rayyan-661155367 | BRAF V600E mutation-specific antibody: A review  | wrong publication type | round I |
| rayyan-661155370 | Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer | wrong publication type | round I |
| rayyan-661155372 | Small-molecule drugs of colorectal cancer: Current status and future directions  | wrong publication type | round I |
| rayyan-661155377 | Update on Mucoadhesive Approaches to target Drug Delivery in Colorectal Cancer   | wrong publication type | round I |
| rayyan-661155383 | RET fusions in a small subset of advanced colorectal cancers at risk of being neglected  | wrong publication type | round I |
| rayyan-661155384 | Immune scores in colorectal cancer: Where are we?  | wrong publication type | round I |
| rayyan-661155386 | Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?   | wrong publication type | round I |
| rayyan-661155392 | Biomarker concordance between primary colorectal cancer and its metastases   | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661155394 | The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice  | wrong publication type | round I |
| rayyan-661155395 | Translational research of new developments in targeted therapy of colorectal cancer   | wrong publication type | round I |
| rayyan-661155399 | Clinicopathological relevance of BRAF mutations in human cancer   | wrong publication type | round I |
| rayyan-661155400 | The updates on metastatic mechanism and treatment of colorectal cancer  | wrong publication type | round I |
| rayyan-661155401 | Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer | wrong publication type | round I |
| rayyan-661155402 | The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: A network meta-analysis  | wrong publication type | round I |
| rayyan-661155404 | Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?  | wrong publication type | round I |
| rayyan-661155408 | Liquid biopsy in colorectal cancer: Onward and upward   | wrong publication type | round I |
| rayyan-661155412 | Treatment sequencing of metastatic colorectal cancer based on primary tumor location  | wrong publication type | round I |
| rayyan-661155416 | Prognostic and predictive molecular biomarkers in advanced colorectal cancer  | wrong publication type | round I |
| rayyan-661155418 | "Colorectal cancer: Genetic alterations   | wrong publication type | round I |
| rayyan-661155423 | Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective  | wrong publication type | round I |
| rayyan-661155436 | The impact of microsatellite stability status in colorectal cancer  | wrong publication type | round I |
| rayyan-661155463 | Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?   | wrong publication type | round I |
| rayyan-661155465 | Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice  | wrong publication type | round I |
| rayyan-661155477 | Systematic review of tumour budding and association with common mutations in patients with colorectal cancer  | wrong publication type | round I |
| rayyan-661155479 | 23 - Colorectal cancer  | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661155480 | "BRAF mutant colorectal cancer: prognosis   | wrong publication type | round I |
| rayyan-661155483 | Current progress of immune checkpoint inhibitors for advanced colorectal cancer: concentrating on the efficacy improvement  | wrong publication type | round I |
| rayyan-661155487 | Prognostic and predictive markers in liver limited stage IV colorectal cancer   | wrong publication type | round I |
| rayyan-661155502 | Metastatic colorectal cancer: mechanisms and emerging therapeutics  | wrong publication type | round I |
| rayyan-661155509 | An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer                        | wrong publication type | round I |
| rayyan-661155518 | Cancers colorectaux avec mutation V600E de BRAF : oÃ¹ en sommes-nous ?  | wrong publication type | round I |
| rayyan-661155520 | "Encorafenib  | wrong publication type | round I |
| rayyan-661155522 | SET nuclear proto-oncogene gene expression is associated with microsatellite instability in human colorectal cancer identified by co-expression analysis                        | wrong publication type | round I |
| rayyan-661155525 | Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants   | wrong publication type | round I |
| rayyan-661155526 | BRAF gene as a potential target to attenuate drug resistance and treat cancer   | wrong publication type | round I |
| rayyan-661155532 | European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer   | wrong publication type | round I |
| rayyan-661155533 | Serrated colorectal cancer: preclinical models and molecular pathways   | wrong publication type | round I |
| rayyan-661155534 | BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications   | wrong publication type | round I |
| rayyan-661155537 | High sensitivity and rapid detection of KRAS and BRAF gene mutations in colorectal cancer using YbTiOx electrolyte-insulator-semiconductor biosensors                           | wrong publication type | round I |
| rayyan-661155538 | "Tucatinib plus trastuzumab for chemotherapy-refractory   | wrong publication type | round I |
| rayyan-661155541 | Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer  | wrong publication type | round I |
| rayyan-661155542 | Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7 | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661155545 | Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines  | wrong publication type | round I |
| rayyan-661155550 | Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer | wrong publication type | round I |
| rayyan-661155553 | Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA  | wrong publication type | round I |
| rayyan-661155558 | Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer  | wrong publication type | round I |
| rayyan-661155559 | The evolving role of microsatellite instability in colorectal cancer: A review   | wrong publication type | round I |
| rayyan-661155561 | Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2  | wrong publication type | round I |
| rayyan-661155562 | The mechanism investigation of mutation genes in liver and lung metastasis of colorectal cancer by using NGS technique   | wrong publication type | round I |
| rayyan-661155565 | Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?   | wrong publication type | round I |
| rayyan-661155566 | BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications                                       | wrong publication type | round I |
| rayyan-661155569 | A review of targeted therapy and immune checkpoint inhibitors for metastatic colorectal cancer   | wrong publication type | round I |
| rayyan-661155576 | The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review  | wrong publication type | round I |
| rayyan-661155579 | Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches  | wrong publication type | round I |
| rayyan-661155582 | Immunopeptidomic Analyses of Colorectal Cancers With and Without Microsatellite Instability  | wrong publication type | round I |
| rayyan-661155583 | "Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis  | wrong publication type | round I |
| rayyan-661155801 | KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis.   | wrong publication type | round I |
| rayyan-661155804 | RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.  | wrong publication type | round I |
| rayyan-661155807 | Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.   | wrong publication type | round I |

|                  |   |                        |         |
|------------------|---|------------------------|---------|
| rayyan-661155808 | Microsatellite instability and colorectal cancer.   | wrong publication type | round I |
| rayyan-661155809 | Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability.   | wrong publication type | round I |
| rayyan-661155814 | Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.  | wrong publication type | round I |
| rayyan-661155817 | Recent advances in understanding colorectal cancer.   | wrong publication type | round I |
| rayyan-661155818 | Serrated pathway in colorectal carcinogenesis.  | wrong publication type | round I |
| rayyan-661155823 | Colorectal cancer: genetics of development and metastasis.  | wrong publication type | round I |
| rayyan-661155825 | Tracking the molecular features of nonpolypoid colorectal neoplasms: a systematic review and meta-analysis.   | wrong publication type | round I |
| rayyan-661155826 | "Smoking and Colorectal Cancer Risk   | wrong publication type | round I |
| rayyan-661155833 | CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway.                        | wrong publication type | round I |
| rayyan-661155841 | Four molecular subtypes of colorectal cancer and their precursor lesions.   | wrong publication type | round I |
| rayyan-661155848 | Targeting the serrated pathway of colorectal cancer with mutation in BRAF.  | wrong publication type | round I |
| rayyan-661155850 | PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis.   | wrong publication type | round I |
| rayyan-661155885 | Molecular markers predictive of chemotherapy response in colorectal cancer.   | wrong publication type | round I |
| rayyan-661155887 | Clinicopathological characteristics of serrated polyps as precursors to colorectal cancer: Current status and management.   | wrong publication type | round I |
| rayyan-661155907 | Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability.     | wrong publication type | round I |
| rayyan-661155914 | The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. | wrong publication type | round I |
| rayyan-661155920 | Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.                                   | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661155924 | "Loss of heterozygosity  | wrong publication type | round I |
| rayyan-661155925 | Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics.  | wrong publication type | round I |
| rayyan-661155930 | Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma  | wrong publication type | round I |
| rayyan-661155932 | MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. | wrong publication type | round I |
| rayyan-661155943 | The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status.  | wrong publication type | round I |
| rayyan-661155944 | [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].   | wrong publication type | round I |
| rayyan-661155945 | Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer.  | wrong publication type | round I |
| rayyan-661155946 | Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors.   | wrong publication type | round I |
| rayyan-661155951 | The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.   | wrong publication type | round I |
| rayyan-661155954 | "Association between methylation in mismatch repair genes  | wrong publication type | round I |
| rayyan-661155956 | Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights.  | wrong publication type | round I |
| rayyan-661155958 | Adjuvant Chemotherapy With or Without Biologics Including Antiangiogenics and Monoclonal Antibodies Targeting EGFR and EpCAM in Colorectal Cancer: A Systematic Review and Meta-analysis.                                | wrong publication type | round I |
| rayyan-661155963 | Meta-analysis of the molecular associations of mucinous colorectal cancer.   | wrong publication type | round I |
| rayyan-661155969 | MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.   | wrong publication type | round I |
| rayyan-661155970 | "[A New Era of Colorectal Cancer Treatment Being Led by a Precise Analysis of Somatic Mutational Profiles Including RAS  | wrong publication type | round I |
| rayyan-661155993 | "Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high  | wrong publication type | round I |
| rayyan-661155999 | "Molecular biomarkers for an early diagnosis   | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661156004 | Molecular classification of colorectal cancer: a dream that can become a reality.  | wrong publication type | round I |
| rayyan-661156016 | Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports.   | wrong publication type | round I |
| rayyan-661156047 | Genetic prognostic and predictive markers in colorectal cancer.  | wrong publication type | round I |
| rayyan-661156050 | "Genetic alterations of APC  | wrong publication type | round I |
| rayyan-661156051 | Pathologic features and biologic importance of colorectal serrated polyps.   | wrong publication type | round I |
| rayyan-661156072 | "Serrated colorectal cancer: Molecular classification  | wrong publication type | round I |
| rayyan-661156079 | Primary signet ring cell carcinoma of the colon and rectum.  | wrong publication type | round I |
| rayyan-661156082 | The role of molecular markers in predicting response to therapy in patients with colorectal cancer.  | wrong publication type | round I |
| rayyan-661156123 | Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.   | wrong publication type | round I |
| rayyan-661156125 | Clinical features and molecular alterations of traditional serrated adenoma in sporadic colorectal carcinogenesis.                                       | wrong publication type | round I |
| rayyan-661156139 | POLE somatic mutations in advanced colorectal cancer.  | wrong publication type | round I |
| rayyan-661156144 | Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.                  | wrong publication type | round I |
| rayyan-661156148 | Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.  | wrong publication type | round I |
| rayyan-661156163 | Genetic aspects of non-polypoid colorectal neoplasms.  | wrong publication type | round I |
| rayyan-661156167 | Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. | wrong publication type | round I |
| rayyan-661156171 | Biomarkers in early-stage colorectal cancer: ready for prime time?   | wrong publication type | round I |
| rayyan-661156172 | Filiform serrated adenomas: a clinicopathologic and immunophenotypic study of 18 cases.  | wrong publication type | round I |

|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661156186 | Is Adjuvant Chemotherapy Efficient in Colon Cancer with High Microsatellite Instability? A Look Towards the Future.  | wrong publication type | round I |
| rayyan-661156194 | Genetic and epigenetic changes in colon cancer.  | wrong publication type | round I |
| rayyan-661156204 | A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.  | wrong publication type | round I |
| rayyan-661156205 | Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. | wrong publication type | round I |
| rayyan-661156213 | [Colorectal carcinoma in consideration of the new German S3 guideline 2013].   | wrong publication type | round I |
| rayyan-661156230 | Surgical Resection for Local and Lateral Lymph Node Recurrence of MSI-high Cecal Cancer with the BRAF V600E Mutation.  | wrong publication type | round I |
| rayyan-661156231 | Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific.   | wrong publication type | round I |
| rayyan-661156233 | Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy.   | wrong publication type | round I |
| rayyan-661156234 | [Pathological diagnosis for individualized therapy of colorectal cancer].  | wrong publication type | round I |
| rayyan-661156245 | Development of invasive colon cancer with microsatellite instability in a patient with hyperplastic polyposis syndrome.  | wrong publication type | round I |
| rayyan-661156246 | ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.   | wrong publication type | round I |
| rayyan-661156247 | Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?   | wrong publication type | round I |
| rayyan-661156250 | What can molecular pathology offer for optimal decision making?  | wrong publication type | round I |
| rayyan-661156251 | A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation.   | wrong publication type | round I |
| rayyan-661156256 | [Insights on colorectal carcinoma based on the biological differences between left-sided and right- sided colon cancers].  | wrong publication type | round I |
| rayyan-661156262 | Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.  | wrong publication type | round I |
| rayyan-661156264 | Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer.  | wrong publication type | round I |



|                  |  |                        |         |
|------------------|--|------------------------|---------|
| rayyan-661156270 | "De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases                            | wrong publication type | round I |
| rayyan-661156273 | "[The alternative way of colorectal cancer developing. The histogenetic and molecular features of serrated lesions (review                         | wrong publication type | round I |
| rayyan-661156275 | "Population-based universal screening for Lynch syndrome: ready  | wrong publication type | round I |
| rayyan-661156276 | [Pathologic diagnosis of colorectal cancer in the era of personalized therapy].  | wrong publication type | round I |
| rayyan-661156281 | Molecular Characterization of Sessile Serrated Adenoma/Polyps From a Large African American Cohort.  | wrong publication type | round I |
| rayyan-661156289 | [Biomarker for colorectal cancer].   | wrong publication type | round I |
| rayyan-661156292 | [Gene mutation and DNA methylation in non-hereditary colon neoplasms].   | wrong publication type | round I |
| rayyan-661156293 | [Serrated lesions and carcinoma of colorectum].  | wrong publication type | round I |
| rayyan-661156294 | [Ways of handling surgical material from patients with colon cancer - standard and additional highly specialized research with colorectal cancer]. | wrong publication type | round I |
| rayyan-661156295 | [Present conditions and problems in gene diagnosis of colon neoplasms].  | wrong publication type | round I |
| rayyan-661156297 | Precision Therapy in RAS Mutant Colorectal Cancer.   | wrong publication type | round I |
| rayyan-661156307 | [Prognostic marker profiles for risk of distant metastases in colorectal cancer].  | wrong publication type | round I |
| rayyan-661156313 | Filiform polyposis: A benign entity? Case report and literature review.  | wrong publication type | round I |
| rayyan-661156316 | [Prognostic biomarkers for metastatic colorectal cancer].  | wrong publication type | round I |
| rayyan-661156329 | Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.  | wrong publication type | round I |
| rayyan-661154035 | Chapter 1 - Special Diagnostic Techniques in Surgical Pathology  | background article     | round I |
| rayyan-661154036 | The natural history of adenomas  | background article     | round I |
| rayyan-661154037 | 20 - Molecular pathology   | background article     | round I |

|                  |  |                    |         |
|------------------|--|--------------------|---------|
| rayyan-661154038 | Chapter 6 - Gastrointestinal System  | background article | round I |
| rayyan-661154039 | Chapter 164 - Adenocarcinoma of the Colon and Rectum   | background article | round I |
| rayyan-661154040 | Chapter Four - Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual       | background article | round I |
| rayyan-661154041 | 13 - Tumours and Tumour-like Lesions of the Liver  | background article | round I |
| rayyan-661154042 | The therapeutic landscape of hepatocellular carcinoma  | background article | round I |
| rayyan-661154043 | Chapter 12 - Genetics of Adrenal Tumors  | background article | round I |
| rayyan-661154044 | 86 - Carcinoma of the Ovaries and Fallopian Tubes  | background article | round I |
| rayyan-661154045 | Chapitre 2 - Anatomie pathologique   | background article | round I |
| rayyan-661154046 | 13 - Neoplasms of the Testis   | background article | round I |
| rayyan-661154047 | Chapter 4 - Tumor Heterogeneity  | background article | round I |
| rayyan-661154049 | 5 - Neoplasia  | background article | round I |
| rayyan-661154051 | Chapter 3 - Pharmacogenetics of therapeutics   | background article | round I |
| rayyan-661154052 | "Chapter 6 - Pharmacoepigenetic Processors: Epigenetic Drugs   | background article | round I |
| rayyan-661154053 | Intraductal Papillary Mucinous Neoplasm: A Clinicopathologic Review                                      | background article | round I |
| rayyan-661154054 | Chapter Seven - Synergistic combination of oncolytic virotherapy with CAR T-cell therapy                 | background article | round I |
| rayyan-661154055 | Chapter 57 - Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies | background article | round I |
| rayyan-661154056 | Gastroenteropancreatic endocrine tumors  | background article | round I |
| rayyan-661154057 | Chapter 9 - Hereditary predisposition to uveal melanoma  | background article | round I |
| rayyan-661154059 | Architects meets Repairers: The interplay between homeobox genes and DNA repair                          | background article | round I |
| rayyan-661154062 | CHAPTER 7 - Molecular Biology  | background article | round I |
| rayyan-661154077 | 1 - Pancreatic Carcinoma: An Introduction  | background article | round I |
| rayyan-661154089 | Chapter 8 - Prognostic epigenetics   | background article | round I |
| rayyan-661154103 | "17 - Pathology  | background article | round I |
| rayyan-661154119 | 14 - Genetic and Epigenetic Alterations in Cancer  | background article | round I |
| rayyan-661154162 | Chapter 4 - Targeted therapy: small molecules  | background article | round I |
| rayyan-661154163 | "The pathophysiology   | background article | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661154164 | Chapter 8 - Oncologyâ€”Acquired   | background article | round I |
| rayyan-661154165 | Mechanisms of MTH1 inhibition-induced DNA strand breaks: The slippery slope from the oxidized nucleotide pool to genotoxic damage                                     | background article | round I |
| rayyan-661154166 | 3 - Molecular Basis of Human Malignancy   | background article | round I |
| rayyan-661154167 | Human height genes and cancer   | background article | round I |
| rayyan-661154168 | Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy  | background article | round I |
| rayyan-661154169 | Chapter 11 - Predictive Value of Epigenetic Signatures  | background article | round I |
| rayyan-661154170 | 51 - Biology of Lung Cancer   | background article | round I |
| rayyan-661154171 | Chapter 17 - The Molecular Biology of Cancer  | background article | round I |
| rayyan-661154172 | CpG Methylation Analysisâ€”Current Status of Clinical Assays and Potential Applications in Molecular Diagnostics: A Report of the Association for Molecular Pathology | background article | round I |
| rayyan-661154174 | Cancer gene discovery in mouse and man  | background article | round I |
| rayyan-661154175 | Chapter 3 - Biomarkers in Oncology and Nephrology   | background article | round I |
| rayyan-661154176 | "Chapter 7 - Development  | background article | round I |
| rayyan-661154177 | The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer   | background article | round I |
| rayyan-661154178 | Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine  | background article | round I |
| rayyan-661154179 | Chapter 5 - State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA   | background article | round I |
| rayyan-661154181 | Chapter Five - T Lymphocyteâ€”Based Cancer Immunotherapeutics   | background article | round I |
| rayyan-661154182 | Chapter 13 - Biomarkers of malignancy   | background article | round I |
| rayyan-661154185 | Chapter 11 - Genetics and Molecular Biology of Pancreatic and Biliary Cancers   | background article | round I |
| rayyan-661154186 | CHAPTER 3 - Genetics and Epigenetics in Cancer Biology  | background article | round I |
| rayyan-661154187 | Pancreatic Cancer: Pathology and Genetics   | background article | round I |
| rayyan-661154188 | Chapter 1 - Immune Checkpoint Inhibitors: Mechanisms and Emerging Therapeutic Opportunities   | background article | round I |
| rayyan-661154190 | Chapter 66 - Mechanisms of Gastrointestinal Malignancies  | background article | round I |
| rayyan-661154192 | "Chapter One - The Evolving   | background article | round I |
| rayyan-661154193 | Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology  | background article | round I |
| rayyan-661154194 | Molecular Pathologyâ€”Translating Research into Clinical Practice: An Expanding Frontier in Surgical Oncology   | background article | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661154195 | Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems  | background article | round I |
| rayyan-661154196 | "From Colonic Polyps to Colon Cancer: Pathophysiology   | background article | round I |
| rayyan-661154197 | Chapter 9B - Molecular pathology of pancreatic cancer and premalignant tumors   | background article | round I |
| rayyan-661154198 | Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?   | background article | round I |
| rayyan-661154199 | Dissecting the genetic alterations involved in lung carcinogenesis  | background article | round I |
| rayyan-661154200 | Chapter 4 - Clinical decision support and molecular tumor boards  | background article | round I |
| rayyan-661154201 | "Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2 | background article | round I |
| rayyan-661154202 | "Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets  | background article | round I |
| rayyan-661154205 | The current status and problems confronted in delivering precision medicine in Japan and Europe   | background article | round I |
| rayyan-661154206 | Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies   | background article | round I |
| rayyan-661154208 | Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas                | background article | round I |
| rayyan-661154213 | Combinatorial therapy in tumor microenvironment: Where do we stand?   | background article | round I |
| rayyan-661154219 | Disentangling the relationship between tumor genetic programs and immune responsiveness   | background article | round I |
| rayyan-661154223 | Chapter 2 - Cancer Epigenetics  | background article | round I |
| rayyan-661154227 | The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis   | background article | round I |
| rayyan-661154228 | Chapter 4 - Immune Checkpoint Inhibitors in Gastrointestinal Malignancies   | background article | round I |
| rayyan-661154229 | Lessons from the Cancer Genome  | background article | round I |
| rayyan-661154230 | Prediction in Rectal Cancer   | background article | round I |
| rayyan-661154231 | RNA sequencing for research and diagnostics in clinical oncology  | background article | round I |
| rayyan-661154234 | Gastric Cancer in the Era of Precision Medicine   | background article | round I |
| rayyan-661154239 | The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care   | background article | round I |
| rayyan-661154240 | Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life                      | background article | round I |
| rayyan-661154243 | Chapter Four - Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers  | background article | round I |
| rayyan-661154244 | "Chapter 1 - Biology  | background article | round I |

|                  |  |                    |         |
|------------------|--|--------------------|---------|
| rayyan-661154245 | NTRK insights: best practices for pathologists   | background article | round I |
| rayyan-661154246 | Chapter 2 - Pharmacogenomics and Personalized Medicines in Cancer Treatment  | background article | round I |
| rayyan-661154247 | Current Challenges in Cancer Treatment   | background article | round I |
| rayyan-661154250 | The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges | background article | round I |
| rayyan-661154252 | Chapter 12 - Genomics and Molecular Profiling of Lung Cancer   | background article | round I |
| rayyan-661154253 | Gastric Cancer   | background article | round I |
| rayyan-661154254 | How Can Gastric Cancer Molecular Profiling Guide Future Therapies?   | background article | round I |
| rayyan-661154256 | Chapter 20 - Applications of molecular techniques in the clinical laboratory   | background article | round I |
| rayyan-661154258 | New agents on the horizon in gastric cancer  | background article | round I |
| rayyan-661154259 | Pancreatic ductal adenocarcinoma in the era of precision medicine  | background article | round I |
| rayyan-661154260 | Chapter 70 - Cancer of the Colon and Gastrointestinal Tract  | background article | round I |
| rayyan-661154272 | Chapter 34 - Cancer Epigenetics  | background article | round I |
| rayyan-661154276 | Chapter Two - Circulating Biomarkers in Malignant Melanoma   | background article | round I |
| rayyan-661154277 | Chapter 24 - Genetic Intratumor Heterogeneity  | background article | round I |
| rayyan-661154279 | "Clinical Next-Generation Sequencing Assays for Solid Tumors: Current Practices  | background article | round I |
| rayyan-661154281 | Chapter 2 - Antiangiogenic drugs: Chemosensitizers for combination cancer therapy  | background article | round I |
| rayyan-661154282 | Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers   | background article | round I |
| rayyan-661154283 | Mitochondria: The metabolic switch of cellular oncogenic transformation  | background article | round I |
| rayyan-661154285 | Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib                                   | background article | round I |
| rayyan-661154286 | "Pathophysiology   | background article | round I |
| rayyan-661154290 | Targeted Therapies: The Rare Cancer Paradigm   | background article | round I |
| rayyan-661154291 | Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics   | background article | round I |
| rayyan-661154293 | Colon cancer   | background article | round I |
| rayyan-661154294 | Chapter Three - Canine models of human cancer: Bridging the gap to improve precision medicine  | background article | round I |
| rayyan-661154297 | Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation                  | background article | round I |
| rayyan-661154299 | Roles of fusion genes in digestive system cancers: Dawn for cancer precision therapy   | background article | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661154301 | Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference | background article | round I |
| rayyan-661154303 | Sebaceous lesions and their associated syndromes: Part II   | background article | round I |
| rayyan-661154305 | Chapter 1 - Epithelial ovarian cancer: Genomic landscape and evolving precision treatment   | background article | round I |
| rayyan-661154306 | Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting                              | background article | round I |
| rayyan-661154307 | Chapter 14 - Cancer Vaccines  | background article | round I |
| rayyan-661154308 | Chapter 1 - Current Trends in Cancer Therapy  | background article | round I |
| rayyan-661154309 | Tumor-on-chip modeling of organ-specific cancer and metastasis  | background article | round I |
| rayyan-661154311 | Chapter 2 - Prognosis and follow-up of CRC patients: Role of diagnostic and therapeutic delay                                     | background article | round I |
| rayyan-661154312 | CHAPTER 11 - Alteration in major cell signaling pathways in cancer  | background article | round I |
| rayyan-661154314 | "Clinical Update: Colon   | background article | round I |
| rayyan-661154316 | Application of PD-1 Blockade in Cancer Immunotherapy  | background article | round I |
| rayyan-661154318 | Adapting Clinical Paradigms to the Challenges of Cancer Clonal Evolution  | background article | round I |
| rayyan-661154320 | The emerging roles of NGS in clinical oncology and personalized medicine  | background article | round I |
| rayyan-661154322 | tRNA Deregulation and Its Consequences in Cancer  | background article | round I |
| rayyan-661154329 | Mutations: Driver Versus Passenger  | background article | round I |
| rayyan-661154330 | Chapter 29 - Targeted molecular therapy: the cancer paradigm  | background article | round I |
| rayyan-661154332 | Personalized Colon Cancer Care in 2010  | background article | round I |
| rayyan-661154333 | Cancer molecular markers: A guide to cancer detection and management  | background article | round I |
| rayyan-661154336 | ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research          | background article | round I |
| rayyan-661154337 | Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents   | background article | round I |
| rayyan-661154338 | Basket trials: From tumour gnostic to tumour agnostic drug development  | background article | round I |
| rayyan-661154339 | "Small molecules  | background article | round I |
| rayyan-661154341 | Chapter Eleven - Anti-cancer drug molecules targeting cancer cell cycle and proliferation   | background article | round I |
| rayyan-661154342 | 3 - Mechanisms of multidrug resistance in cancer  | background article | round I |
| rayyan-661154343 | Chapter 4 - Cancer Genetic Screening and Ethical Considerations for Precision Medicine  | background article | round I |
| rayyan-661154344 | 15 - Systemic Therapy for Colon Cancer  | background article | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661154345 | microRNAs in colon cancer: A roadmap for discovery  | background article | round I |
| rayyan-661154347 | Chapter 3 - Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology | background article | round I |
| rayyan-661154353 | piRNA: A promising biomarker in early detection of gastrointestinal cancer  | background article | round I |
| rayyan-661154354 | "The Interaction of Genomics  | background article | round I |
| rayyan-661154355 | The current evidence for a biomarker-based approach in cancer of unknown primary  | background article | round I |
| rayyan-661154360 | Neuroendocrine Neoplasms: Genetics and Epigenetics  | background article | round I |
| rayyan-661154361 | "How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges                                | background article | round I |
| rayyan-661154363 | Chapter 36 - Oral administration of cytostatic drugs in the treatment of CRC  | background article | round I |
| rayyan-661154364 | Chapter 4 - Current clinically validated applications of liquid biopsy  | background article | round I |
| rayyan-661154365 | Chapter 40 - Immunology and immunotherapy in CRC  | background article | round I |
| rayyan-661154370 | Re-Evaluating Clonal Dominance in Cancer Evolution  | background article | round I |
| rayyan-661154375 | CHAPTER 3 - Etiology of cancer  | background article | round I |
| rayyan-661154376 | The clinical role of circulating free tumor DNA in gastrointestinal malignancy  | background article | round I |
| rayyan-661154377 | "Chapter Four - Immune Contexture   | background article | round I |
| rayyan-661154378 | A perspective on the role of autophagy in cancer  | background article | round I |
| rayyan-661154379 | 75 - Cancer of the Rectum   | background article | round I |
| rayyan-661154380 | Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine   | background article | round I |
| rayyan-661154387 | Chapter 163 - Colorectal Polyps and Polyposis Syndromes   | background article | round I |
| rayyan-661154398 | Lynch Syndromeâ†  | background article | round I |
| rayyan-661154400 | Age-related biological differences in childrenâs and adolescentsâ very rare tumors  | background article | round I |
| rayyan-661154407 | Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis  | background article | round I |
| rayyan-661154411 | 24 - MOLECULAR BIOLOGY OF COLORECTAL CANCER   | background article | round I |
| rayyan-661154412 | ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development   | background article | round I |
| rayyan-661154414 | Chapter 35 - Cancer Epigenetics   | background article | round I |
| rayyan-661154415 | Gut eukaryotic virome in colorectal carcinogenesis: Is that a trigger?  | background article | round I |
| rayyan-661154417 | Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms  | background article | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661154421 | Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards | background article | round I |
| rayyan-661154423 | Target therapy in cancer treatment  | background article | round I |
| rayyan-661154424 | Chapter 36 - Colorectal Cancer  | background article | round I |
| rayyan-661154426 | Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms  | background article | round I |
| rayyan-661154427 | Rectal cancer genomics  | background article | round I |
| rayyan-661154428 | Chapter 4 - Cancer prognosis and immune system  | background article | round I |
| rayyan-661154434 | Expression and genomic profiling of colorectal cancer   | background article | round I |
| rayyan-661154435 | Chapter 46 - Colorectal Cancer and Colon Cancer Screening   | background article | round I |
| rayyan-661154436 | The burgeoning role of cytochrome P450-mediated vitamin D metabolites against colorectal cancer   | background article | round I |
| rayyan-661154437 | Chapter 62 - Colorectal Cancer  | background article | round I |
| rayyan-661154439 | Universal encoding of pan-cancer histology by deep texture representations  | background article | round I |
| rayyan-661154440 | NTRK fusions in solid tumours: what every pathologist needs to know   | background article | round I |
| rayyan-661154441 | Colorectal Cancer Therapeutics and the Challenges of Applied Pharmacogenomics   | background article | round I |
| rayyan-661154442 | Chapter 8 - Predictive biomarkers of drug resistance in colorectal cancer”Recent updates  | background article | round I |
| rayyan-661154444 | 13 - Molecular Testing of Gastrointestinal Neoplasms  | background article | round I |
| rayyan-661154446 | Biomarkers for personalized medicine in GI cancers  | background article | round I |
| rayyan-661154448 | Molecular mechanistic pathway of colorectal carcinogenesis associated with intestinal microbiota  | background article | round I |
| rayyan-661154450 | 77 - Colorectal Cancer  | background article | round I |
| rayyan-661154461 | ctDNA as a cancer biomarker: A broad overview   | background article | round I |
| rayyan-661154462 | Chapter 2 - Drug transporters in the development of multidrug resistance in colorectal cancer   | background article | round I |
| rayyan-661154464 | "Chapter 5 - Cancer screening and prevention: Sex and gender evidence in lung   | background article | round I |
| rayyan-661154468 | Precision diagnostics: integration of tissue pathology and genomics in cancer   | background article | round I |
| rayyan-661154469 | Molecular Pathology of Gastrointestinal Cancer  | background article | round I |
| rayyan-661154470 | Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours   | background article | round I |
| rayyan-661154473 | Targeting ERK1/2 protein-serine/threonine kinases in human cancers  | background article | round I |
| rayyan-661154485 | "Chapter 12 - Genetic and genomic medicine relevance to cancer prevention   | background article | round I |



|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661154489 | "The cell of cancer origin provides the most reliable roadmap to its diagnosis                    | background article | round I |
| rayyan-661154490 | "Chapter 25 - Epigenetic profiling in cancer: triage  | background article | round I |
| rayyan-661154494 | "Oral tumor heterogeneity   | background article | round I |
| rayyan-661154496 | Chapter 7 - PDX Models of Colorectal Tumors   | background article | round I |
| rayyan-661154500 | Clinical Updates for Colon Cancer Care in 2022  | background article | round I |
| rayyan-661154501 | The role of epigenetic therapies in colorectal cancer   | background article | round I |
| rayyan-661154502 | The long road to colorectal cancer therapy: Searching for the right signals                       | background article | round I |
| rayyan-661154511 | Prognostic markers in colorectal pathology: is morphology enough?                                 | background article | round I |
| rayyan-661154512 | Molecular Testing in Colorectal Carcinoma   | background article | round I |
| rayyan-661154513 | "Do more targets allow more cancer treatments   | background article | round I |
| rayyan-661154515 | Promising Targets and Drugs in Development for Colorectal Cancer                                  | background article | round I |
| rayyan-661154517 | Chapter Nine - Modeling colorectal cancers using multidimensional organoids                       | background article | round I |
| rayyan-661154525 | Chapter 15 - Precision Nutrition and Cancer   | background article | round I |
| rayyan-661154534 | Chapter 6 - Colorectal Cancer Metastasis  | background article | round I |
| rayyan-661154539 | CHAPTER 3 - Colorectal Cancer: Pathogenesis and Risk Factors                                      | background article | round I |
| rayyan-661154543 | New insights into the molecular pathogenesis of colorectal cancer                                 | background article | round I |
| rayyan-661154550 | The management of colorectal liver metastases   | background article | round I |
| rayyan-661154554 | Hereditary Cancer and Cancer Predisposition Syndromes   | background article | round I |
| rayyan-661154561 | 74 - Colorectal Cancer  | background article | round I |
| rayyan-661154565 | Chapter 4 - The Genetics and Epigenetics of Colorectal Cancer Health Disparity                    | background article | round I |
| rayyan-661154571 | Chapter 17 - Pathophysiology roles and translational opportunities of miRNAs in colorectal cancer | background article | round I |
| rayyan-661154572 | The pathology of colorectal polyps and cancers (including biopsy)                                 | background article | round I |
| rayyan-661154573 | Colorectal cancer   | background article | round I |
| rayyan-661154575 | Genome-guided discovery of cancer therapeutic targets   | background article | round I |
| rayyan-661154576 | Towards personalized medicine of colorectal cancer  | background article | round I |
| rayyan-661154647 | Clinicopathologic features and treatment advances in cancers with HER2 alterations                | background article | round I |

|                  |  |                    |         |
|------------------|--|--------------------|---------|
| rayyan-661154652 | Chapter Seven - Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy        | background article | round I |
| rayyan-661154660 | The Chromosomal Instability Pathway in Colon Cancer  | background article | round I |
| rayyan-661154661 | Precision Medicine in Colorectal Surgery   | background article | round I |
| rayyan-661154662 | Genetic and Epigenetic Biomarkers of Colorectal Cancer   | background article | round I |
| rayyan-661154671 | Serum and tissue markers in colorectal cancer: State of art  | background article | round I |
| rayyan-661154674 | "Colorectal Cancer: Epidemiology   | background article | round I |
| rayyan-661154780 | Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas              | background article | round I |
| rayyan-661154783 | Translational lung cancer research   | background article | round I |
| rayyan-661154791 | Improving outcomes in colorectal cancer: Where do we go from here?                                       | background article | round I |
| rayyan-661154800 | Context mattersâ€”consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials    | background article | round I |
| rayyan-661154806 | Chapter 46 - Signaling pathways in CRC   | background article | round I |
| rayyan-661154809 | Chapter 89 - Vitamin D and colorectal cancer   | background article | round I |
| rayyan-661154820 | Chapter 18 - Resistance to EGFR Targeting Treatments in Colorectal Cancer                                | background article | round I |
| rayyan-661154824 | Poorly Differentiated Clusters: Clinical Impact in Colorectal Cancer                                     | background article | round I |
| rayyan-661154828 | "Immunotherapy for GI Cancers: Who Benefits  | background article | round I |
| rayyan-661155040 | DNA methylation and chromatin modifiers in colorectal cancer   | background article | round I |
| rayyan-661155045 | From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy                 | background article | round I |
| rayyan-661155048 | Molecular Markers for Colorectal Cancer  | background article | round I |
| rayyan-661155050 | Colorectal cancer  | background article | round I |
| rayyan-661155056 | Assessing colorectal cancer heterogeneity: one step closer to tailored medicine                          | background article | round I |
| rayyan-661155059 | Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use | background article | round I |
| rayyan-661155063 | Current advances in detecting genetic and epigenetic biomarkers of colorectal cancer                     | background article | round I |
| rayyan-661155067 | Systemic Therapy for Colon Cancer  | background article | round I |
| rayyan-661155068 | BRAF gene: From human cancers to developmental syndromes   | background article | round I |
| rayyan-661155070 | Chapter 12 - Targeting the altered tyrosine kinases in colorectal cancer: From inhibitors to drugs       | background article | round I |
| rayyan-661155073 | "Overview of biomarkers in metastatic colorectal cancer: Tumour  | background article | round I |

|                  |  |                    |         |
|------------------|--|--------------------|---------|
| rayyan-661155074 | Chapter Five - Immunotherapy in colorectal cancer  | background article | round I |
| rayyan-661155081 | Therapeutic modulation of k-ras signaling in colorectal cancer   | background article | round I |
| rayyan-661155099 | Improving the management of pain from advanced cancer in the community   | background article | round I |
| rayyan-661155117 | FOCUS4: Molecular selection of therapy in colorectal cancer  | background article | round I |
| rayyan-661155121 | 5-ALA in bowel cancer surgery  | background article | round I |
| rayyan-661155236 | Chapter 49 - Colorectal carcinoma: From molecular pathology to clinical practice   | background article | round I |
| rayyan-661155237 | Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer  | background article | round I |
| rayyan-661155238 | Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies | background article | round I |
| rayyan-661155245 | Molecular Determinants of Gastrointestinal Cancers   | background article | round I |
| rayyan-661155247 | 40 - Colorectal cancer   | background article | round I |
| rayyan-661155249 | Chapter 10 - Predictive "omic" biomarkers of drug response: Colorectal cancer as a model   | background article | round I |
| rayyan-661155250 | Colorectal cancer screening " Methodology  | background article | round I |
| rayyan-661155252 | Genomic heterogeneity in primary colorectal carcinomas and their metastases: born bad or brought up a villain?                                 | background article | round I |
| rayyan-661155255 | Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II  | background article | round I |
| rayyan-661155257 | Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR         | background article | round I |
| rayyan-661155258 | Chapter 16 - Systemic treatment of localized colorectal cancer   | background article | round I |
| rayyan-661155259 | "The Unmet Needs of the Diagnosis  | background article | round I |
| rayyan-661155260 | Chapter 176 - Adjuvant and Neoadjuvant Therapy for Colorectal Cancer: Molecular-Based Therapy  | background article | round I |
| rayyan-661155261 | Overview of Colorectal Cancer Genetics   | background article | round I |
| rayyan-661155271 | Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer                  | background article | round I |
| rayyan-661155276 | Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer   | background article | round I |
| rayyan-661155280 | "Colorectal cancer heterogeneity and targeted therapy: Clinical implications   | background article | round I |
| rayyan-661155282 | "Recent progress of targeted nanocarriers in diagnostic  | background article | round I |
| rayyan-661155289 | Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies                                   | background article | round I |
| rayyan-661155320 | Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory                        | background article | round I |
| rayyan-661155321 | FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival    | background article | round I |

|                  |  |                    |         |
|------------------|--|--------------------|---------|
| rayyan-661155325 | Molecular Taxonomy and Tumourigenesis of Colorectal Cancer   | background article | round I |
| rayyan-661155330 | Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts  | background article | round I |
| rayyan-661155337 | Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features  | background article | round I |
| rayyan-661155341 | Molecular Diagnostics in Colorectal Carcinoma  | background article | round I |
| rayyan-661155350 | Colorectal Cancer: Pathology and Genetics  | background article | round I |
| rayyan-661155369 | KRAS insertions in colorectal cancer: What do we know about unusual KRAS mutations?  | background article | round I |
| rayyan-661155374 | Chapter 19 - Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors          | background article | round I |
| rayyan-661155378 | Updated Management of Colorectal Cancer Liver Metastases: Scientific Advances Driving Modern Therapeutic Innovations                           | background article | round I |
| rayyan-661155379 | Molecular Diagnostics in Colorectal Carcinoma: Advances and Applications for 2018  | background article | round I |
| rayyan-661155385 | BRAF inhibitors in cancer therapy  | background article | round I |
| rayyan-661155387 | Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer  | background article | round I |
| rayyan-661155388 | The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing                              | background article | round I |
| rayyan-661155389 | Chapter 33 - Molecularly targeted therapy in metastatic CRC  | background article | round I |
| rayyan-661155390 | Chapter 34 - A roadmap for medical treatment of metastatic CRC   | background article | round I |
| rayyan-661155396 | Sex and gender perspectives in colorectal cancer   | background article | round I |
| rayyan-661155398 | Molecular typing of colorectal cancer: applications in diagnosis and treatment   | background article | round I |
| rayyan-661155409 | Chapter 25 - Molecular testing in colorectal cancer  | background article | round I |
| rayyan-661155413 | Chapter 12 - Colorectal cancer   | background article | round I |
| rayyan-661155415 | Biomarker-driven and molecular targeted therapies for colorectal cancers   | background article | round I |
| rayyan-661155420 | Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome | background article | round I |
| rayyan-661155424 | Immunotherapy for Colorectal Cancer  | background article | round I |
| rayyan-661155435 | Clinical application of circulating tumour DNA in colorectal cancer  | background article | round I |
| rayyan-661155436 | The impact of microsatellite stability status in colorectal cancer   | background article | round I |
| rayyan-661155450 | Precision Oncology in Gastrointestinal and Colorectal Cancer Surgery   | background article | round I |
| rayyan-661155455 | Chapter 4 - Use of molecular markers and other personalized factors in treatment decisions for metastatic colorectal cancer                    | background article | round I |
| rayyan-661155456 | RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer  | background article | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661155458 | Molecular Approach to Colorectal Carcinoma: Current Evidence and Clinical Application   | background article | round I |
| rayyan-661155464 | "RAS Signaling in Colorectal Carcinomas through Alteration of RAS   | background article | round I |
| rayyan-661155479 | 23 - Colorectal cancer  | background article | round I |
| rayyan-661155480 | "BRAF mutant colorectal cancer: prognosis   | background article | round I |
| rayyan-661155481 | How we treat metastatic colorectal cancer   | background article | round I |
| rayyan-661155492 | Colorectal cancer   | background article | round I |
| rayyan-661155516 | Pathologic Evaluation of Therapeutic Biomarkers in Colorectal Adenocarcinoma  | background article | round I |
| rayyan-661155528 | Targeted Therapy for Colorectal Cancer  | background article | round I |
| rayyan-661155581 | Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy   | background article | round I |
| rayyan-661155820 | Colorectal Cancer: Genetics is Changing Everything.   | background article | round I |
| rayyan-661155827 | Molecular diagnostics of colorectal cancer.   | background article | round I |
| rayyan-661155831 | Genetic unraveling of colorectal cancer.  | background article | round I |
| rayyan-661155851 | [Molecular pathology of colorectal cancer].   | background article | round I |
| rayyan-661155931 | BRAF mutation and microsatellite instability status in colonic and rectal carcinoma: context really does matter.  | background article | round I |
| rayyan-661155933 | Serrated adenoma: a distinct form of non-polypoid colorectal neoplasia?   | background article | round I |
| rayyan-661155942 | Predictive factors to targeted treatment in gastrointestinal carcinomas.  | background article | round I |
| rayyan-661156042 | K-Ras and MSI: potential markers of both patient prognosis and treatment efficacy.  | background article | round I |
| rayyan-661156096 | [Research progress of serrated polyposis syndrome].   | background article | round I |
| rayyan-661156102 | [Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification].            | background article | round I |
| rayyan-661156103 | [Evaluation of BRAF V600E Mutations in High-Level Microsatellite Instability(MSI-H)Colon Cancer - Comparison Between Genetic Testing and Immunohistochemical Staining]. | background article | round I |
| rayyan-661156202 | Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology.   | background article | round I |
| rayyan-661156218 | [How and when to search for microsatellite instability in colorectal cancer in 2008?].  | background article | round I |
| rayyan-661156315 | Genetic mechanisms in interval colon cancers.   | background article | round I |
| rayyan-661154084 | Chapter 99 - Vitamin D and Colon Cancer   | wrong outcome      | round I |
| rayyan-661154124 | Pharmacogenetic screening for drug therapy: From single gene markers to decision making in the next generation sequencing era   | wrong outcome      | round I |

|                  |  |               |         |
|------------------|--|---------------|---------|
| rayyan-661154160 | Non-tumor adjacent tissue of advanced stage from CRC shows activated antioxidant response  | wrong outcome | round I |
| rayyan-661154220 | "Circulating tumor DNA   | wrong outcome | round I |
| rayyan-661154224 | Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer   | wrong outcome | round I |
| rayyan-661154236 | Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses  | wrong outcome | round I |
| rayyan-661154270 | Altered cancer metabolism in mechanisms of immunotherapy resistance  | wrong outcome | round I |
| rayyan-661154275 | Rectal cancer with synchronous liver metastases: Do we have a clear direction?   | wrong outcome | round I |
| rayyan-661154287 | Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers  | wrong outcome | round I |
| rayyan-661154288 | Available technologies and clinical applications of targeted chemotherapy in pancreatic cancer   | wrong outcome | round I |
| rayyan-661154298 | Precursors of urinary bladder cancer: molecular alterations and biomarkers   | wrong outcome | round I |
| rayyan-661154349 | Deregulation of cell signaling in cancer   | wrong outcome | round I |
| rayyan-661154351 | Medicinal plants of the genres Salvia and Hypericum are sources of anticolon cancer compounds: Effects on PI3K/Akt and MAP kinases pathways  | wrong outcome | round I |
| rayyan-661154389 | Looking into the toxicity potential and clinical benefits of tyrosine kinase inhibitors (TKIs)   | wrong outcome | round I |
| rayyan-661154433 | Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases   | wrong outcome | round I |
| rayyan-661154579 | Mismatch repairâ€“deficient colorectal cancer: a model of immunogenic and immune cellâ€“rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells | wrong outcome | round I |
| rayyan-661154592 | Clonal and subclonal mutational landscapes in circulating tumor DNA in metastatic colorectal cancer: an exploratory analysis from the phase III PARADIGM study                     | wrong outcome | round I |
| rayyan-661154636 | A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis  | wrong outcome | round I |
| rayyan-661154781 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)   | wrong outcome | round I |
| rayyan-661154849 | Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation   | wrong outcome | round I |
| rayyan-661155069 | Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer   | wrong outcome | round I |
| rayyan-661155098 | Effects of gene expression pattern and RAS/BRAF mutations on the course of colorectal cancer   | wrong outcome | round I |
| rayyan-661155219 | Phase III randomised double-blind placebo controlled study of rofecoxib (VIOXX) in colorectal cancer patients following potentially curable therapy                                | wrong outcome | round I |
| rayyan-661155240 | Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity   | wrong outcome | round I |
| rayyan-661155246 | "AD80  | wrong outcome | round I |
| rayyan-661155263 | A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology   | wrong outcome | round I |
| rayyan-661155326 | Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience  | wrong outcome | round I |

|                  |   |               |         |
|------------------|---|---------------|---------|
| rayyan-661155349 | Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach   | wrong outcome | round I |
| rayyan-661155371 | KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior  | wrong outcome | round I |
| rayyan-661155375 | Combined Analysis of COX-2 and p53 Expressions Reveals Synergistic Inverse Correlations with Microsatellite Instability and CpG Island Methylator Phenotype in Colorectal Cancer                  | wrong outcome | round I |
| rayyan-661155385 | BRAF inhibitors in cancer therapy   | wrong outcome | round I |
| rayyan-661155426 | Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study   | wrong outcome | round I |
| rayyan-661155444 | Microsatellite instability status affects gene expression profiles in early onset colorectal cancer patients  | wrong outcome | round I |
| rayyan-661155459 | Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?   | wrong outcome | round I |
| rayyan-661155464 | "RAS Signaling in Colorectal Carcinomas through Alteration of RAS   | wrong outcome | round I |
| rayyan-661155466 | "KRAS   | wrong outcome | round I |
| rayyan-661155470 | Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging  | wrong outcome | round I |
| rayyan-661155478 | Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization | wrong outcome | round I |
| rayyan-661155486 | Analysis of DNA Mismatch Repair Proteins Expression and BRAF V600E Mutation in a Subset of Early- and Late-onset Colorectal Carcinoma Patients in Mexico  | wrong outcome | round I |
| rayyan-661155501 | BRAF V600E mutations in right-side colon cancer: Heterogeneity detected by liquid biopsy  | wrong outcome | round I |
| rayyan-661155503 | Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis   | wrong outcome | round I |
| rayyan-661155546 | Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan                  | wrong outcome | round I |
| rayyan-661155547 | Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer                    | wrong outcome | round I |
| rayyan-661155565 | Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?  | wrong outcome | round I |
| rayyan-661155589 | Association between clinicopathological characteristics and RAS mutation in colorectal cancer   | wrong outcome | round I |
| rayyan-661155797 | The consensus molecular subtypes of colorectal cancer.  | wrong outcome | round I |
| rayyan-661155799 | Microbial Community Heterogeneity Within Colorectal Neoplasia and its Correlation With Colorectal Carcinogenesis.   | wrong outcome | round I |
| rayyan-661155810 | Subtyping of microsatellite instability-high colorectal cancer.   | wrong outcome | round I |
| rayyan-661155811 | Fusobacterium nucleatum Load Correlates with KRAS Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma.  | wrong outcome | round I |
| rayyan-661155812 | Irinotecan or Oxaliplatin: Which is the First Move for the Mate?  | wrong outcome | round I |

|                  |   |               |         |
|------------------|---|---------------|---------|
| rayyan-661155813 | KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.                           | wrong outcome | round I |
| rayyan-661155815 | "Correlations among KRAS Mutation   | wrong outcome | round I |
| rayyan-661155816 | Microsatellite Instability in Greek Colorectal Carcinoma Patients: Clinicopathological and Molecular Correlations.  | wrong outcome | round I |
| rayyan-661155819 | "KRAS   | wrong outcome | round I |
| rayyan-661155821 | Colorectal serrated adenocarcinoma.   | wrong outcome | round I |
| rayyan-661155824 | "Epidemiological and molecular evaluation of BRAF   | wrong outcome | round I |
| rayyan-661155829 | Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study.                                   | wrong outcome | round I |
| rayyan-661155836 | "Molecular Profiling Based on KRAS/BRAF Mutation  | wrong outcome | round I |
| rayyan-661155839 | Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status.   | wrong outcome | round I |
| rayyan-661155844 | Postmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways.   | wrong outcome | round I |
| rayyan-661155853 | BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.   | wrong outcome | round I |
| rayyan-661155855 | BRAF mutation in sporadic colorectal cancer and Lynch syndrome.   | wrong outcome | round I |
| rayyan-661155856 | Mutational profiling of colorectal cancers with microsatellite instability.   | wrong outcome | round I |
| rayyan-661155863 | KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.   | wrong outcome | round I |
| rayyan-661155866 | BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression. | wrong outcome | round I |
| rayyan-661155869 | Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy.                                | wrong outcome | round I |
| rayyan-661155871 | Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans.  | wrong outcome | round I |
| rayyan-661155880 | Mucinous adenocarcinoma of the colon and rectum: A genomic analysis.  | wrong outcome | round I |
| rayyan-661155881 | "p53 mutation is common in microsatellite stable  | wrong outcome | round I |
| rayyan-661155882 | Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.   | wrong outcome | round I |
| rayyan-661155884 | Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.  | wrong outcome | round I |
| rayyan-661155886 | The role of heavy metals in the development of colorectal cancer.   | wrong outcome | round I |
| rayyan-661155896 | Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.   | wrong outcome | round I |
| rayyan-661155897 | Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes.  | wrong outcome | round I |
| rayyan-661155898 | Association Between Smoking and Molecular Subtypes of Colorectal Cancer.  | wrong outcome | round I |



|                  |  |               |         |
|------------------|--|---------------|---------|
| rayyan-661155902 | Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?   | wrong outcome | round I |
| rayyan-661155903 | "CpG island methylator phenotype   | wrong outcome | round I |
| rayyan-661155904 | Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.  | wrong outcome | round I |
| rayyan-661155905 | Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes.   | wrong outcome | round I |
| rayyan-661155915 | RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.  | wrong outcome | round I |
| rayyan-661155916 | Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age.   | wrong outcome | round I |
| rayyan-661155919 | Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.   | wrong outcome | round I |
| rayyan-661155922 | Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer.  | wrong outcome | round I |
| rayyan-661155927 | Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.  | wrong outcome | round I |
| rayyan-661155934 | Mutation profiling of cancer drivers in Brazilian colorectal cancer.   | wrong outcome | round I |
| rayyan-661155935 | "Microsatellite instability  | wrong outcome | round I |
| rayyan-661155938 | "Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene  | wrong outcome | round I |
| rayyan-661155943 | The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status.  | wrong outcome | round I |
| rayyan-661155947 | "Intake of Dietary Fruit   | wrong outcome | round I |
| rayyan-661155961 | Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma.  | wrong outcome | round I |
| rayyan-661155964 | "Genetic instability   | wrong outcome | round I |
| rayyan-661155967 | Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.  | wrong outcome | round I |
| rayyan-661155972 | MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.                                   | wrong outcome | round I |
| rayyan-661155977 | "Gene methylation of SFRP2   | wrong outcome | round I |
| rayyan-661155979 | "Impact of BRAF  | wrong outcome | round I |
| rayyan-661155982 | The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.   | wrong outcome | round I |
| rayyan-661155983 | Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer. | wrong outcome | round I |
| rayyan-661155985 | Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability.  | wrong outcome | round I |
| rayyan-661155986 | Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans.   | wrong outcome | round I |
| rayyan-661155987 | Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.  | wrong outcome | round I |

|                  |  |               |         |
|------------------|--|---------------|---------|
| rayyan-661155990 | "TP53 mutations in colorectal cancer from Tunisia: relationships with site of tumor origin   | wrong outcome | round I |
| rayyan-661155991 | A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers.  | wrong outcome | round I |
| rayyan-661155994 | Unique clinicopathologic and genetic alteration features in early onset colorectal carcinoma compared with age-related colorectal carcinoma: a large cohort next generation sequence analysis.                 | wrong outcome | round I |
| rayyan-661155996 | MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.   | wrong outcome | round I |
| rayyan-661156000 | Molecular subtypes of colorectal cancers determined by PCR-based analysis.   | wrong outcome | round I |
| rayyan-661156001 | AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.  | wrong outcome | round I |
| rayyan-661156002 | Multivariate analysis as a method for evaluating the pathogenicity of novel genetic MLH1 variants in patients with colorectal cancer and microsatellite instability.   | wrong outcome | round I |
| rayyan-661156003 | "Relationship between Fusobacterium nucleatum  | wrong outcome | round I |
| rayyan-661156006 | "MicroRNA-31 expression in relation to BRAF mutation   | wrong outcome | round I |
| rayyan-661156009 | Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP.   | wrong outcome | round I |
| rayyan-661156012 | Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.                            | wrong outcome | round I |
| rayyan-661156019 | Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status. | wrong outcome | round I |
| rayyan-661156021 | DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability.  | wrong outcome | round I |
| rayyan-661156025 | A Changing Spectrum of Colorectal Cancer Biology With Age: Implications for the Young Patient.   | wrong outcome | round I |
| rayyan-661156026 | Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia.   | wrong outcome | round I |
| rayyan-661156030 | Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.                      | wrong outcome | round I |
| rayyan-661156040 | Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.   | wrong outcome | round I |
| rayyan-661156041 | Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.  | wrong outcome | round I |
| rayyan-661156046 | "P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin  | wrong outcome | round I |
| rayyan-661156050 | "Genetic alterations of APC  | wrong outcome | round I |
| rayyan-661156053 | Distinct molecular features of colorectal cancer in Ghana.   | wrong outcome | round I |
| rayyan-661156055 | MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.  | wrong outcome | round I |

|                  |   |               |         |
|------------------|---|---------------|---------|
| rayyan-661156058 | DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.                                  | wrong outcome | round I |
| rayyan-661156061 | Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.                | wrong outcome | round I |
| rayyan-661156062 | Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?  | wrong outcome | round I |
| rayyan-661156067 | Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. | wrong outcome | round I |
| rayyan-661156068 | Prevalence and prognostic relevance of BrafV600E mutation in colorectal carcinomas from Kashmir (North India) valley.   | wrong outcome | round I |
| rayyan-661156070 | Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.   | wrong outcome | round I |
| rayyan-661156074 | Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk.  | wrong outcome | round I |
| rayyan-661156075 | NRAS mutations are rare in colorectal cancer.   | wrong outcome | round I |
| rayyan-661156078 | Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status.                                       | wrong outcome | round I |
| rayyan-661156080 | Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan.   | wrong outcome | round I |
| rayyan-661156085 | Distinct molecular features of different macroscopic subtypes of colorectal neoplasms.  | wrong outcome | round I |
| rayyan-661156087 | "Left-sided early-onset vs late-onset colorectal carcinoma: histologic  | wrong outcome | round I |
| rayyan-661156088 | BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.  | wrong outcome | round I |
| rayyan-661156089 | "Smoking  | wrong outcome | round I |
| rayyan-661156090 | Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer.  | wrong outcome | round I |
| rayyan-661156092 | Validation microsatellite path score in a population-based cohort of patients with colorectal cancer.   | wrong outcome | round I |
| rayyan-661156093 | The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.                        | wrong outcome | round I |
| rayyan-661156095 | "SMO expression in colorectal cancer: associations with clinical  | wrong outcome | round I |
| rayyan-661156097 | "Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability  | wrong outcome | round I |
| rayyan-661156100 | Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women.  | wrong outcome | round I |
| rayyan-661156101 | [Molecular analysis of sporadic colon cancer].  | wrong outcome | round I |
| rayyan-661156104 | Differences in K-ras and mitochondrial DNA mutations and microsatellite instability between colorectal cancers of Vietnamese and Japanese patients.           | wrong outcome | round I |
| rayyan-661156105 | NDRG4 stratifies the prognostic value of body mass index in colorectal cancer.  | wrong outcome | round I |
| rayyan-661156106 | Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population.   | wrong outcome | round I |
| rayyan-661156108 | Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.                                     | wrong outcome | round I |

|                  |  |               |         |
|------------------|--|---------------|---------|
| rayyan-661156112 | Somatic BRAF-V600E mutations in familial colorectal cancer.  | wrong outcome | round I |
| rayyan-661156113 | "Filiform serrated adenoma is an unusual   | wrong outcome | round I |
| rayyan-661156114 | "An integrated analysis of lymphocytic reaction  | wrong outcome | round I |
| rayyan-661156120 | Whole-genome methylation analysis of benign and malignant colorectal tumours.  | wrong outcome | round I |
| rayyan-661156121 | Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors.   | wrong outcome | round I |
| rayyan-661156122 | "Traditional Serrated Pathway-associated Colorectal Carcinoma: Morphologic Reappraisal of Serrated Morphology  | wrong outcome | round I |
| rayyan-661156124 | KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis.  | wrong outcome | round I |
| rayyan-661156125 | Clinical features and molecular alterations of traditional serrated adenoma in sporadic colorectal carcinogenesis.   | wrong outcome | round I |
| rayyan-661156126 | "Influence of anatomical subsite on the incidence of microsatellite instability  | wrong outcome | round I |
| rayyan-661156132 | RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.  | wrong outcome | round I |
| rayyan-661156133 | "Association between risk factors  | wrong outcome | round I |
| rayyan-661156140 | Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations.         | wrong outcome | round I |
| rayyan-661156143 | The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel.  | wrong outcome | round I |
| rayyan-661156149 | Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.  | wrong outcome | round I |
| rayyan-661156150 | Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal Cancer.                       | wrong outcome | round I |
| rayyan-661156153 | Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers.   | wrong outcome | round I |
| rayyan-661156155 | Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.  | wrong outcome | round I |
| rayyan-661156156 | Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.  | wrong outcome | round I |
| rayyan-661156157 | The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease.   | wrong outcome | round I |
| rayyan-661156158 | Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population.  | wrong outcome | round I |
| rayyan-661156161 | Population-based molecular screening for Lynch syndrome: implications for personalized medicine.   | wrong outcome | round I |
| rayyan-661156162 | Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations.  | wrong outcome | round I |
| rayyan-661156164 | Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer.   | wrong outcome | round I |
| rayyan-661156175 | Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. | wrong outcome | round I |
| rayyan-661156176 | "Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss                          | wrong outcome | round I |

|                  |   |               |         |
|------------------|---|---------------|---------|
| rayyan-661156177 | Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.                            | wrong outcome | round I |
| rayyan-661156178 | Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis.   | wrong outcome | round I |
| rayyan-661156179 | Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene.             | wrong outcome | round I |
| rayyan-661156180 | Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. | wrong outcome | round I |
| rayyan-661156181 | Transcriptional profiles underpin microsatellite status and associated features in colon cancer.  | wrong outcome | round I |
| rayyan-661156187 | "Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer   | wrong outcome | round I |
| rayyan-661156200 | Associations between intake of folate and related micronutrients with molecularly defined colorectal cancer risks in the Iowa Women's Health Study.           | wrong outcome | round I |
| rayyan-661156207 | Hereditary non-polyposis colorectal cancer/Lynch syndrome in three dimensions.  | wrong outcome | round I |
| rayyan-661156209 | Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.                   | wrong outcome | round I |
| rayyan-661156214 | TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.                                      | wrong outcome | round I |
| rayyan-661156215 | The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile.                                  | wrong outcome | round I |
| rayyan-661156220 | Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.                          | wrong outcome | round I |
| rayyan-661156224 | Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.                           | wrong outcome | round I |
| rayyan-661156227 | Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.                    | wrong outcome | round I |
| rayyan-661156234 | [Pathological diagnosis for individualized therapy of colorectal cancer].   | wrong outcome | round I |
| rayyan-661156237 | Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort.                            | wrong outcome | round I |
| rayyan-661156257 | The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer.   | wrong outcome | round I |
| rayyan-661156258 | Mutational analysis of the BRAF gene in colorectal mucinous carcinoma in association with histological configuration.   | wrong outcome | round I |
| rayyan-661156260 | [Molecular characterization of hereditary colorectal cancer in Peru].   | wrong outcome | round I |
| rayyan-661156268 | Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.                                | wrong outcome | round I |
| rayyan-661156269 | "Association of smoking   | wrong outcome | round I |
| rayyan-661156271 | Frequency of defective DNA mismatch repair in colorectal cancer among the Alaska Native people.   | wrong outcome | round I |
| rayyan-661156274 | Molecular biology from bench-to-bedside - which colorectal cancer patients should be referred for genetic counselling and risk assessment.                    | wrong outcome | round I |
| rayyan-661156280 | Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.   | wrong outcome | round I |
| rayyan-661156283 | "A population-based study of age-related variation in clinicopathological features  | wrong outcome | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661156299 | BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.  | wrong outcome      | round I |
| rayyan-661156304 | Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. | wrong outcome      | round I |
| rayyan-661156306 | Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer.   | wrong outcome      | round I |
| rayyan-661156308 | "Early onset MSI-H colon cancer with MLH1 promoter methylation  | wrong outcome      | round I |
| rayyan-661156309 | Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients.  | wrong outcome      | round I |
| rayyan-661156310 | "Somatic alterations  | wrong outcome      | round I |
| rayyan-661156311 | BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.                | wrong outcome      | round I |
| rayyan-661156312 | The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer.  | wrong outcome      | round I |
| rayyan-661156318 | Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.   | wrong outcome      | round I |
| rayyan-661156319 | "KRAS   | wrong outcome      | round I |
| rayyan-661156320 | Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.   | wrong outcome      | round I |
| rayyan-661156321 | "Expression of MUC2   | wrong outcome      | round I |
| rayyan-661156322 | Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.     | wrong outcome      | round I |
| rayyan-661156323 | Lynch-like syndrome is as frequent as Lynch syndrome in early-onset nonfamilial nonpolyposis colorectal cancer.   | wrong outcome      | round I |
| rayyan-661156327 | "Simplified identification of Lynch syndrome: a prospective   | wrong outcome      | round I |
| rayyan-661154697 | A phase Ib biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer  | wrong study desing | round I |
| rayyan-661154698 | Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer      | wrong study desing | round I |
| rayyan-661154712 | A study on microsatellite instability status for colorectal serrated lesions  | wrong study desing | round I |
| rayyan-661154744 | Hide and Seek with Hereditary Cancer: improving detection of colorectal cancer patients with a high risk of Lynch syndrome                                  | wrong study desing | round I |
| rayyan-661154769 | Effectiveness of each Bethesda marker in defining microsatellite instability when screening for Lynch syndrome  | wrong study desing | round I |
| rayyan-661154771 | Effects of a decision support intervention on decisional conflict associated with microsatellite instability testing  | wrong study desing | round I |
| rayyan-661154773 | Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial                       | wrong study desing | round I |
| rayyan-661154780 | Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas   | wrong study desing | round I |
| rayyan-661154791 | Improving outcomes in colorectal cancer: Where do we go from here?  | wrong study desing | round I |
| rayyan-661154802 | Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer   | wrong study desing | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661154810 | An Update on Colorectal Cancer  | wrong study desing | round I |
| rayyan-661154822 | Precision Treatment and Prevention of Colorectal Cancer”Hope or Hype?   | wrong study desing | round I |
| rayyan-661154825 | Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas | wrong study desing | round I |
| rayyan-661154828 | "Immunotherapy for GI Cancers: Who Benefits   | wrong study desing | round I |
| rayyan-661154839 | Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF-mutated serrated lesions   | wrong study desing | round I |
| rayyan-661154841 | Clinical and Molecular Biologic Characteristics of Early-onset Versus Late-onset Colorectal Carcinoma in Filipinos  | wrong study desing | round I |
| rayyan-661154842 | Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer  | wrong study desing | round I |
| rayyan-661154849 | Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation  | wrong study desing | round I |
| rayyan-661154979 | Comparing international data between keyhole and robotic rectal cancer surgery  | wrong study desing | round I |
| rayyan-661155274 | KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice  | wrong study desing | round I |
| rayyan-661155314 | BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall   | wrong study desing | round I |
| rayyan-661155315 | Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer  | wrong study desing | round I |
| rayyan-661155319 | Prognosis in colorectal cancer beyond TNM   | wrong study desing | round I |
| rayyan-661155320 | Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory   | wrong study desing | round I |
| rayyan-661155327 | Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm  | wrong study desing | round I |
| rayyan-661155333 | Colorectal cancer cell exosome and cytoplasmic membrane for homotypic delivery of therapeutic molecules   | wrong study desing | round I |
| rayyan-661155336 | Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy   | wrong study desing | round I |
| rayyan-661155338 | A practical guide to biomarkers for the evaluation of colorectal cancer   | wrong study desing | round I |
| rayyan-661155339 | "A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies   | wrong study desing | round I |
| rayyan-661155342 | Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency                             | wrong study desing | round I |
| rayyan-661155344 | The diverse molecular profiles of lynch syndrome-associated colorectal cancers are (highly) dependent on underlying germline mismatch repair mutations            | wrong study desing | round I |
| rayyan-661155345 | HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer  | wrong study desing | round I |
| rayyan-661155347 | Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR    | wrong study desing | round I |
| rayyan-661155362 | Nano-enabled colorectal cancer therapy  | wrong study desing | round I |

|                  |  |                    |         |
|------------------|--|--------------------|---------|
| rayyan-661155363 | Genomic profiling of sporadic liver metastatic colorectal cancer   | wrong study desing | round I |
| rayyan-661155365 | HER2 targeted therapy in colorectal cancer: New horizons   | wrong study desing | round I |
| rayyan-661155367 | BRAF V600E mutation-specific antibody: A review  | wrong study desing | round I |
| rayyan-661155370 | Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer | wrong study desing | round I |
| rayyan-661155372 | Small-molecule drugs of colorectal cancer: Current status and future directions  | wrong study desing | round I |
| rayyan-661155373 | "Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF                                    | wrong study desing | round I |
| rayyan-661155377 | Update on Mucoadhesive Approaches to target Drug Delivery in Colorectal Cancer   | wrong study desing | round I |
| rayyan-661155381 | Dichotomous colorectal cancer behaviour  | wrong study desing | round I |
| rayyan-661155384 | Immune scores in colorectal cancer: Where are we?  | wrong study desing | round I |
| rayyan-661155394 | The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice   | wrong study desing | round I |
| rayyan-661155395 | Translational research of new developments in targeted therapy of colorectal cancer  | wrong study desing | round I |
| rayyan-661155399 | Clinicopathological relevance of BRAF mutations in human cancer  | wrong study desing | round I |
| rayyan-661155400 | The updates on metastatic mechanism and treatment of colorectal cancer   | wrong study desing | round I |
| rayyan-661155405 | Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer   | wrong study desing | round I |
| rayyan-661155408 | Liquid biopsy in colorectal cancer: Onward and upward  | wrong study desing | round I |
| rayyan-661155412 | Treatment sequencing of metastatic colorectal cancer based on primary tumor location   | wrong study desing | round I |
| rayyan-661155414 | Treatment sequencing in metastatic colorectal cancer   | wrong study desing | round I |
| rayyan-661155415 | Biomarker-driven and molecular targeted therapies for colorectal cancers   | wrong study desing | round I |
| rayyan-661155416 | Prognostic and predictive molecular biomarkers in advanced colorectal cancer   | wrong study desing | round I |
| rayyan-661155418 | "Colorectal cancer: Genetic alterations  | wrong study desing | round I |
| rayyan-661155422 | NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?"Case series and review of the literature  | wrong study desing | round I |
| rayyan-661155423 | Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective   | wrong study desing | round I |
| rayyan-661155452 | Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions   | wrong study desing | round I |
| rayyan-661155456 | RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer  | wrong study desing | round I |
| rayyan-661155459 | Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?                          | wrong study desing | round I |



|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661155463 | Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?   | wrong study desing | round I |
| rayyan-661155465 | Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice  | wrong study desing | round I |
| rayyan-661155466 | "KRAS   | wrong study desing | round I |
| rayyan-661155473 | The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy  | wrong study desing | round I |
| rayyan-661155478 | Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization   | wrong study desing | round I |
| rayyan-661155482 | "Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than   | wrong study desing | round I |
| rayyan-661155483 | Current progress of immune checkpoint inhibitors for advanced colorectal cancer: concentrating on the efficacy improvement  | wrong study desing | round I |
| rayyan-661155484 | Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?   | wrong study desing | round I |
| rayyan-661155487 | Prognostic and predictive markers in liver limited stage IV colorectal cancer   | wrong study desing | round I |
| rayyan-661155488 | Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? | wrong study desing | round I |
| rayyan-661155491 | Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone   | wrong study desing | round I |
| rayyan-661155492 | Colorectal cancer   | wrong study desing | round I |
| rayyan-661155500 | Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer  | wrong study desing | round I |
| rayyan-661155503 | Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis   | wrong study desing | round I |
| rayyan-661155534 | BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications   | wrong study desing | round I |
| rayyan-661155537 | High sensitivity and rapid detection of KRAS and BRAF gene mutations in colorectal cancer using YbTixOy electrolyte-insulator-semiconductor biosensors  | wrong study desing | round I |
| rayyan-661155824 | "Epidemiological and molecular evaluation of BRAF   | wrong study desing | round I |
| rayyan-661155852 | Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.   | wrong study desing | round I |
| rayyan-661155862 | Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients.  | wrong study desing | round I |
| rayyan-661155867 | KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.   | wrong study desing | round I |
| rayyan-661155912 | Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.   | wrong study desing | round I |
| rayyan-661155913 | BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.   | wrong study desing | round I |

|                  |   |                    |         |
|------------------|---|--------------------|---------|
| rayyan-661155914 | The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. | wrong study desing | round I |
| rayyan-661155916 | Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50Å years of age.   | wrong study desing | round I |
| rayyan-661155920 | Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.                                   | wrong study desing | round I |
| rayyan-661155922 | Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer.   | wrong study desing | round I |
| rayyan-661155929 | Improved Detection of Microsatellite Instability in Early Colorectal Lesions.   | wrong study desing | round I |
| rayyan-661155934 | Mutation profiling of cancer drivers in Brazilian colorectal cancer.  | wrong study desing | round I |
| rayyan-661155960 | Colorectal Cancers with the Uncommon Findings of KRAS Mutation and Microsatellite Instability.  | wrong study desing | round I |
| rayyan-661155978 | Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia.  | wrong study desing | round I |
| rayyan-661155986 | Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans.  | wrong study desing | round I |
| rayyan-661155992 | KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability.             | wrong study desing | round I |
| rayyan-661156001 | AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.       | wrong study desing | round I |
| rayyan-661156037 | "Comprehensive analysis of CpG island methylator phenotype (CIMP)-high  | wrong study desing | round I |
| rayyan-661156043 | "Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis   | wrong study desing | round I |
| rayyan-661156052 | "Comparison of microsatellite instability   | wrong study desing | round I |
| rayyan-661156068 | Prevalence and prognostic relevance of BrafV600E mutation in colorectal carcinomas from Kashmir (North India) valley.   | wrong study desing | round I |
| rayyan-661156162 | Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations.   | wrong study desing | round I |
| rayyan-661156217 | A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.   | wrong study desing | round I |
| rayyan-661156219 | "Tumor TP53 expression status   | wrong study desing | round I |
| rayyan-661156229 | The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability.  | wrong study desing | round I |
| rayyan-661156230 | Surgical Resection for Local and Lateral Lymph Node Recurrence of MSI-high Cecal Cancer with the BRAF V600E Mutation.   | wrong study desing | round I |
| rayyan-661156237 | Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort.                                      | wrong study desing | round I |
| rayyan-661156243 | Decreased Tumoral Expression of Colon-Specific Water Channel Aquaporin 8 Is Associated With Reduced Overall Survival in Colon Adenocarcinoma.                           | wrong study desing | round I |
| rayyan-661156272 | CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.    | wrong study desing | round I |
| rayyan-661156286 | BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients.  | wrong study desing | round I |

|                  |  |  |          |
|------------------|--|--|----------|
| rayyan-661156296 | [Search for molecular marker/target molecule useful for colorectal cancer treatment].  | wrong study desing   | round I  |
| rayyan-661156307 | [Prognostic marker profiles for risk of distant metastases in colorectal cancer].  | wrong study desing   | round I  |
| rayyan-661154045 | Chapitre 2 - Anatomie pathologique   | foreing language   | round I  |
| rayyan-661154085 | A - ERKRANKUNGEN DER VERDAUUNGSORGANE  | foreing language   | round I  |
| rayyan-661154833 | Cancers du cÃ´lon : prise en charge molÃ©culaire   | foreing language   | round I  |
| rayyan-661155518 | Cancers colorectaux avec mutation V600E de BRAF : oÃ¹ en sommes-nous ?   | foreing language   | round I  |
| rayyan-661156059 | "[Impacts of microsatellite status   | foreing language   | round I  |
| rayyan-661155888 | Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis.   | wrong drug   | round I  |
| rayyan-661154267 | Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial | subsequent publication with the same patients  | round II |
| rayyan-661154295 | Comparison of 627 patients with right- and left-sided colon cancer in China: Differences in clinicopathology, recurrence, and survival                                   | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154369 | Enhanced expression of GABRD predicts poor prognosis in patients with colon adenocarcinoma   | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154394 | Dilemma of Stage II Colon Cancer and Decision Making for Adjuvant Chemotherapy   | wrong article type including book chapter, review or molecoular phase I and II study | round II |
| rayyan-661154403 | Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer  | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154429 | Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial  | wrong outcomes not reported survival and   | round II |

|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | recurrence data for primary outcome  |          |
| rayyan-661154443 | KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer   | wrong article type including book chapter, review or molecoular phase I and II study | round II |
| rayyan-661154445 | Progression inference for somatic mutations in cancer   | wrong article type including book chapter, review or molecoular phase I and II study | round II |
| rayyan-661154447 | RNA biomarkers in colorectal cancer   | wrong article type including book chapter, review or molecoular phase I and II study | round II |
| rayyan-661154458 | Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer  | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154476 | Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17 | wrong population including stage IV, I or other neoplasia diagnosis                  | round II |
| rayyan-661154498 | Genetic Alterations in Locally Advanced Stage II/III Colon Cancer: A Search for Prognostic Markers                                      | wrong article type including book chapter, review or molecoular phase I and II study | round II |
| rayyan-661154505 | Association of Clinicopathologic and Molecular Markers on Stage-specific Survival of Right Versus Left Colon Cancer                     | wrong population including stage IV, I or other neoplasia diagnosis                  | round II |
| rayyan-661154516 | SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)                                | wrong outcomes not   | round II |

|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | reported survival and recurrence data for primary outcome                            |          |
| rayyan-661154519 | Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features   | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154556 | EGFR and KRAS in Colorectal Cancer  | wrong article type including book chapter, review or molecoular phase I and II study | round II |
| rayyan-661154582 | Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania "Luigi Vanvitelli" | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154585 | Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial  | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154591 | Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer                             | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154593 | Risk assessment in Stage II colorectal cancer   | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661154595 | Prognostic and predictive relevance of microsatellite instability in colorectal cancer  | wrong outcomes not reported survival and recurrence data                             | round II |

|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | for primary outcome  |          |
| rayyan-661154596 | Evaluating immunotherapy in nonmetastatic colorectal cancer   | study in recruiting stage with not available results                         | round II |
| rayyan-661154600 | Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661154626 | A prospective blinded study of microsatellite instability (MSI) as a marker of overall survival (OS) in the adjuvant treatment of colorectal cancer (CRC) patients  | study not retrieval  | round II |
| rayyan-661154648 | Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154688 | Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC)   | study not retrieval  | round II |
| rayyan-661154726 | Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154748 | Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154750 | Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study   | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154761 | Association of family history with cancer recurrence and survival among patients with stage III colon cancer  | wrong outcomes not reported survival and recurrence data                     | round II |

|                  |  |  |          |
|------------------|--|--|----------|
|                  |  | for primary outcome  |          |
| rayyan-661154763 | Postdiagnosis Marine Omega-3 Fatty Acid Intake and Survival of Stage III Colon Cancer in North Center Cancer Treatment Group (NCCTG) Phase III Trial N0147 (Alliance)  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154778 | Perioperative/Adjuvant atezolizumab with or without the immunomodulatory IMM-101 in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapyâ€” a randomized Phase II study | study not retrieval  | round II |
| rayyan-661154779 | Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154835 | Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies               | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154837 | Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502)               | study in recruiting stage with not available results                         | round II |
| rayyan-661154838 | p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154845 | KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661154846 | Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803  | subsequent publication with the same patients                                | round II |
| rayyan-661154847 | Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial  | wrong outcomes not reported survival and                                     | round II |

|                  |  |  |          |
|------------------|--|--|----------|
|                  |  | recurrence data for primary outcome  |          |
| rayyan-661155017 | A phase II trial to find the durable clinical benefit of nivolumab in class II expressing microsatellite colorectal cancer                         | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155043 | Prognostic value of disease-free interval in colorectal cancer: Is it time?  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155146 | Follow-up to the MOSAIC study (multicentre international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer) | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155185 | SCOT - Short Course Oncology Therapy: a study of adjuvant chemotherapy in colorectal cancer  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155278 | Novel molecular classification of colorectal cancer and correlation with survival  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155306 | MTOR/4EBP1 signaling and MMR status in colorectal cancer: New correlations and arising perspectives  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155329 | Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort                           | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155348 | Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS   | wrong population including stage   | round II |



|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | IV, I or other neoplasia diagnosis   |          |
| rayyan-661155357 | The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database   | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155393 | Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155438 | The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLA-E/Î²2m overexpression | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155461 | Prognosis and molecular characteristics of IBD-associated colorectal cancer: Experience from a French tertiary-care center  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155515 | A comparison of performance of 6-monomucleotide site panel and NCI panel for microsatellite instability detection in patients with colorectal adenocarcinoma                            | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155521 | Distinct Molecular Profiles of Sporadic Early-Onset Colorectal Cancer: A Population-Based Cohort and Systematic Review  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155563 | Clinical Utility of KRAS and BRAF Mutations in a Cohort of Patients With Colorectal Neoplasms Submitted for Microsatellite Instability Testing  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155830 | Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.  | wrong outcomes not   | round II |

|                  |  |  |          |
|------------------|--|--|----------|
|                  |  | reported survival and recurrence data for primary outcome                    |          |
| rayyan-661155837 | The prognostic role of microsatellite instability in colorectal cancer patients.   | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155838 | Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer.  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155846 | Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155847 | The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155849 | The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer.                                  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155854 | Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155859 | CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155860 | Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer.  | wrong population including stage   | round II |

|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | IV, I or other neoplasia diagnosis   |          |
| rayyan-661155861 | Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155864 | The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155868 | BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer.  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155873 | Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.                       | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155875 | Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability. | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155876 | Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers.                                       | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155878 | Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.                        | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155883 | Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.                       | wrong population including stage IV, I or other                              | round II |

|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | neoplasia diagnosis  |          |
| rayyan-661155892 | PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation. | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155894 | BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.                             | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155899 | Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.                | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155900 | Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.     | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155901 | TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.                            | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155921 | Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer.   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155926 | BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.                                  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155928 | Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer.                                  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |

|                  |  |  |          |
|------------------|--|--|----------|
| rayyan-661155936 | KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer.  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155941 | The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.                              | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155959 | Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155965 | Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability. | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155966 | Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.   | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155974 | PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.   | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661155976 | Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.                                   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661155980 | Molecular classification of colorectal cancer using the gene expression profile of tumor samples.  | wrong outcomes not reported survival and recurrence data                     | round II |

|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | for primary outcome  |          |
| rayyan-661155981 | Evaluating the Combination of Microsatellite Instability and Mutation in BRAF as Prognostic Factors for Patients With Colorectal Cancer.  | wrong article type including book chapter, review or molecoular phase I and II study | round II |
| rayyan-661155988 | Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.  | wrong population including stage IV, I or other neoplasia diagnosis                  | round II |
| rayyan-661155989 | Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.  | wrong population including stage IV, I or other neoplasia diagnosis                  | round II |
| rayyan-661155995 | Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.   | wrong population including stage IV, I or other neoplasia diagnosis                  | round II |
| rayyan-661156008 | The long-term survival characteristics of a cohort of colorectal cancer patients and baseline variables associated with survival outcomes with or without time-varying effects. | wrong population including stage IV, I or other neoplasia diagnosis                  | round II |
| rayyan-661156027 | f   | wrong outcomes not reported survival and recurrence data for primary outcome         | round II |
| rayyan-661156029 | Association between molecular subtypes of colorectal cancer and patient survival.   | wrong population including stage IV, I or other neoplasia diagnosis                  | round II |
| rayyan-661156044 | Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors.        | wrong population including stage IV, I or other neoplasia diagnosis                  | round II |

|                  |   |   |          |
|------------------|---|---|----------|
| rayyan-661156045 | Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies.                  | wrong population including stage IV, I or other neoplasia diagnosis | round II |
| rayyan-661156071 | High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer.                              | wrong population including stage IV, I or other neoplasia diagnosis | round II |
| rayyan-661156081 | Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.                                   | wrong population including stage IV, I or other neoplasia diagnosis | round II |
| rayyan-661156086 | Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.                                | wrong population including stage IV, I or other neoplasia diagnosis | round II |
| rayyan-661156091 | Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer.  | wrong population including stage IV, I or other neoplasia diagnosis | round II |
| rayyan-661156115 | Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.  | wrong population including stage IV, I or other neoplasia diagnosis | round II |
| rayyan-661156117 | DNA methylation predicts recurrence from resected stage III proximal colon cancer.  | wrong population including stage IV, I or other neoplasia diagnosis | round II |
| rayyan-661156119 | Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). | wrong population including stage IV, I or other neoplasia diagnosis | round II |
| rayyan-661156134 | Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.  | wrong population including stage IV, I or other                     | round II |

|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | neoplasia diagnosis  |          |
| rayyan-661156136 | Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.                       | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156138 | Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer.           | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156154 | Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients.         | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156160 | Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156168 | High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.   | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156170 | A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.                          | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156174 | Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661156184 | Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.   | wrong population   | round II |



|                  |  |  |          |
|------------------|--|--|----------|
|                  |  | including stage IV, I or other neoplasia diagnosis                           |          |
| rayyan-661156185 | Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661156191 | DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.                                   | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156192 | Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer.  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661156201 | Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156208 | The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156223 | Is KRAS mutation associated with interval colorectal cancers?  | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661156225 | Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.   | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661156254 | Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer: Insight into the survival paradox.                              | wrong outcomes not reported  | round II |

|                  |   |  |          |
|------------------|---|--|----------|
|                  |   | survival and recurrence data for primary outcome                             |          |
| rayyan-661156261 | Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.                                  | wrong outcomes not reported survival and recurrence data for primary outcome | round II |
| rayyan-661156277 | BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.       | wrong population including stage IV, I or other neoplasia diagnosis          | round II |
| rayyan-661156285 | ASO Visual Abstract: Conditional Survival After Diagnosis of Non-metastatic Colon Cancer: Impact of Laterality, MSI, and KRAS Status. | study not retrival   | round II |

Table S2. Newcastle-Ottawa scale of selected studies<sup>a</sup>

| Reference                  | Selection domain                         |  |                                  |                              | Comparability domain | Outcome domain                 |                              |                               | Quality score |
|----------------------------|--|--|----------------------------------|------------------------------|----------------------|--------------------------------|------------------------------|-------------------------------|---------------|
|                            | Representativeness of the exposed cohort | Non-exposed cohort drawn from the same community | Secure ascertainment of exposure | Outcome not present at start |                      | Adequate assessment of outcome | Adequate length of follow-up | Completeness of the follow up |               |
| <b>Hutchins G, 2011</b>    | *  | *  | *                                | *                            | No                   | *                              | *                            | *                             | 8             |
| <b>Taieb J, 2023</b>       | *  | *  | *                                | *                            | *                    | *                              | *                            | *                             | 8             |
| <b>Domingo E, 2018</b>     | *  | *  | *                                | *                            | *                    | *                              | *                            | *                             | 8             |
| <b>Maestro M L, 2006</b>   | *  | *  | *                                | *                            | No                   | *                              | *                            | No                            | 6             |
| <b>Batur S, 2016</b>       | *  | *  | No                               | *                            | No                   | *                              | *                            | No                            | 5             |
| <b>De Cuba E M V, 2016</b> | *  | *  | *                                | *                            | No                   | *                              | *                            | No                            | 6             |
| <b>Kadowaki S, 2015</b>    | *  | *  | No                               | *                            | No                   | No                             | *                            | *                             | 5             |

|                |   |   |    |   |    |   |   |    |   |
|----------------|---|---|----|---|----|---|---|----|---|
| Nakaji Y, 2017 | * | * | No | * | No | * | * | No | 5 |
|----------------|---|---|----|---|----|---|---|----|---|

<sup>a</sup> Good quality: > 7 stars; Fair quality: 5-7 stars; Poor quality: < 5 sta